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Abstract 
 
Type 2 Diabetes (T2D) affects over 415 million people globally and is 
characterised by cellular stresses including: poor glucose homeostasis, 
dyslipidaemia, inflammation, hypoxia and ER stress. Studies in mice have shown 
that exposure to these stresses influences beta cell differentiation status as well 
as cell survival and may explain the extent of beta cell mass loss that is seen in 
the disease. To date, studies of altered beta cell differentiation have largely been 
confined to murine models. I used the EndoC-H1 human beta cell line, along 
with human pancreatic tissue sections, to better characterise this mechanism in 
human disease.  
 
To elucidate these mechanisms, I firstly established a humanised version of cell 
culture techniques for the EndoC βH1 cell model and assessed the influence on 
cell function. Secondly, I evaluated the effects of the diabetic microenvironment 
on beta cell differentiation and gene expression patterns. Finally, I investigated 
whether a diabetomimetic microenvironment induced differences in microRNA 
regulation in the cells.  
 
I found that the humanised EndoC-βH1 culture techniques improved glucose 
sensitive insulin release in the cell model. EndoC-βH1 cells exposed to a Diabetic 
microenvironment showed some degree of transdifferentiation and this may be 
due to dysregulation of splicing factor expression. These effects may be 
compounded by altered microRNA regulation in response to these cell stresses. 
These data suggest that altered gene regulation caused by a diabetic 
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microenvironment may alter gene regulation to produce a reversible delta-like 
phenotype in human beta cells. 
 
  
 
 
 
4 
List of Contents 
 
Beta cell differentiation status in Type 2 Diabetes ........................................ 1 
Abstract ............................................................................................................. 2 
List of Contents ................................................................................................ 4 
List of tables ..................................................................................................... 9 
List of figures .................................................................................................. 10 
List of supplementary information ............................................................... 11 
Abbreviations ................................................................................................. 13 
Acknowledgements ........................................................................................ 17 
Chapter 1:........................................................................................................ 18 
Introduction .................................................................................................... 18 
1.1 Background to Type 2 Diabetes ........................................................................ 19 
1.2 Mechanisms of type 2 Diabetes: features of the diabetic microenvironment ...... 20 
1.2.1 Insulin synthesis ......................................................................................... 20 
1.2.2 Insulin secretion ......................................................................................... 20 
1.2.3 Insulin method of activity ............................................................................ 21 
1.2.4 Glucose sensing in beta cells ..................................................................... 21 
1.2.5 Islet architecture ......................................................................................... 22 
1.2.6 Mechanism of peripheral insulin resistance ................................................ 22 
1.2.7 Physiological cellular stresses associated with type 2 Diabetes ................. 25 
1.3 Beta cell differentiation status and Type 2 Diabetes .......................................... 29 
1.3.1 Beta cell mass loss in T2D ......................................................................... 29 
1.3.2 Beta cell differentiation status ..................................................................... 29 
1.3.3 Factors important to beta cell differentiation status ..................................... 33 
1.3.3 Transcription factors with roles in regulation of cell fate .............................. 36 
 
 
 
5 
1.4 Gene expression ............................................................................................... 43 
1.4.1 Control and regulation of gene expression ................................................. 43 
1.4.2 Constitutive and alternative Splicing ........................................................... 46 
1.4.3 Alternative Splicing ..................................................................................... 49 
1.4.4 Alternative splicing and Type 2 Diabetes .................................................... 52 
1.4.5 MicroRNAs ................................................................................................. 53 
1.4.6 MicroRNAs and Type 2 Diabetes ............................................................... 55 
1.4.7 Epigenetic modifications ............................................................................. 57 
1.5 Developments in human model systems ........................................................... 58 
1.5.1 Human beta cell lines ................................................................................. 58 
1.5.2 Islets........................................................................................................... 60 
1.5.3 Stem cells .................................................................................................. 61 
1.6 Conclusion ........................................................................................................ 62 
1.7 Research hypothesis ......................................................................................... 63 
1.8 Aims and objectives of thesis ............................................................................ 63 
1.8.1 Chapter 3: Determining the effect of species origin of the cellular 
microenvironment................................................................................................ 64 
1.8.2 Chapter 4: Determining the effect of cellular stressors on beta cell 
differentiation status ............................................................................................ 65 
1.8.3 Chapter 5: Cellular stress responses may be coordinated by microRNAs .. 66 
Chapter 2:........................................................................................................ 68 
Methods........................................................................................................... 68 
2.1 Tissue culture .................................................................................................... 69 
2.1.1 General Culture conditions for EndoC-βH1 cells ........................................ 69 
2.1.2 Standard culture conditions for EndoC-βH1 cell microenvironment using 
animal derived reagents ...................................................................................... 69 
2.1.3 Modified culture conditions for EndoC βH1 cell microenvironment using 
human derived reagents...................................................................................... 70 
2.1.4 Glucose-stimulated insulin secretion .......................................................... 71 
2.1.5 EndoC-βH1 insult assays to mimic diabetic microenvironment ................... 72 
2.2 Immunofluorescent cytochemistry. .................................................................... 75 
2.2.1 Image analysis ........................................................................................... 76 
2.3 Immunofluorescent characterisation of pancreatic tissue sections from patients 
with T1D and T2D ................................................................................................... 76 
2.3.1 Image analysis ........................................................................................... 78 
2.4 Candidate genes for expression analysis .......................................................... 78 
2.5 Alternatively spliced genes candidate selection ................................................. 80 
 
 
 
6 
2.5.1 Insulin ......................................................................................................... 81 
2.5.2 Paired box protein 6 (PAX6) ....................................................................... 82 
2.5.3 POU class 5 homeobox 1 (POU5F1 (OCT4)) ............................................. 83 
2.5.4 Nanog homeobox (NANOG) ....................................................................... 84 
2.5.5 Protein tyrosine phosphate PTPN1 ............................................................ 84 
2.6 RNA extraction .................................................................................................. 85 
2.7 Reverse transcription ........................................................................................ 86 
2.7.1 Superscript™ VILO™ cDNA synthesis. ...................................................... 87 
2.7.2 Taqman™ Advanced microRNA cDNA synthesis. ...................................... 87 
2.7.3 EvoScript Universal cDNA Master cDNA synthesis. ................................... 88 
2.8 Quantitative real-time Polymerase Chain reaction (qRT PCR) assessment of 
gene expression...................................................................................................... 89 
2.8.1 Relative Quantification ............................................................................... 91 
2.8.3 Other Statistical approaches ...................................................................... 92 
2.9 Splicing factor expression ................................................................................. 93 
2.10 Modification of gene expression using and siRNA to knock down the expression 
of PAX6 isoform, PAX6(5a). .................................................................................... 93 
2.11 High throughput global microRNA screen by open array ................................. 94 
2.11.1 miRNA enrichment analysis ..................................................................... 95 
2.11.2 Validation of dysregulated miRNAs .......................................................... 96 
2.11.3 Validation of miRNA target gene mRNA levels ......................................... 98 
Chapter 3:...................................................................................................... 100 
Data chapter. ................................................................................................. 100 
The species origin of the cellular microenvironment influences markers of 
beta cell fate and function in EndoC-βH1 cells .......................................... 100 
3.1 Introduction ..................................................................................................... 101 
3.2 Methods .......................................................................................................... 103 
3.2.1 Standard culture protocol: non-human microenvironment ......................... 103 
3.2.3 Immunofluorescence characterisation of EndoC-βH1 cells cultured in human 
microenvironment.............................................................................................. 104 
3.2.4 Assessment of glucose-stimulated insulin secretion ................................. 105 
3.2.5 Candidate genes for expression analysis ................................................. 106 
3.2.6 Quantitative real-time polymerase chain reaction (qRT PCR) assessment of 
gene expression ................................................................................................ 106 
3.3 Results ............................................................................................................ 108 
 
 
 
7 
3.3.1 EndoC-βH1 cells show morphological changes when cultured in a more 
‘human-like’ microenvironment .......................................................................... 108 
3.3.2 EndoC-βH1 cells cultured in a more human microenvironment demonstrate 
no alteration in insulin secretion, insulin processing or protein expression of 
mature beta cell markers ................................................................................... 110 
3.3.3 EndoC-βH1 cells cultured in a more human microenvironment exhibit 
enhanced glucose stimulated insulin secretion (GSIS) compared with those 
cultured in a non-human microenvironment....................................................... 114 
3.3.4 EndoC-βH1 cells cultured in human reagents have an increase in key genes 
involved in beta cell fate .................................................................................... 116 
3.4 Discussion ...................................................................................................... 118 
Chapter 4:...................................................................................................... 123 
Data Chapter. ................................................................................................ 123 
Cellular stressors may influence the differentiation status of human beta 
cells by moderation of alternative splicing patterns. ................................ 123 
4.1 Introduction ..................................................................................................... 124 
4.2 Research Design and Methods ....................................................................... 127 
4.2.1 Culture and treatment of EndoC-βH1 cells ............................................... 127 
4.2.2 Immunofluorescent characterisation of EndoC-βH1 cells in vitro .............. 128 
4.2.3 Immunofluorescent characterisation of human pancreatic tissue sections 
from patients with Type 1 or Type 2 Diabetes ................................................... 129 
4.2.4 RNA extraction, reverse transcription and assessment of total gene 
expression in EndoC-βH1 cells ......................................................................... 130 
4.2.5 Determination of Splicing Factor expression in EndoC-βH1 cells ............. 131 
4.2.6 Assessment of alternative splicing in EndoC-βH1 cells ............................ 132 
4.2.7 Reversal of delta cell phenotype in EndoC-βH1 cells by restoration of 
homeostasis ...................................................................................................... 134 
4.2.8 Reversal of delta cell phenotype in EndoC-βH1 cells by restoration of 
homeostasis or by small molecule inhibition of AKT pathway ............................ 134 
4.3 Results ............................................................................................................ 135 
4.3.1 Metabolic and ER stress is associated with beta cell to delta cell-like trans-
differentiation in EndoC-βH1 cells ..................................................................... 135 
4.3.2 Pancreatic sections from donors with T1D or T2D demonstrate increased 
numbers of delta cells ....................................................................................... 137 
4.3.3 Key beta cell fate and function genes show disrupted expression in 
response to cell stress stimuli in EndoC-βH1 cells ............................................ 140 
4.3.4 Changes to the expression of splicing factors and beta cell splicing patterns 
in response to cell stress stimuli in EndoC-βH1 cells ......................................... 141 
 
 
 
8 
4.3.5 Changes in beta cell identity and beta cell expression patterns are reversible 
upon restoration of homeostatic conditions in EndoC-βH1 cells ........................ 146 
4.3.6 Restoration of splicing patterns and splicing factor activity with the AKT 
inhibitor SH-6 renders cells immune to transdifferentiation in EndoC-βH1 cells. 148 
4.4 Discussion ...................................................................................................... 150 
Chapter 5:...................................................................................................... 187 
Data Chapter. ................................................................................................ 187 
Cellular stress responses in the human beta cell line EndoC-βH1 may be 
co-ordinated by microRNAs. ....................................................................... 187 
5.1 Introduction ..................................................................................................... 188 
5.2 Research Design and Methods ....................................................................... 190 
5.2.1 Culture and treatment of EndoC-βH1 cells ............................................... 190 
5.2.2 RNA extraction and reverse transcription ................................................. 190 
5.2.3 Large-scale miRNA screen ....................................................................... 191 
5.2.4 Validation of dysregulated miRNAs .......................................................... 191 
5.2.5 miRNA pathway enrichment analysis ....................................................... 192 
5.2.6 Validation of miRNA target gene mRNA levels ......................................... 193 
5.3 Results ............................................................................................................ 194 
5.3.1 Large scale dysregulation of miRNAs in response to the diabetic milieu .. 194 
5.3.3 The Lysine degradation, HIPPO and FOXO pathways are enriched in genes 
targeted by dysregulated miRNAs ..................................................................... 198 
5.3.4 Correlation of miRNA and mRNA target expression ................................. 198 
5.3.5 STK11, SOX9 and FOXO1 mRNA expression demonstrates negative 
associations with miR199a, miR-21 and miR-29a following diabetes-related 
cellular stresses. ............................................................................................... 200 
5.4 Discussion ...................................................................................................... 202 
Chapter 6:...................................................................................................... 238 
Discussion .................................................................................................... 238 
Summary of thesis ................................................................................................ 239 
Summary of data chapters .................................................................................... 240 
Chapter 3. The species origin of the cellular microenvironment influences markers 
of beta cell fate and function in EndoC-βH1 cells .............................................. 240 
Summary .................................................................................................................................... 240 
Importance of findings ....................................................................................... 240 
 
 
 
9 
Future work ................................................................................................................................. 241 
Chapter 4. Cellular stressors may influence transdifferentiation in human beta 
cells by moderation of alternative splicing patterns. ........................................... 242 
Summary .......................................................................................................... 242 
Importance of findings ....................................................................................... 243 
Future work ....................................................................................................... 244 
Chapter 5. Cellular stress responses in the human beta cell line EndoC-βH1 may 
be co-ordinated by microRNAs. ......................................................................... 245 
Summary .......................................................................................................... 245 
Importance of findings ....................................................................................... 246 
Future work ....................................................................................................... 246 
Discussion of thesis .............................................................................................. 247 
Conclusion ............................................................................................................ 259 
References .................................................................................................... 261 
Appendix ....................................................................................................... 271 
 
List of tables 
 
TABLE 1 MICRORNAS IMPLICATED IN T2D(160, 164, 179) ............................................ 57 
TABLE 2 FLUOPHORE FILTER EXCITATION AND EMISSION DETAILS ............................ 76 
TABLE 3 GENE ASSAY IDS. .................................................................................. 79 
TABLE 4 ALTERNATIVELY SPLICED GENE ASSAY IDS. .............................................. 85 
TABLE 5 MICRORNA ASSAY IDS FOR MOST ALTERED MIRS SELECTED FROM LARGE 
GLOBAL SCREEN. ......................................................................................... 97 
TABLE 6 TARGETS FROM DIANA PATHWAYS ANALYSIS. ......................................... 99 
TABLE 7 EXPRESSION OF GENES INVOLVED IN BETA CELL DIFFERENTIATION, FATE OR 
FUNCTION IN ENDOC ßH1 CELLS CULTURED IN HUMAN VERSUS NON-HUMAN 
MICROENVIRONMENTS. ............................................................................... 117 
TABLE 8 LARGE SCALE MICRORNA SCREEN. ....................................................... 195 
 
 
 
10 
TABLE 9 LARGE SCALE MICRO RNA SCREEN. ...................................................... 196 
 
List of figures 
 
FIGURE 1 DIFFERENCES IN ISLET ARCHITECTURE BETWEEN RODENTS (PART A) AND 
HUMAN (PART B) ......................................................................................... 32 
FIGURE 2 DIFFERENCES IN EXPRESSION OF BETA CELL DEVELOPMENT(88, 89). .......... 34 
FIGURE 3 MRNA PROCESSING. ............................................................................ 45 
FIGURE 4 SPLICING AND THE SPLICEOSOME. ......................................................... 48 
FIGURE 5 SCHEMATIC OF CONSTITUTIVE AND ALTERNATIVE SPLICING. ..................... 50 
FIGURE 6 TYPES OF ALTERNATIVE SPLICING. ......................................................... 51 
FIGURE 7 MICRORNA SYNTHESIS. ........................................................................ 54 
FIGURE 8 CULTURE MORPHOLOGY AND PSEUDO ISLET STRUCTURE OF ENDOC-ΒH1 
CELLS GROWN IN DIffERENT SPECIES MICROENVIRONMENTS. .......................... 109 
FIGURE 9 PROINSULIN AND INSULIN EXPRESSION IN ENDOC-ΒH1 CELLS GROWN IN 
HUMAN VS NON-HUMAN MICROENVIRONMENTS. ............................................. 111 
FIGURE 10 NEUROD1 AND PDX1 EXPRESSION IN ENDOC-ΒH1 CELLS GROWN IN 
DIffERENT SPECIES MICROENVIRONMENTS. ................................................... 112 
FIGURE 11 (A) ASSESSMENT OF GLUCOSE STIMULATED INSULIN SECRETION AND 
INSULIN CONTENT IN ENDOC-ΒH1 CELLS GROWN IN DIFFERENT SPECIES 
MICROENVIRONMENTS. (B) CHANGE IN GENE EXPRESSION IN ENDOC-ΒH1 CELLS 
GROWN IN DIFFERENT SPECIES MICROENVIRONMENTS. .................................. 115 
FIGURE 12. SCHEMATIC DIAGRAM SHOWING REGIONS WHERE ISOFORMS PROBES WERE 
DESIGNED. ................................................................................................ 133 
FIGURE 13. THE EFFECTS OF CELL STRESSORS ON HORMONE EXPRESSION. .......... 136 
 
 
 
11 
FIGURE 14 HORMONE STAINING PATTERNS OF DONOR ISLETS FROM CONTROLS OR 
INDIVIDUALS WITH T2D. .............................................................................. 139 
FIGURE 15 EFFECTS OF CELL STRESSES ON GENE EXPRESSION OF GENES WITH ROLES 
IN BETA CELL DIFFERENTIATION OR FUNCTION. .............................................. 142 
FIGURE 16 EFFECTS OF CELL STRESSES ON SPLICING FACTOR EXPRESSION. ......... 144 
FIGURE 17 EFFECTS OF CELL INSULT TREATMENTS ON ALTERNATIVELY SPLICED GENE 
EXPRESSION. ............................................................................................. 145 
FIGURE 18 RESCUE OF PHENOTYPE BY RESTORATION TO NORMAL CULTURE 
CONDITIONS. ............................................................................................. 147 
FIGURE 19 ENDOC  H1 CELLS TREATED WITH THE AKT PATHWAY INHIBITOR SH6 AND 
EXPOSED TO 25 MM GLUCOSE. ................................................................... 149 
FIGURE 20 TARGETED MICRORNA EXPRESSION OF MOST ALTERED MIRNAS FROM 
LARGE SCALE MIRNA SCREEN. ................................................................... 197 
FIGURE 21 MRNA EXPRESSION OF PREDICTED TARGET GENES FROM DIANA 
PATHWAYS ANALYSIS. ................................................................................. 199 
FIGURE 22 TARGETED EXPRESSION OF MICRORNAS STRONGLY VALIDATED TO BETA 
CELL GENES. ............................................................................................. 201 
FIGURE 23. SCHEMATIC REPRESENTATION OF TRANSCRIPTIONAL NETWORK AND MODEL 
OF FOXO1 INHIBITION OF SPLICING FACTOR EXPRESSION. ............................ 250 
 
List of supplementary information 
 
Supplementary table S1 details of antibodies and experimental conditions  154  
Supplementary table S2 patient data table…………….………………………………155 
Supplementary table S3 total gene expression assay IDs…………………….....156 
Supplementary table S4 splicing factor expression assay IDs………..………...157 
 
 
 
12 
Supplementary table S5 alternatively spliced gene isoform sequences.........158 
Supplementary table S6 effects of cell assays on total gene expression…..159 
Supplementary table S7 effects of cell assays on splicing factor 
expression…………………………………………………………………………..…….173 
Supplementary table S8 effects of cell assays on alternatively spliced  
gene expression…………………………………………………..…………………....178 
Supplementary table S9 effects of rescue from treatment…….………………….181 
Supplementary table S10 effects of SH6 AKT inhibition on cells treated 
with high glucose………………………………………………………………………..184 
Supplementary table S11 large scale microRNA screen results…………….…207 
Supplementary table S12 beta cell genes in target panel……………...…………216 
Supplementary table S13 microRNA assay IDs…………………………………......218 
Supplementary table S14  targets identified from DIANA gene set  
enrichment analysis……………………………………...……….………….219 
Supplementary table S15 DIANA gene set target assay IDs……………………220 
Supplementary table S16 effects of cell assays on microRNA  
expression…………………………………………………………………………………221 
Supplementary table S17 target expression of most altered 
microRNAs from large scale screen………………………………………………224 
Supplementary table S18 validation of gene targets from DIANA  
gene set enrichment analysis……………………………………………..229 
Supplementary table S19 targeted expression of microRNAs  
predicted to target beta cell genes……………………………...………………...233 
Supplementary table S20 effects of cell treatments on total gene  
expression in beta cell target genes………………………………………………236 
  
 
 
 
13 
Abbreviations 
Ago2    Argonaute 2 
ARNT    Aryl hydrocarbon receptor nuclear translocator 
ARX     Aristaless related homeobox  
BCL2L11    BCL2 like family 11 
cDNA    Complementary DNA 
CDK2    Cyclin dependent kinase 2 
DAG    Diacylglycerol 
DDIT3    DNA damage inducible transcript 3 
DLG2     Discs Large MAGUK Scaffold protein 2 
DNMT1   DNA methyltransferase 1 
DNMT3A   DNA methyltransferase 3 alpha 
ELISA    Enzyme linked immunosorbent assay 
ER    Endoplasmic reticulum 
ESE    Exonic splicing enhancer 
ESRP1   Epithelial splicing regulatory protein 1 
ESRP2   Epithelial splicing regulatory protein 2 
ESS    Exonic splicing silencer 
FOXO1    Forkhead box protein O1 
FFAs    Free fatty acids 
GCG     Glucagon 
GCK     Glucokinase 
GRG3    Transducin like enhancer of split 3 groucho 3 
GSEA    Gene set enrichment analysis 
GSIS     Glucose sensitive insulin secretion 
 
 
 
14 
GUSB    Beta-glucorinidase 
H3K4me3   Trimethylation of histone 3 at lysine 4 
HDAC1   Histone deacetylase 1 
HES1     Hes family BHLH Transcription factor 1 
HESCs   Human embryonic stem cells 
HHEX    Haematopoietically expressed homeobox protein 
HIF1A    Hypoxia inducible factor 1 subunit alpha 
hnRNPs   Heterogenous nuclear ribonuclear proteins 
HPRT1    Hypoxanthine phosphoribosyltransferase 1 
HNF1α   Hepatic nuclear factor 1 alpha 
IF    Immunofluorescence 
IL-6    Interleukin 6 
IL-1β    Interleukin 1 beta 
IL-IR1    Interleukin type 1 receptor 
INFγ    Interferon gamma 
INS     Insulin 
iPSCs    Induced pluripotent stem cells 
IRS-1    Insulin receptor substrate 1 
ISE    Intronic splicing enhancer 
ISS    Intronic splicing silencer 
JNK    Jun N terminal kinase 
KMT2C    Lysine methyltransferase 2C 
LDHA    Lactate dehydrogenase A 
lncRNA   Long non-coding RNA 
MAFA    MAF BZIP transcription factor A 
MAFB    MAF BZIP transcription factor B 
 
 
 
15 
MAPK1    Mitogen-activated protein kinase 1 
miRNA   MicroRNA 
MOB1A    MOB kinase activator 1A 
MODY   Mature onset Diabetes of the Young 
MYCL    MYCL proto-oncogene BHLH transcription factor  
NANOG    Nanog homeobox 
NEUROD1    Neuronal differentiation 1 
NEUROG3 (NGN3)  Neurogenin 3 
NFκB1   Nuclear factor kappa B 
NKX2-2    NKX homeobox 2 
NKX6-1    NKX homeobox 1 
NMD    Nonsense mediated decay 
PAX4     Paired box 4 
PAX6     Paired box protein pax-6 
PCR    Polymerase chain reaction 
PDK1     Pyruvate dehydrogenase Kinase 1 
PDX1 (IPF1)   Insulin promoter factor 1 
PKC    Protein kinase C 
POU5F1    POU Class 5 homeobox 1 
PPIA     Peptidylprolyl isomerase A 
PTPN1    Protein tyrosine phosphatase no receptor type 1 
qPCR    Quantitative PCR 
qRT PCR   Quantitative real time polymerase chain reaction 
RISC    RNA induced silencing complexes 
RRMs    RNA recognition motifs 
RT    Reverse transcription 
 
 
 
16 
SCL16A1    Solute carrier family 16 member 1 
SERPINE 1    Serpin family E Member 1 
SF    Splicing factor 
siRNA    Silencer RNA 
SLC2A2 (GLUT2)  Solute carrier family 2 member 2 
SNP    single nucleotide polymorphism 
snRNPs   Small nuclear ribonuclear proteins 
SOCS    Cytokine signalling proteins 
SOD     superoxide dismutase 1 
SOX9    SRY-Box 9 
SP1     SP1 transcription factor 
SRSF    Serine/ arginine rich splicing factor 
SST     Somatostatin 
STK11 (LKB1)   Serine threonine kinase 11 
SYP     Synaptophysin 
T1D    Type 1 Diabetes 
T2D     Type 2 Diabetes 
TEAD1    Integrin subunit alpha M 
TF    Transcription factor 
TLDA    Taqman low density array 
TNFα    Tumour necrosis factor alpha 
UPR    Unfolded protein response 
VEGF-A   Vascular endothelial growth factor A 
 
 
  
 
 
 
17 
Acknowledgements 
 
I’d like to thank my supervisors, Professor Lorna Harries and Dr Sarah 
Richardson, who have provided continued support during the 3 years of my PhD. 
Professor Lorna Harries deserves special mention for inspiring me to do a PhD 
in the first place. She thought I’d like it, and she was right, as she always is. I owe 
her a great deal for her confidence in me.  
 
My colleagues in Team RNA have been extremely helpful throughout. I would 
particularly like to thank Ben Lee for his unwavering patience and sound advice 
during the last 3 years.  Dr Eva Latorre has been inspirational, her work ethic is 
a thing of wonder. Also, thanks to Shanaz Haque and Cyrielle Tonneau for their 
friendship and support. Thank you all for being so lovely, I owe everyone 
chocolate and/ or beer. 
 
Very special thanks go to my family. My husband was long suffering before I 
started my PhD and he definitely deserves a medal now. My beautiful grown up 
girls, Isobel and Katie are my inspiration. If it wasn’t for them, I wouldn’t have 
discovered my passion for medical science in the first place. Finally, thanks to my 
parents who are always proud of me whatever I get up to and who have given 
me a solid foundation of love throughout my life.  
 
 
 
 
 
 
 
18 
Chapter 1: 
Introduction 
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1.1 Background to Type 2 Diabetes 
 
Type 2 Diabetes (T2D) affects over 415 million people globally. In the UK, 90% 
of the people diagnosed with diabetic disease have T2D. 
(https://www.diabetes.org.uk/diabetes-the-basics/what-is-type-2-diabetes). T2D 
is a polygenic disease associated with obesity and a sedentary lifestyle and is 
characterised by chronic high blood sugar, dyslipidaemia, hypoxia and chronic 
inflammation, as a result of insulin resistance and impaired beta cell function(1). It 
occurs when the cells that utilise insulin become less able to respond to it, further 
reducing the ability to remove excess glucose from the circulation. This state is 
referred to as insulin resistance. As the disease progresses, chronic high blood 
glucose results in a state of hyperinsuliaemia, where the insulin producing beta 
cells have to produce abnormal quantities of insulin to try and re-establish 
glucose homeostasis. Over time this impairs beta cell function and they are no 
longer capable of producing sufficient insulin, a state referred to as insulin 
deficiency.  
 
This combination of impaired insulin release and resistance mean that patients 
may require insulin therapy. Poor glucose control also increases risks of 
cardiovascular disease, stroke, vascular dementia, diabetic nephropathy, 
diabetic retinopathy and peripheral neuropathy(2-5). As a result, the disease can 
be very disabling and, in the UK alone, accounts for over £20 billion of the overall 
NHS spend each annually and over 10% of UK health expenditure(6-9). Globally 
the costs are over £825 billion per year, predicted to rise to trillions of dollars by 
2030(10).   
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1.2 Mechanisms of type 2 Diabetes: features of the diabetic 
microenvironment 
 
1.2.1 Insulin synthesis 
 
Insulin is an anabolic hormone that comprises two chains joined by disulphide 
bonds. It has a highly conserved amino acid sequence, which has enabled insulin 
replacement therapy using animal forms of insulin. The translated insulin mRNA 
transcript has only one chain, termed preproinsulin. On insertion into the 
endoplasmic reticulum (ER) for processing the signal peptide is cleaved and this 
action forms proinsulin. At this stage the structure has an amino terminal B chain 
and a carboxyl terminal A chain which are connected by the C peptide. 
Endopeptidases within the ER excise the C peptide and generate the mature form 
of insulin. It is then packaged into secretory vesicles in the golgi which 
accumulate in the cytoplasm. Dysregulation of this process is a feature of T2D, 
as improper ER processing can occur during hyperinsulinaemia leading to the 
accumulation of misfolded proteins which trigger the unfold protein response 
(UPR) leading to ER stress(11, 12).  
 
1.2.2 Insulin secretion 
 
Insulin is secreted from beta cells that sit within the islets of Langerhans in the 
pancreas. The role of islet cells is maintenance of glucose homeostasis and beta 
cells achieve this by secreting insulin, which can be used by cells such as skeletal 
myocytes, lipocytes and hepatocytes to remove glucose from the blood stream. 
Insulin is secreted by beta cells in response to increased concentrations of 
glucose in their immediate cellular microenvironment. Glucose is transported into 
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beta cells via facilitated diffusion through glucose transporter channels. The 
glucose molecules enter glycolysis leading to an increase in the ratio of 
intracellular ATP/ ADP. Increased ATP levels allow the ATP sensitive potassium 
(K+) channels to close, preventing the positively charged ions from leaving. This 
change in membrane potential opens voltage gated calcium ion channels in the 
cell membrane allowing calcium ions to passively diffuse into the cell. Calcium 
ions are required for insulin containing vesicle fusion with the cell membrane and 
subsequent exocytosis. 
 
1.2.3 Insulin method of activity 
 
Insulin acts via insulin receptors on the cell membrane of target cells. In 
hepatocytes it facilitates storage of glycogen and suppresses gluconeogenesis. 
In skeletal myocytes and lipocytes insulin facilitates glucose transport through the 
insertion of GLUT4 glucose transporter channels in the cell membrane. As well 
as these activities it has pleiotropic effects in many other cell types and recent 
studies suggest that it has regulatory roles in beta cell survival and gene 
expression(13). 
 
1.2.4 Glucose sensing in beta cells 
 
 
There are two main types of glucose transporter: sodium-glucose linked (SGLTs) 
and facilitated diffusion glucose (GLUT) transporters, which have three sub-
classes incorporating fourteen isoforms that vary in their tissue specificity and 
affinity for glucose(14, 15). Class one GLUT transporters, include isoforms GLUT1, 
GLUT2, GLUT3 and GLUT4, of which GLUT1 is the primary variant in human 
beta cells(16). GLUT2 is also expressed in beta cells and a loss of expression is 
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known to be associated with failure of glucose sensitive insulin secretion. 
However, the principal glucose sensor in beta cells is glucokinase(17), rather than 
GLUT1 and GLUT2, both of which have a low affinity for glucose(16, 18).   
 
1.2.5 Islet architecture 
 
 
Pancreatic endocrine cells are clustered to form the Islets of Langerhans with the 
principal role of regulating glucose homeostasis. Islets consist of 5 cell types 
incorporating: beta cells, alpha cells, delta cells, epsilon cells and pancreatic 
polypeptide (PP) cells(19-22). As described above, beta cells are glucose sensing, 
releasing insulin in response to a glucose stimulus. Alpha cells release glucagon 
in response to low blood glucose concentrations which acts on hepatocytes and 
myocytes to convert glycogen stores into glucose in a process termed 
gluconeogenesis(20-22). Islet delta cells secrete somatostatin in response to 
Urocortin3 and ghrelin, secreted from epsilon cells, which in turn regulates insulin 
and glucagon secretion. Pancreatic polypeptide cells secret pancreatic 
polypeptide which is required for regulating pancreatic secretions, gut motility and 
metabolism. Islet architecture varies significantly between species(19, 22). In 
mouse, beta cells are generally situated centrally within the islets with alpha cells 
located around the periphery, while in human alpha cells can also be located 
centrally(19, 20, 23).  
 
  
1.2.6 Mechanism of peripheral insulin resistance 
 
Insulin resistance arises from a complex series of interactions initiated by 
chronically high blood glucose, dyslipidaemia, innate immune responses, 
activation of the unfold protein response, and hyperinsulinaemia(24). It is caused 
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by a number of lifestyle factors including: obesity, inactivity, heredity, ageing and 
certain medications. As previously described, chronic hyperglycaemia causes 
beta cells to increase insulin secretion resulting in hyperinsulinaemia. Insulin 
receptors on the surface of target cells respond by either increasing the 
translocation of GLUT4 transporters to the cell membrane or increasing glycogen 
storage to remove glucose from the circulation. However, both of these 
processes rely upon appropriate myocyte, lipocyte and hepatocyte cellular 
responses.  
 
In the pathogenesis of T2D these functions are impaired due to dyslipidaemia 
arising from increased adiposity. This results in the circulation of free fatty acids 
(FFAs) and ectopic lipid accumulation within muscle, adipose and hepatic 
tissues. This has been shown to impair insulin signalling and GLUT4 
translocation. Studies in rodents and humans have shown that accumulations of 
diacylglycerol (DAG) in myocytes impaired insulin signalling(25, 26). DAG is a 
signalling intermediary that activates protein kinase C (PKC). Increased 
accumulation of DAG impaired insulin signalling via generation of novel PKC 
isoforms. Similarly, ectopic lipid accumulations in hepatocytes have also been 
identified as a cause of lipid related insulin resistance(27). In hepatocytes it is 
thought that lipid accumulations disrupt PKC isoforms, which sequester Akt2, 
impairing FOXO1 inactivation thereby increasing gluconeogenesis and 
decreasing glycogen synthesis(24).  Excess lipid storage in hepatocytes also 
causes increased release and circulation of FFAs, including toxic FFAs that have 
cytotoxic effects. Beta cells have been shown to be sensitive to toxic fatty acids 
such as palmitic acid, which is associated with increased rates of cell death(28, 29). 
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The interaction of dyslipidaemia and hyperinsulinaemia is also thought to 
contribute to insulin resistance through the UPR. As discussed, in beta cells, 
increased rates of insulin translation lead to the accumulation of mis-folded 
proteins which trigger ER stress(1, 11, 24). In myocytes, lipocytes and hepatocytes, 
lipogenesis has been shown to trigger the UPR through a variety of mechanisms 
which function to regulate cellular metabolic responses via lipogenesis, lipid 
droplet formation, lipid storage and regulation of glucose metabolism(11, 30-33). 
Through a combination of these mechanisms the UPR is believed to play an 
indirect, but contributory, role in insulin resistance. 
 
Along with dyslipidaemia, increased adiposity can induce oxidative and ER 
stress(26, 33, 34). This activates cellular pathways, such as JNK, IKKβ and NFκB, 
via ligand binding of proinflammatory molecules including TNFα, IL-6, INFγ and 
IL1β, in a positive feedback loop that increases the transcription of 
proinflammatory factors(35, 36). IL1β induces insulin resistance by binding the 
interleukin 1 type 1 receptor (IL-IR1) which in turn inhibits insulin receptor 
substrate 1 (IRS-1) expression(3, 37). It regulates the production of IL-6, increasing 
its production via IL-IR1 activation, which compounds ectopic lipid accumulation 
due to the suppression of lipase(3, 37). This then feeds into the lipid associated 
mechanisms of insulin resistance. IL-6 is also known to impair insulin signalling 
by activation of cytokine signalling proteins (SOCS) which in turn block insulin 
receptor activation(3, 37). Similarly, TNFα activates JNK and NFκB pathways which 
again inhibit IRS1 activity, leading to impaired insulin signalling and subsequent 
insulin resistance(3, 37). Fatty acid mediated activation of IL1β and INFγ pathways 
has also been shown to induce ER stress, impacting maintenance of beta cell 
fate and survival(38-40). All of these mechanisms act in a synergistic, 
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interdependent manner that reduces sensitivity to insulin leading to insulin 
resistance. The long-term effects of insulin resistance are poor glucose 
homeostasis and, over time, this can lead to beta cell failure. 
 
1.2.7 Physiological cellular stresses associated with type 2 Diabetes  
 
The impact of an obesogenic environment on beta cell differentiation and 
transcription factor expression has been the subject of a number of studies(41-46). 
Chronic hyperglycaemia is known to be toxic and the effects of obesity on the 
cellular environment include hypoxia, lipotoxicity and increased inflammation. In 
primates given a high fat/ high sugar diet, decreased expression of FOXO1, 
NKX6.1, NKX2.2 and PDX1 was observed. This resulted in a switch from beta to 
alpha expression profile, characterised by increased expression of the alpha cell 
specific markers ARX, GCG and DNMT1, which was then rescued by treatment 
with resveratrol(44).Studies have also shown a highly selective decrease in the 
expression of transcription factors FOXO1, MAFA, MAFB, NKX6-1 and PDX1 in 
beta cells exposed to oxidative stress resulting from hyperglycaemia(42, 47-49). 
FOXO1 under-expression precedes downregulation of MAFA, but both are early 
indicators of beta cell stress(42, 47). In the context of T2D this has relevance 
relating to prediabetes or metabolic syndrome where postprandial 
hyperglycaemia may impact FOXO1 and MAFA expression, with subsequent 
disruption to insulin secretion(42). It has recently been proposed that beta cells 
transition between two states to balance high rates of insulin biosynthesis, with 
accompanying risk of pro-insulin misfolding, and UPR recovery of ER stress(50). 
In this model, hyperglycaemia overwhelms the unfolded protein response 
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resulting in uncontrolled ER stress, impaired beta cell function and increased 
rates of apoptosis(11, 38).  
 
Beta cells are also highly sensitive to hypoxia, which also acts to induce the ER 
stress pathway, leading to the accumulation of unfolded pro-insulin and 
compromised beta cell function(51).  Hypoxia can occur as a result of 
hyperinsulinaemia where the cells energy output exceeds its oxygen supply(52, 
53). A study investigating the effects of hypoxia in MIN6 cells showed it induced 
beta cell dysfunction and caused downregulation of Mafa, Pdx1, Slc2a2, Kcnj11 
and Neurod1, resulting in abnormal insulin secretion(45). This study also indicated 
that Mafa expression increased on Hif1a knockdown, which suggests Hif1 is 
involved in regulation of its expression(45). 
 
Not all FFAs are toxic to beta cells and some have protective activity(28), however 
lipotoxicity is an important feature of T2D(1, 29, 34, 54). Historically, it was thought 
that lipotoxicity in beta cells arose from altered PKC signalling leading to reduced 
glucose sensitivity(54). Many studies now suggest that exposure to FFAs activate 
cell stress responses, such as oxidative stress, ER stress, and autophagy(1, 29, 31, 
34, 54). One of the proposed mechanisms for beta cell dysfunction is that disrupted 
lipoprotein lipase signals may contribute to reduction of the lipid component of 
glucose stimulated insulin secretion (GSIS)(55). Palmitate is also known to impair 
glucose transport, calcium signalling and insulin secretion also resulting in 
reduced GSIS(54). It is also associated with increased rates of beta cell apoptosis. 
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Inflammation has been well studied in relation to insulin resistance and beta cell 
failure in T2D(2, 36, 39, 48, 56). It is known that immune cell filtration of islets is a 
feature of the disease. An emerging field of study is the role of proinflammatory 
cytokines on beta cell differentiation status(2). Studies have shown that IL1β, IL-6 
and TNFα repress the expression of genes that maintain mature beta cell 
differentiation status, including Ins2, Slc2a2 and Pdx1(2, 36). Loss of Pdx1 
expression is associated with changes in beta cell fate(57, 58). Cytokines IL1β, 
INFγ,TNFα and IL-6 are also associated with increased rates of apoptosis(2, 56). 
However, to date, the exact mechanism by which proinflammatory factors may 
be driving changes in beta cell fate remains to be elucidated. 
 
It has also been shown that cellular ageing is an important feature of T2D 
and it has been identified that it leads to the upregulation of Pdx1 and Neurod1(59), 
genes that have roles in the maintenance of beta cell function and mass. A recent 
study using single cell mass cytometry in human islets has clearly shown that 
beta cell proliferation declines with age and suggests that different classes of beta 
cell subset predominate throughout the ageing process, with cells switching from 
a proliferative to a quiescent state(60). A study in mice found a global methylation 
drift in ageing beta cells and decreased proliferations but no associated decrease 
in function(59). This is corroborated by other studies which show that beta cell 
replication declines with age but function is unaffected(61-63). Given the potential 
association of decreased cell density with increased cell plasticity, ageing is 
another potential driver for changes in beta cell differentiation status(59). Rodent 
models of T2D have also shown that increased incidence of de-differentiation and 
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trans-differentiation are observed in aged mice with Foxo1 knockout, suggesting 
that ageing increases likelihood of changes to cell fate(43, 64).  
 
Beta cell mass loss exerts its own stresses and several studies have considered 
the importance of cell density in beta cell mass via proliferation and changes to 
beta cell differentiation status(47, 65-69). A mathematical model looking at the 
crosstalk between two signalling mechanisms, lateral inhibition and lateral 
stabilization, which exert environmental control over cell fate stability and the 
transdifferentiation of pancreatic cells, noted that cell density affects efficiency of 
conversion from one cell type to another(70). NGN3, crucial for endocrine 
differentiation, is regulated in this way, influencing beta cell replication rate(71). 
Contact inhibition acts via the Wnt signalling pathway and in vitro studies have 
shown that β-catenin is recruited to the plasma membrane only in confluent 
cells(66). Interestingly, an in vitro study of stem cell differentiation showed that 
initial seeding density influenced the pancreatic endocrine progenitor 
commitment, with high densities resulting in cells co-secreting insulin and 
glucagon(68). This suggests that paracrine environmental conditions affecting cell 
density may be of significant importance in determining cell fate, and with this, 
cell mass. Further, Brissova et al.(72) used a model of inducible and reversible 
beta cell specific VEGF-A overexpression to investigate how VEGF-A signalling 
modulates intra-islet vasculature, islet microenvironment and beta cell mass. The 
study showed that increased vasculature created a local microenvironment, 
which resulted in beta cell proliferation and the restoration of beta cell mass. 
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1.3 Beta cell differentiation status and Type 2 Diabetes 
 
1.3.1 Beta cell mass loss in T2D 
 
Until recently, the loss of beta cell mass seen in T2D was considered to be the 
result of increased rates of apoptosis(73). Global data from autopsy results of 
patients with T2D show significantly reduced numbers of pancreatic beta cells 
compared with those of non-diabetic control subjects. These findings are 
supported by studies reporting increased rates of apoptosis in the islets of 
patients with T2D, and there is also evidence of a beta cell deficit in people with 
prediabetes and impaired fasting glucose levels.(74-76) Such studies do not, 
however, address whether the observed incidence of reduced beta cell  mass is 
a result of the disease process or is attributable to a lower starting point in these 
individuals that may have conferred increased T2D risk(77, 78). It is also worth 
noting that there is some overlap between the extent of beta cell mass loss seen 
between people with and without diabetes. More recently it has been proposed 
that apoptosis alone does not account for the extent of beta cell mass loss seen 
in T2D, and loss of beta cell function is an important feature of the disease(75).  
 
1.3.2 Beta cell differentiation status 
 
One of the possible mechanisms, distinct from inadequate glucose sensing, that 
drives loss of beta cell function involves changes in the differentiation status of 
mature beta cells. Trans-differentiation into alpha cells and dedifferentiation of 
beta cells to progenitor cell types have been studied, particularly in mouse 
models, and the mechanisms instigating changes in cell fate are beginning to be 
characterized(61). 
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A recent study by Johnston et al(79) presents the intriguing possibility that beta 
cells have the potential to convert into other pancreatic endocrine cell types in 
response to loss of function, a phenomenon referred to as cellular plasticity. 
Increased beta cell plasticity may occur via the expression of immature beta cell 
markers in islet hubs and appears to be linked to the capacity for beta cell hubs 
to coordinate islet function, including increased glucose responsivity(79). It is 
possible that the expression of immature beta cell markers, and consequent 
increased plasticity, causes the hubs to be more sensitive to the effects of a 
diabetic microenvironment, losing beta cell function and insulin positivity. 
Understanding how the diabetic milieu effects the transcriptional profile of genes 
involved in beta cell fate is therefore an important next step in this field of 
research. 
 
Dedifferentiation can be defined as the loss in expression of mature beta cell 
markers with accompanying loss of function so that the cells lose their insulin 
positivity. Trans-differentiation refers to the process of a change in cell type, 
commonly from mature beta cells into alpha cells, with accompanying gain of 
glucagon positivity and expression of alpha cell markers(80). Similarly, knockout 
studies of alpha cell regulators Arx and Dnmt1 have shown a loss of mature alpha 
cell status with gain of beta cell-like electrophysiology and glucose sensitive 
insulin secretion(81). Some studies have suggested that, in non-human 
mammalian models, the change in differentiation status is rapid rather than 
gradual(58). This has been shown in studies using lineage tracers where trans-
differentiation has occurred within 2 days of the loss of expression of mature beta 
cell markers(58). There are two proposed pathways for trans-differentiation: de-
differentiation to progenitor cell followed by re-differentiation into an alternative 
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islet cell type, or dual hormone positivity, such as where individual cells express 
insulin and glucagon at the same time(82). 
 
To date, much of the work on changes to differentiation status in the literature 
has been carried out using murine models, which, while providing valuable 
insights into the role of inducible stress triggers in cell fate, are not without 
problems. Studies on human tissues are few, but early results from recent studies 
suggest similar phenomena may also occur in humans(80). A study looking at 
transdifferentiation in human pancreatic tissues found expression of 
mesenchymal and beta cell markers in insulin-positive islet beta cells and also 
reported co-expression of glucagon and insulin(80). These results do have to be 
considered cautiously, as the study was based on a very small sample size and 
so further study is required to corroborate their findings. 
 
The significant differences between murine and human islet structure, however, 
make definite comparison difficult. Mouse islets are mainly arranged with alpha 
cells around the outside of the islet, with beta and delta cells within the centre. 
This is described as a mantle of alpha cells surrounding a core of beta and delta 
cells(19). Conversely, in humans and monkeys, alpha cells are not exclusive to the 
periphery or mantle and instead are dispersed throughout the islet (Figure 1).  
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Figure 1 Differences in Islet architecture between Rodents (part A) and 
Human (part B) 
Red = alpha cells. Blue = beta cells. Green = delta cells. Yellow = PP cells. Pink = epsilon 
cells. In rodents alpha cells tend to be arranged around the periphery of the islet. In beta 
cells they can also be located centrally within the islet. 
 
 
 
These differences in architecture are considered to influence sensitivity for 
glucose sensing, with human islets being more efficient at detecting low glucose 
concentrations(22, 83). It has also been shown that there are mechanistic 
differences in terms of gene expression between species and their 
responsiveness to the stress conditions associated with T2D, as seen with 
NGN3, NANOG, POU5F1 (Oct4) and MYCL1 expression(58). The problems of 
comparison between murine and human models are also illustrated in differences 
in the expression levels of Pax4, which has been shown to be highly expressed 
in mouse models, favouring the beta cell fate; however, in human cells PAX4 
expression has been shown to be poorly expressed in fully mature beta cells, 
suggesting it may not be a good marker of active transcription factors with specific 
roles in beta cell fate(84). Other differences in gene expression include MAFB 
expression, which persists in human adult beta cells but not in mouse(85). 
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1.3.3 Factors important to beta cell differentiation status  
 
Understanding the factors involved in beta cell development is key to appreciating 
the close relationship between alpha and beta cell maturation and, therefore, the 
potential for changes in mature endocrine cell differentiation status that allow 
trans-differentiation to occur(58). It is also apparent that subpopulations of alpha 
and beta cells exist. It has been suggested that beta cell plasticity may confer 
protection against cell stress caused by hyperglycaemia, also allowing the cell to 
re-differentiate should the paracrine environmental condition improve(86). NGN3 
is critical for endocrine differentiation and is activated by ONECUT (Hnf6) and 
FOXA2. It is absolutely required for induction of PAX4, and also has PAX6, ISL1 
and NEUROD1 expression as its immediate down-stream targets(87). Beta cell 
progenitors also express NKX2.2 and NKX6.1, and as they continue to mature, 
ISL1 and PAX6 (Figure 2).  
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Figure 2 Differences in Expression of Beta cell development(88, 89).  
Schematic showing gene expression during pancreatic development and beta cell 
differentiation. NGN3 is activated by ONECUT (Hnf6) and FOXA2 and is critical for 
endocrine differentiation. Downstream targets for NGN3 are: PAX4, PAX6, ISL1 and 
NEUROD1. Beta cell progenitors express NKX2.2 and NKX6.1, PDX1 and PAX6 
 
MAFA, MAFB, FOXO1, INS 
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The importance of NGN3, as a regulator of differentiation status, can be seen by 
its own tight regulation, with the number of NGN3-positive differentiating cells 
limited by lateral inhibition via notch signalling(71, 90). PAX4 and NKX2.2 act in 
parallel to continue the process of beta cell differentiation, with a resulting 
increase in the expression of PDX1, along with concomitant induction of HB9 
expression and, ultimately, insulin synthesis. 
 
Many of the genes important to the maturation of beta cells are also expressed 
in progenitor alpha cells, with the exception of specific markers such as ARX in 
alpha cells and the mature beta cell markers NKX6.1 and PDX1. It is therefore 
the tight regulation of these cell fate-specific transcription factors that ensures 
maintenance of cell fate. In beta cells the transcription factors PDX1, FOXO1, 
MAFA and NKX2.2 are critical to maintaining the function of beta cells. There are 
also increases in the expression of “disallowed” beta cell genes, such as 
SLC16A1 and LDHA in T2D(91). These genes are “disallowed” to ensure that 
pyruvate and lactate generated during exercise do not stimulate insulin release, 
and are typically inactivated by histone modifications and micro-RNA mediated 
silencing(91). Expression of such genes could therefore considerably exacerbate 
the effects of oxidative stress responses in beta cells, further driving changes in 
differentiation status. 
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1.3.3 Transcription factors with roles in regulation of cell fate 
 
1.3.3.1 PAX4 
 
Given the importance of cell-specific transcription factors in the maintenance of 
cell fate, it is helpful to consider the role of these key genes in turn. In mouse 
models, Pax4 is a beta cell-specific transcription factor; however, as discussed, 
there are some species differences. In a study of human islet cells, PAX4 was 
detected in 43% of human alpha cells and 39% of beta cells, with much lower 
levels of expression than those seen in mouse islet cells. This is consistent with 
reports of weak PAX4 mRNA expression in human cells. In studies of PAX4 
expression, in which cells were subjected to an obesogenic environment, there 
was no significant change in expression. This suggests that PAX4 may not be 
affected by T2D, although there was a decrease in PAX4-positive alpha cells in 
T2D patient samples, where there was no change in beta cell PAX4 
expression(41). Murine models have also characterized the PAX4/ ARX regulatory 
negative feedback axis, whereby PAX4 favours the beta cell fate and ARX 
favours alpha cells(92, 93). PAX4 regulates the balance between alpha and beta 
cells by antagonizing ARX in endocrine progenitors(65, 93). In a study of PAX4 and 
NKX2.2, it was seen that these transcription factors regulate parallel pathways 
and are both necessary to initiate the beta cell differentiation programme and act 
in parallel to increase PDX1 expression; however, it is still unclear how this role 
is accomplished(84). 
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1.3.3.2 PDX1 (IPF1) 
 
PDX1 (IPF1) is the first transcription factor produced in the developing pancreas 
but becomes confined to beta cells during development(57, 90). Given the close 
developmental relationship between alpha and beta cells, several studies have 
looked at forced changes to expression of Pdx1, to observe its effects on 
endocrine cell fate(58, 94, 95). In a study of the conversion of adult alpha cells to 
beta cells after extreme beta cell loss, Pdx1 expression was shown to have an 
important role in alpha cell conversion. Here it was also shown that the extent of 
beta cell loss determines whether there is any regeneration(65). This was 
corroborated by another study by Gao et al.(58) which used lineage tracing to 
follow the fate of adult beta cells after Pdx1 deletion, and which also observed 
that many of the cells became alpha cells, and similarly found that isolated beta 
cells differentiated into alpha cells. This offers up the intriguing possibility that a 
key driver of beta cell fate is possibly cell density, which has significant 
connotations in the context of T2D, with its associated loss of beta cell mass. 
Interestingly, these studies showed that the reprogrammed alpha cells crucially 
lack the alpha specific transcription factor Arx(94, 96). 
 
Studies have also investigated the role of alpha to beta cell reprogramming 
by considering upregulation of Pdx1 expression. Yang et al.(94) forced Pdx1 
expression in cells from the Ngn3 commitment point onward and saw two periods 
of reprogramming. The first occurred during early organogenesis and resulted in 
fewer alpha cells, while the second forced reprogramming at the peri-postnatal 
stage, resulting in redirection of alpha cells into a beta cell lineage. All studies of 
IPF1 (Pdx1) conclude that it is a master regulator of beta cell fate and has roles 
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in repressing genes that are associated with alpha cell identity, most notably 
Mafb, where a transcriptional shift showed de-repression of the gene(84, 94, 96). 
Pdx1 normally binds within Mafb and glucagon promoters in beta cells 
competitively inhibiting them so they are not expressed(41, 42). These studies 
suggest that Pdx1 is not required for beta cell survival but is associated with a 
loss of beta cell identity. 
 
1.3.3.3 ARX 
 
As described above, ARX is a specific transcription factor for the alpha cell fate. 
It is expressed in endocrine progenitors and then restricted to glucagon-
producing alpha cells(97). Deletion of Arx in mice leads to the loss of alpha cell 
identity, resulting in alpha to beta cell-like conversion with the cells expressing 
Pdx1, Mafa and Glut2(98). A study by Wilcox et al.(98) showed that ablation of Arx 
in neonatal glucagon positive cells resulted in the loss of alpha cell identity but in 
adult animals there was no such reduction and no increase in beta cells. This 
suggests that Arx is important for the early maintenance of alpha cell fate but is 
no longer required in adult animals for alpha cell fate maintenance. It has a similar 
role, therefore, to the beta cell-specific transcription factor PAX4 and these 
findings indicate that in both alpha and beta cells, plasticity decreases as cells 
mature(98). 
 
Specific mature endocrine cell transcription factors such as PAX4 and 
ARX are tightly regulated to ensure maintenance of cell fate(92, 93, 99). This is 
demonstrated by the mechanism of the NKX2.2 repressor complex which 
regulates beta cell fate and prevents beta to alpha cell reprogramming. The 
repressor complex includes DNMT3A, GRG3 and HDAC1, and works by blocking 
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the ARX promoter to prevent transcription(97). Antagonistic expression of specific 
beta or alpha cell transcription factors is an important determinant of endocrine 
cell fate. 
 
1.3.3.4 MAFA and MAFB 
 
The transcription factor MAFA is an important regulator of the insulin gene and is 
not typically expressed in alpha cells(42). MAFB is another transcription factor 
whose expression precedes an increase in Pdx1 expression and marks the start 
of insulin transcription(58). It persists in human mature beta cells but importantly 
is not seen in the adult beta cells of mice(41, 42, 85), and a recent study has shown 
that MAFA compensates for the absence of MAFB in mice as it is functionally 
similar(100). In a study of human islets looking at the effects of obesogenic 
environment on cell fate it was noted that MAFA and MAFB were expressed in 
both alpha and beta cells, which is consistent with the results of the 2015 
Bramswig study(41, 101). MAFA expression in both alpha and beta cells was shown 
to be altered in a significant proportion of patients with T2D, which suggests a 
greater degree of plasticity in human islets than has been previously observed in 
murine models(41). 
 
1.3.3.5 FOXO1 
 
FOXO1 has roles in gluconeogenesis and beta cell differentiation and is most 
abundant in beta cells. It effectively integrates beta cell proliferation with adaptive 
function and, in human embryonic stem cells, is an important regulator 
pluripotency via OCT4, NANOG and SOX2(47, 64). It also suppresses beta cell 
neogenesis in pancreatic duct cells. Studies have shown that in beta cells under 
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metabolic stress, it is protective, enabling the maintenance of insulin secretion 
via MAFA(43, 90, 102). In this way it is protective against beta cell failure via the 
transcription factors MAFA and NEUROD1, regulating their transcription and 
maintaining insulin secretion(43, 47). In studies where expression of the FOXO1 
gene was ablated there was a resultant de-differentiation of beta cells in stress 
conditions(64). Knockout of Foxo1 in mice and loss of beta cell mass was also 
attributable to de-differentiation rather than cell death(61). Here beta cells reverted 
to progenitor-like cells, whereas some beta cells trans-differentiated into alpha 
cells. The knockout caused hyperglycaemia in the mice and was compounded by 
additional stresses such as age or pregnancy(61). 
 
FOXO1 is phosphorylated by AKT as well as the JNK kinases NFkB and 
CDK2(39, 47, 103). When AKT phosphorylates FOXO1 it causes it to leave the 
nucleus and go to the cytoplasm, inactivating its transcription factor capability. 
This shows that AKT signalling is important in pancreatic cell plasticity because 
of its regulation of FOXO1 activity. Overexpression of the AKT gene has been 
shown to induce expansion of ductal structures and is implicated in acinar to 
ductal, as well as beta cell to acinar/ductal trans-differentiation. In this way AKT 
plays a critical role in maintaining cell fate, as well as beta cell function, given the 
role of FOXO1 in the stress response(104). 
 
1.3.3.6 NKX6 genes 
 
Nkx6 genes have been shown to be important to both alpha and beta cell 
differentiation in mice, as well as other animal models(105). Decreased expression 
of the beta cell-specific transcription factor NKX6.1 is seen in T2D and leads to 
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loss of beta cell function(106). Reduced expression is also associated with Ngn3 
induction in mouse models of the disease, with cells acquiring a delta-like 
expression profile. Nkx6.1 has also been shown to have as its target the alpha 
cell-specific Arx, and acts to repress its expression, which preserves beta cell 
identity(107, 108). Nkx6.1 acts antagonistically with Isl1 to regulate alpha vs beta cell 
identity, again highlighting the close relationship and crosstalk between these 
islet cell types(96, 106, 108, 109). 
 
Nkx6.2, is known to be expressed during embryonic development, from 
E10.5(110). In a study by Nelson et al.(110) it was observed that, while Nkx6.2-
deficient mice did not exhibit a distinct phenotype, the double knockout 
Nkx6.1/Nkx6.2 mice showed decreased numbers of insulin-positive beta cells. 
They point to a divergent spatial temporal relationship between the expression of 
Nkx6 genes, which is key to understanding their role in the maintenance of beta 
or alpha cell lineages(111). 
 
1.3.3.7 NGN3 
 
As indicated earlier, NGN3 plays a pivotal role in endocrine development, 
including the induction of PAX4 as well as the downstream targets PAX6, ISL1 
and NEUROD1(87). In a 2002 study by Gu et al.(112) the progeny of NGN3-positive 
cells was followed and it was determined that cells derived from those expressing 
NGN3 coalesced to form mature islets. NGN3 was therefore shown to be a 
progenitor for the endocrine lineage and not a ductal progenitor. Further, this 
study indicated that NGN3 expression is required for all types of pancreatic 
endocrine islet cell and exists in the mature pancreas, facilitating maintenance of 
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endocrine islet cell fate. Wang et al.(113) examined the effect of a diabetic state in 
mouse cells and islets and noted that beta cells lost mature beta cell markers, 
de-differentiating into insulin negative progenitors expressing Ngn3. When blood 
glucose was lowered using insulin therapy, lineage-tracing experiments revealed 
a restoration of insulin positivity, and Ngn3 expression was lost. Control islets 
showed negligible Ngn3 positivity(113); however, Guo et al.(42) observed no similar 
increases in NGN3 expression in a recent study of human islets from patients 
with T2D. NGN3 has been reported in the islets of adult mice with such studies 
suggesting a role for NGN3 in maintenance of islet cell function(114). However, 
this finding is complicated by data from other studies which show that NGN3 
expression in adult islets is linked to islet cell injury and exposure to ER stress, 
which reactivates NGN3 expression, suggesting that expression may be 
associated with cell stress(115, 116). Such discrepancies may be the result of 
differences in antibody specificity but more work needs to be done to elucidate 
the mechanism of altered NGN3 expression in mature islet cells. This again also 
highlights the differences between murine and human islet cell transcription factor 
expression and the importance for such findings to be corroborated using human 
model systems. 
 
1.3.3.8 NKX2.2 
 
In mice, Nkx2.2 is expressed in endocrine progenitors but, as part of the 
secondary transition, it is restricted to mature beta cells as well as a subset of 
alpha and PP cells(117). During development of the pancreas, Nkx2.2, along with 
Arx, specifies distinct islet cell subtypes. Kordowich et al.(118) note that Arx null 
mice fail to develop alpha cells, with a concomitant increase in beta and delta cell 
number. Nkx2.2 mutants exhibit impaired alpha and beta cell development as 
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well as markedly increased Arx expression. These data suggest that Nkx2.2 is 
necessary to maintenance of beta cell function, maintenance of beta cell fate and 
suppression of alpha cell identity(119, 120). 
 
As indicated above, Nkx2.2 forms a repressor complex which regulates beta cell 
fate. It acts to support transcriptional networks induced by Pax4 and Arx, as part 
of an axis to counteract Arx expression in pre-beta cells that are committed to a 
beta cell identity(118). The repressor complex works via the methyltransferase 
Dnmt3a, and the histone deacetylase Hdac1, to methylate CG dinucloetides. 
Together, the complex competitively binds the Arx promoter region, thereby 
inhibiting Arx transcription.(71, 97) Nkx2.2 is therefore required for endocrine 
differentiation, maintenance of beta cell fate and prevention of trans-
differentiation to an alpha cell phenotype.  
 
1.4 Gene expression  
 
1.4.1 Control and regulation of gene expression 
 
Gene regulation occurs throughout multiple and interlinked processes of 
modifications to chromatin structure, transcription, post transcriptional regulation, 
translation, protein modification, and mRNA and protein degradation. It allows a 
range of mechanisms to regulate initiation of transcription, nonsense mediated 
decay (NMD) for aberrant or deleterious mRNA synthesis, alternative splicing, 
miRNA targeting of transcripts, post translational modifications including protein 
folding and ubiquitination. Tight regulation of gene expression is essential to 
stability of the cellular environment and allows an adaptive response to changes 
in the cellular microenvironment.  
 
 
 
44 
 
The nucleosome is the fundamental unit for chromatin, comprising 145-7 base 
pairs of DNA wound around a histone octomer(121, 122). Regulation of chromatin 
structure can determine gene expression in a dynamic process termed 
nucleosome positioning, which affects transcription factor binding(123, 124). A range 
of epigenetic modifications including DNA methylation, histone marks, long non-
coding RNA (lncRNA) mediated imprinting and chromosome coordination via 
Lamin A, also influence initiation of transcription(125, 126). In eukaryotic cells, the 
pre-mRNA molecule is synthesized from a DNA template and processed into a 
mature mRNA molecule by splicing, which removes introns and ligates exons, 5’ 
end capping and polyadenylation, the addition of a poly A tail(127), please refer to 
Figure 3.  
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Figure 3 mRNA processing.  
Figure shows removal of introns by splicing, the addition of 5’ cap, consisting of 5’ to 5’ 
triphosphate bridge and 7-methylguanosine, and 3’ polyadenylation. During mRNA 
processing constitutive splicing/ alternative splicing typically removes introns and ligates 
the exons. The 5’ cap is added at the same time, along with the polyadenylation at the 
3’ end of the transcript. 
 
 
The process of alternative splicing allows one gene to code for more than one 
protein isoform, often with tissue specific and functionally distinct cellular roles(36). 
Once processed, expression of the mature mRNA transcript can be regulated by 
small non-coding RNAs, including microRNAs, which can affect translational 
efficiency and allow for transcript degradation(128). MicroRNA expression is itself 
regulated, via changes to transcription or promotor hypermethylation and 
changes to microRNA processing and degradation, thereby adding a further level 
of regulation of gene expression(129). Following translation, the protein product is 
also subject to post translational modifications, including degradation via the 
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ubiquitination pathway, protein folding and phosphorylation which controls the 
activity of the product(130).  
 
1.4.2 Constitutive and alternative Splicing 
 
Constitutive splicing, where the mRNA molecule is spliced in exactly the same 
way each time,  occurs as part of mRNA processing and is the mechanism by 
which introns are excised and exons ligated to form the mature mRNA molecule, 
as shown in Figure 3(131, 132). Splice sites are defined by the GU residue splice 
donor sequences, the AG residue splice acceptor sequences, the A residue 
branch sites and the polypyrimidine tract. Splice site selection is also regulated 
by cis acting elements and trans acting factors, which variously act upon auxiliary 
splice site elements to enhance or inhibit splice events. These are termed exonic 
splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing 
enhancers (ISEs) and intronic splicing silencers (ISSs). Typically, though not 
absolutely, serine/ arginine rich SR proteins bind to enhancers, either ESSs or 
ISSs to promote splice site usage. Conversely, heterogenous nuclear 
ribonucleoproteins (hnRNPS) bind to silencers, either ESSs or ISSs, to inhibit 
splice site usage(131, 132).  
 
Following splice site recognition, the spliceosome complex is assembled and 
recruited, which is facilitated by completion of the consensus sequence from 
sequence residues surrounding the splice site(131). The spliceosome comprises 
five uridine rich small nuclear ribonucleoproteins (snRNPs), called U1, U2, U4, 
U5 and U6 and ~100 splicing factor proteins(132, 133).  Of these, U1, U2 and U5 
contain RNA recognition motifs (RRMs) which recognise specific sequences at 
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the intron-exon boundary. The splicing process then involves a two-step 
transesterification reaction where the first step cleaves the 5’ splice site forming 
a lariat structure known as the C complex. The second part of the reaction 
cleaves the 3’ end and ligates the two exons to form the mRNA molecule(131, 133). 
 
This process is achieved by the U1 snRNP being recruited to the 5’ splice site. 
Simultaneously, SF1 is recruited to the branch site, U2AF 65 to the polypyrimidine 
tract and U2AF 35 to the 3’ splice site, where it forms the E complex(133). SF1 
forms the A complex at the branch site with U2 and two U2AF subunits. U5 forms 
a trimer and is recruited to the 3’ splice site while U6 trimer replaces U1 at the 5’ 
splice site forming the B complex(131, 133). The subsequent dissociation of U4 
facilitates a reaction between U6 and U2 snRNPs which draws the 5’ splice site 
and branch site together. This allows formation of the lariat and the two exon 
coding regions to be ligated in the second step of the reaction(131, 132). U2, U5 and 
U6 snRNPs cleave the 3’ splice site to join the exons, after which the mature 
mRNA molecule is released, and the lariat degraded(131, 133), please refer to figure 
4, splicing and the spliceosome. 
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Figure 4 Splicing and the spliceosome.  
A. Formation of the E complex (commitment complex) and the A complex. This is formed 
by the association of the U1 snRNP with the 5’ splice site  
B. Formation of the B complex. An intermediary complex that is inactive until it undergoes 
conformational changes resulting from dissociation of U1 and U4 
C. Formation of the C complex and release of U4 and the lariat, this catalyses the second 
step of the splicing reaction.  
D. Spliced mRNA transcript. 
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1.4.3 Alternative Splicing 
 
As previously described, alternative splicing is the mechanism by which one gene 
can code for more than one protein isoform, please refer to figure 5(134, 135). In 
humans ~95% of genes are alternatively spliced allowing for protein isoform 
specificity in tissues and development, as well as functionally distinct protein 
isoforms in the same cell(134, 135). Alternative splicing typically involves the various 
inclusion or exclusion of exons, termed cassette exons, however, figure 6 shows 
the various types of alternative splicing. Exons can also be mutually exclusive, 
where one or the other must be excised(135-137). This form of splicing can allow for 
the inclusion of intron sequence, alternative splice sites, promoter sequences, 
alternative first exons and termination sites(137). It may also include non-coding 
sequence that has a regulatory role, such as regulation of translational efficiency 
or introduction of a premature stop codon to initiate nonsense mediated decay(138, 
139). Multiple splice events can occur at the same time and the process is 
dependent upon splice site recognition by the spliceosome(133). This activity is 
itself regulated by the competing actions of splice enhancers and silencers. In 
this way, alternative splicing acts as both a form of gene regulation as well as 
allowing for translation specific, development specific or functionally distinct 
protein isoforms(134, 136).  
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Figure 5 Schematic of constitutive and alternative splicing.  
Constitutive splicing refers to the excision of introns and inclusion of exons as part of 
mRNA processing. Alternative splicing allows for the excision or inclusion of cassette 
exons, as well as intronic, splice site, codon and promoter sequence inclusion. Such 
inclusions may include coding sequence or confer a regulatory role for the mRNA 
transcript. 
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Figure 6 Types of alternative splicing.  
Figure shows different types of alternative splicing: cassette exons, mutually exclusive 
exons, intron retention, alternative 5’ or 3’ splice sites, alternative promoters and 
alternative splicing and polyadenylation. 
 
 
 
  
Alternative splicing and polyadenylation 
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1.4.4 Alternative splicing and Type 2 Diabetes 
Alternative splicing is particularly important in response to cell stresses caused 
by the physiological changes associated with T2D. Different isoforms are 
expressed at varying points in endocrine cell development and in response to 
environmental conditions(134, 140). It has been shown that hepatic nuclear factor 1 
alpha (HNF1α), which regulates the insulin gene, can produce 3 transcript 
variants and specific mutations in these isoforms is associated with lower insulin 
production and development of diabetes(140, 141). The insulin gene (INS) itself is 
alternatively spliced with an intronic inclusion which confers increased 
translational efficiency of variants that have increased glucose 
responsiveness(142). Studies using monkey models of diabetes have also 
identified that impaired insulin sensitivity is associated with increased expression 
of the insulin receptor A isoform (IR A)(143). Protein tyrosine phosphatase non-
receptor type 1 (PTPN1) is a gene that is associated with beta cell function, 
insulin secretion and regulation of insulin signalling and has two functionally 
distinct isoforms. The long isoform has been shown to correlate with body fat 
percentage and is a biomarker for hyperinsulinaemia(144, 145). Oct4 has three 
isoforms, of which one, Oct4b, is important to stress response, while the other 
isoforms are linked to plasticity and the activation or repression of 
differentiation(134). It can also cause miRNA mediated degradation as a result of 
exon skipping, demonstrating a regulatory hierarchy from miRNAs to splicing 
networks. Further, alternative splicing is important to cell plasticity and stem cell 
pluripotency. Differentially expressed isoforms of OCT4, NANOG and SOX2 
produce functionally different protein counterparts at specific stages of beta cell 
differentiation(134). Downregulation of RNA binding proteins Epithelial Splicing 
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Proteins 1 and 2 (ESRP1 and ESRP2) is also important for epithelial to 
mesenchymal splicing changes inferring plasticity(134). Of note, it has also been 
shown that the splicing factor protein SRSF3 regulates insulin receptor exon 11 
skipping, which contains sequence that modulates insulin binding(146, 147). The 
neuron specific splicing factor NOVA1 has been shown to be highly expressed in 
human islets and at protein level in beta and alpha cells. In a study by Eizirik et 
al, knockdown of Nova1 has been shown to modify splicing in beta cells(40). Such 
examples highlight the importance of proper regulation of alternative splicing in 
T2D and diabetic disease. Regulation of splicing is therefore potentially critical to 
endocrine cell fate, particularly in the context of T2D. Intervening in this process 
via the use of small molecules, antisense oligonucleotides and morpholinos to 
regulate splicing events is already being explored in other diseases, such as 
Duchenne’s muscular dystrophy (DMD)(148). Stage 3 clinical trials are in process 
for pharmacological modulation of alternative splicing in DMD(148) and therefore 
characterising aberrant splicing events which contribute to T2D may also offer 
similar opportunities for small molecule splicing modifications in diabetes 
therapeutics.  
1.4.5 MicroRNAs 
 
MicroRNAs (miRNAs) are short non-coding RNA molecules of ~22 nucleotides 
(nts) which have roles in post-transcriptional gene regulation(128). Their main 
function is to act as a guide sequence that targets transcripts for degradation or 
repression via RNA-induced silencing complexes (RISC)(149). They have well 
defined roles in disease and are useful biomarkers as well as therapeutic 
treatment targets(150, 151). Single miRNAs are known to target multiple genes and 
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conversely, genes may be targeted by multiple miRNAs allowing many levels of 
regulation of gene expression(128, 152). The synthesis and transcription of miRNAs 
is itself tightly regulated(152, 153), as shown in figure 7. Pri-miRNA are transcribed 
in the nucleus from DNA template by RNA polymerase II (pol II)(149). This 
molecule is cleaved by the drosha enzyme into the step-loop pre-miRNA 
structure which undergoes nuclear export via the exportin-5, Ran and GTP 
complex(149, 153). In the cytosol dicer cleaves the pre-miRNA into two short strands 
that are incorporated into the RISC complex, which includes argonaute 2 (Ago2) 
proteins(149, 153, 154).  Target mRNA transcripts are recognised by their sequence 
complementarity to the first 6-8 nts of the miRNA known as the seed region. 
Through complementary base pairing the miRNA is able to bind to mRNA 3’ 
regions(149).  
Figure 7 microRNA synthesis.  
Schematic shows synthesis of pri-miRNA from DNA template by RNA polymerase II, 
cleavage by drosha to form the pre-miRNA molecule and nuclear export by exportin 5. 
In the cytoplasm pre-miRNA is cleaved by Dicer to form the mature miRNA and 
degradation of transcripts by the RISC complex. 
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1.4.6 MicroRNAs and Type 2 Diabetes 
 
A number of miRNAs are implicated in the pathogenesis of T2D in relation to 
glucose homeostasis, beta cell differentiation and survival and response to cell 
stress, please refer to table 1(155). Studies on miR-375 in rodent models show that 
it is implicated in impaired glucose sensitive insulin secretion (GSIS)(155, 156). 
Similarly, increased miR-187 expression in human islets correlates with reduced 
GSIS(156).  Dysregulation of miRNA expression has also been linked with impaired 
insulin secretion(157). In particular, reduced expression of miR-185 is seen in T2D, 
which in turn correlates with blood glucose concentration and impaired insulin 
secretion(158, 159). Beta cell microRNAs directly target components of the insulin 
secretory machinery(160) in response to hyperglycaemia. Poor glucose 
homeostasis leading to ER stress induces stress induced miR-708 expression, 
which is again linked to impaired GSIS(161).  
 
There are also well-established roles for miRNAs in relation to beta cell 
differentiation. Notably, miR-375 is absolutely required for both pancreatic 
development and mature beta cell differentiation(162, 163). Regulation of beta cell 
mass by miR-375 during beta cell differentiation is conserved between species 
and the location of binding sites for beta cell differentiation genes PDX1, NGN3, 
and NEUROD1 have been identified in enhancer regions that are required for full 
miR-375 gene activity(164, 165). Studies of the role of microRNAs during pancreatic 
development in rodents and humans have identified that Dicer is required for 
pancreatic lineage differentiation(155, 166, 167). Dicer1 null mice show a significant 
reduction in Ngn3 positive progenitor cells along with decreases in endocrine cell 
mass(166, 168). Expression of a number of miRNAs are known to be altered during 
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beta cell differentiation(169), however, microRNA expression patterns differ 
significantly between species, highlighting the importance of using human model 
systems when studying T2D in man(164, 169, 170).  
 
MicroRNAs are also required for the maintenance of mature beta cell 
differentiation status by repressing the expression of disallowed beta cell genes 
as well as by mediating beta cell responses(171). Studies in rodents and human 
islets have shown that microRNAs are essential for beta cell response to the 
obesity related stresses hyperglycaemia, dyslipidaemia, ER stress, inflammation 
and hypoxia(156, 172-175). The cellular stress response is intimately connected with 
miRNA expression, with stress granules linked to miRNA regulation(176) and 
increased expression of Dicer complex proteins associated with increased stress 
tolerance(177, 178).  The miR-200 family is known to regulate beta cell apoptosis(160) 
and miRNA regulation of beta cell responses to inflammatory factors have also 
been shown to induce apoptosis(151). miR-7 and mir-708 are known to regulate 
beta cell proliferation(161, 169) and miR-708 is associated with increased rates of 
apoptosis(161). 
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Table 1 MicroRNAs implicated in T2D(160, 164, 179) 
Table shows microRNAs that have been experimentally validated to have well 
established roles in beta cell function and are known to target genes with known roles in 
beta cell differentiation and function. 
 
 
MicroRNA ID Role in beta cell function 
miR-7 Inhibition of insulin signalling and beta cell proliferation 
let-7a Beta cell insulin signalling, pancreas development 
miR-9 Inhibition of insulin signalling 
miR-15a Increased insulin biosynthesis 
miR-21 Beta cell apoptosis and survival 
miR-29 Inhibition of GSIS. Overexpression causes apoptosis 
miR-30a Targets NEUROD1 – role in glucotoxicity 
miR-30-d Increases insulin expression by increasing MAFA 
miR-34a Beta cell differentiation and beta cell apoptosis 
miR-124 Beta cell differentiation, proliferation and insulin secretion 
miR-148 Targets ABCA1, decreases insulin mRNA 
miR-152 Negatively affects insulin secretion 
miR-199a Targets mTOR signalling: insulin secretion 
miR-375 Decreases GSIS via Mtpn, decreases insulin gene via PDK1, increases 
beta cell proliferation 
 
 
1.4.7 Epigenetic modifications 
 
Alongside these mechanistic changes, inheritance of epigenetic information from 
environmental stimuli can regulate pancreatic endocrine cell identity (59, 101, 180). 
An example of this is seen where ARX is bound by the protein MeCP2, thereby 
linking two epigenetic processes: methylation and histone modification. In a study 
looking at the effects of activating and repressing epigenetic histone 
modifications in alpha, beta and exocrine cells, PDX1 was shown to have a gene- 
activating H3K4me3 modification in beta cells(62, 101); however, in alpha cells, 
there is bivalent marking of both activating and repressing modifications(101).  
Further, in beta cells ARX expression is downregulated via the presence of the 
repression histone mark H3K27me3. This suggests that the presence of bivalent 
epigenetic modifications relates directly to increased plasticity(181). Studies have 
identified the ARX gene as methylated and repressed in beta cells, whereas it is 
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hypomethylated and highly expressed in alpha cells. In a study by Dhawan et 
al.(62) the ARX locus in beta cells was bound by MeCP2 protein, which methylates 
the histone H3R2, thereby linking methylation and histone modification. DNMT1 
propagates methylation of ARX during cell division, and by doing so, preserves 
beta cell identity, effectively stopping them from becoming alpha cells(62). In 
Dnmt1 ablated cells there was a gradual switch in cell identity from beta cell to 
alpha cell. Insulin and glucagon staining also revealed dual secreting cells(62). In 
mice it is considered that the switch is gradual because Dnmt1 propagates 
methylation during cell division and so effects are only seen in the progeny(62). It 
is thought that Dnmt1 knockout causes passive demethylations linked to rates of 
beta cell replication and newly divided cells are not able to re-enter the cell cycle 
after cell division(62). 
 
1.5 Developments in human model systems  
 
1.5.1 Human beta cell lines 
 
The recent development of the EndoC human beta lines by Scharfmann et al.(182, 
183) has offered a practical alternative to the use of rodent-derived cell lines in the 
study of diabetes. This cell line was created by transduction of foetal pancreatic 
buds using an SV40LT lentiviral vector controlled by the insulin promoter and 
grafted into SCID mice to develop into pancreatic tissue(182). This allowed beta 
cell differentiation and proliferation of insulinomas which were subsequently 
transduced with human telomerase reverse transcriptase (hTERT) and re-grafted 
into SCID mice to amplify beta cell proliferation(182). To culture the cell line, the 
transplanted grafts were removed and cells dissociated to expand in culture(183).      
Physiological characterization of the targeted oncogene-derived cell lines has 
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shown that EndoC-βH1 cells contain and secrete insulin in response to glucose 
stimulation and are stable at least for 80 passages, although it is worth noting 
that the EndoCBH1 cell line contains only 10% of the insulin seen in normal beta 
cells(184). Characterization of physiological changes across passages is also yet 
to be realized and requires investigation. Despite these compromises, however, 
gene expression profiling has shown that they express all key beta cell markers 
at both gene and protein level. Further, they exhibit characteristics that more 
closely mimic human beta cells than other permanent murine cell lines, with 
higher levels of glucose-sensitive insulin secretion and no response to pyruvate 
and lactate, when compared with rodent cell line equivalents(185). A recent study 
from Gloyn and Rorsman et al showed that they share many of the same 
electrophysiological characteristics as primary human beta cells and from this 
perspective make an effective model(186).  
 
Given the differences in levels of gene expression in key transcription 
factors between mice and humans, as described above, the EndoC cell lines are 
more appropriate to studies involving the genetic characterization of the 
physiological effects of diabetes on beta cell function as they carry the human 
genome. This facilitates a deeper understanding of the transcriptomic changes 
associated with T2D on mRNA processing and epigenetics. In comparison to the 
use of isolated human pancreatic islets, human beta cell lines are less affected 
by admixtures of other islet cell types. The EndoC βH2 and βH3 cell lines that 
have since been developed also offer the potential for excision of the 
immortalizing trans-gene, and early physiological characterization suggests they 
are closer to human beta cells(185). Although the EndoC βH1 cell line has many 
characteristics which make it a good model for studying human disease, there 
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are nevertheless a number of issues that need to be considered relating to their 
use. This is an immortalised cell line and so it is not possible to use this model to 
investigate the effects of ageing on beta cell function. Similarly, they are not, in 
isolation, a good model to study lifestyle factors like BMI, gender and activity 
level, which would be better studied by incorporating other model systems into 
the study, such as ex vivo islets. As a beta cell-only monolayer culture the model 
is also an imperfect model for investigating effects of cell-cell interactions and, 
again, it would be preferable to include the use of human islets. Despite these 
considerations, the EndoC βH1 cell line is a significant advancement in the study 
of diabetes using human models.  
 
1.5.2 Islets 
 
The use of isolated human islets in research has been vital to research into T2D, 
enabling greater understanding of the behaviour of beta cells in response to a 
diabetic microenvironment within the context of native islet biology(187); however, 
there are a number of difficulties around their usage for research, not the least of 
which is that of supply and demand. Islets are a precious resource that is difficult 
to obtain, which stands at odds with the requirement for high-volume availability 
in order to satisfy repeated experimentation(187). Alongside these issues, it is well 
documented in the literature that lack of standardization in pancreas and islet 
processing can result in impure or compromised samples. This can result in 
hypoxia, contamination from other pancreatic cell types and a high incidence of 
beta cell death(96, 187, 188). Despite these challenges, the significant differences 
between murine and human islet architecture mean that the use of isolated 
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human islets, in conjunction with human beta cell lines, is the most robust 
approach for researching human disease. 
 
1.5.3 Stem cells 
 
Human embryonic stem cells (HESCs) are derived from undifferentiated cells 
taken from the embryonic blastocyst which have been donated to research. As 
such, there are a number of ethical considerations surrounding their use. In 
contrast, induced pluripotent stem cells (iPSCs) result from fully differentiated 
adult cells, from human donors, that have been transfected to temporarily 
express transcription factors involved in the determination of cell fate. As such, 
there are fewer ethical considerations(189). 
 
Both HESCs and iPSCs have been used to generate pancreatic beta cells, with 
varying success. Some of the difficulties encountered have included observations 
that stem cell-derived beta cells had a fetal, rather than adult beta cell phenotype, 
as well as some important differences in gene expression profiles(190-193). More 
recently, there has been progress using step-wise differentiation protocols, which 
has overcome many of these issues, and trials are currently being conducted for 
the use of stem cell-derived beta cells in the treatment of type 1 diabetes(189, 192, 
194). Disagreements remain, however, over the status, characterization and 
assessment of maturing versus mature stem cell-generated beta cells. Currently, 
as indicated above, combined use of isolated human islets and human beta cell 
lines remains the most practical method for research into T2D. 
 
 
 
 
 
62 
1.6 Conclusion 
 
As discussed, apoptosis may not account for the extent of beta cell mass loss 
seen in T2D, and loss of beta cell function relates to changes in beta cell 
differentiation status along with disruption to beta cell function genes. Most of the 
work in this field has been carried out using murine models, but differences 
between murine and human islet structure make definite comparison difficult. 
This, coupled with mechanistic differences in gene expression between species, 
means that these studies need to be corroborated in human models. 
Understanding these processes in newly available human beta cell lines will 
elucidate whether changes to beta cell differentiation status account for some of 
the beta cell mass loss that is seen in T2D in humans. This would be an important 
step in characterizing the mechanisms that lead to beta cell failure and could 
inform potential future therapies. The studies within this thesis have been 
performed under the auspices of Animal Free Research UK policies which state 
that animal products could not be used.  
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1.7 Research hypothesis 
 
We believe that altered RNA processing or gene regulation, caused by 
cellular stresses associated with T2D, can affect mature beta cell 
differentiation status. The beta cell mass loss that is seen in T2D is due, in 
part, to loss of beta cell function as a result of changes in beta cell 
differentiation status.  
 
1.8 Aims and objectives of thesis 
 
It has been shown in mouse models that changes in mature beta cell 
differentiation status occur in response to cellular stresses seen in T2D(61). The 
objective of this thesis is to investigate whether cellular stresses, associated with 
T2D, alter mature beta cell differentiation status in humans. Such a finding would 
be important because changes in beta cell differentiation may be identified as an 
important feature of the disease in humans. This may also offer potential 
treatment targets in the management of the disease.  
 
I have assessed this by investigating the importance of species origin on the 
cellular microenvironment for the EndoC H1 human cell line. This established 
physiologically relevant culture conditions in which to assess the effect of cell 
stresses associated with T2D including: altered glycaemia, hypoxia, 
dyslipidaemia, inflammation and the ER stress inducer tunicamycin.  I have used 
this model to identify changes in the expression of relevant beta cell genes, 
altered splicing factor expression and dysregulated expression of specific 
alternatively spliced genes.  This led to development of a hypothesis, where 
dysregulated splicing may be an important feature of altered mature beta cell 
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status. To support these data, I have investigated changes in protein expression 
in both the EndoC H1 model and in situ islets from patients with long duration 
T1D and T2D. Having identified important changes in protein expression, I 
investigated the hypothesis that removal of cell stresses may allow ‘rescue’ of a 
mature beta cell phenotype.  
 
I have then gone on to assess the fine control of gene regulation by investigating 
altered microRNA expression in response to these cell stresses. This included 
gene enrichment analysis of the most altered microRNAs to identify the pathways 
implicated in stress response, along with subsequent validation of these target 
genes. I will describe in more detail the specific aims of this thesis within each 
data chapter.  
 
1.8.1 Chapter 3: Determining the effect of species origin of the cellular 
microenvironment  
 
Summary 
 
The aim of chapter 3 was to investigate the importance of the species origin of 
the cellular microenvironment.  This allowed the development of an optimised, 
physiologically relevant, set of culture conditions from which to assess the effects 
of cell stresses in a human beta cell model system.  The aim was for work from 
this chapter to form the basis for ongoing investigation of the effects of cell 
stresses associated with T2D on beta cell differentiation status.  To investigate 
the effects of species origin, I aimed to culture cells using non-human reagents 
and compare this to cells cultured in human derived reagents. This incorporated 
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assessment of altered gene expression for a panel of relevant beta cell genes. I 
aimed to investigate beta cell function by assessing changes in glucose sensitive 
insulin secretion between non-human and human culture reagents. To assess 
the effects of species origin, I aimed to use immunofluorescence microscopy to 
investigate the expression of markers of mature beta cell status.  
 
1.8.2 Chapter 4: Determining the effect of cellular stressors on beta cell 
differentiation status 
 
Summary 
 
The aim of chapter 4 was to investigate the effects of the cell stresses 
hyperglycaemia, hypoglycaemia, hypoxia, dyslipidaemia, inflammation and ER 
stress inducer tunicamycin, on beta cell differentiation status in man. This utilised 
the optimised EndoC H1 cell line, demonstrated in chapter 3, along with in situ 
pancreatic islets from patients with T1D and T2D. We hypothesized that these 
cell stresses would dysregulate the expression of relevant beta cells genes, 
chosen for roles in beta cell fate and function, markers of cell stress and markers 
for other pancreatic endocrine islet cell types. I aimed to use this targeted 
transcriptomic profiling to analyse altered splicing factor expression and changes 
in the isoform expression of specific alternatively spliced genes. I further aimed 
to investigate changes in hormone expression in response to the cell stresses 
using immunofluorescence microscopy in both the cell model and cases from 
patients with long duration T1D and T2D. Having identified changes in protein 
expression I aimed to investigate whether the removal of cellular stresses allowed 
rescue of a mature beta cell phenotype.  
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Following on from this work, we hypothesized that beta cell differentiation status 
may be influenced by dysregulated splicing. To investigate this, I designed an 
siRNA knock down to determine the effects of alternative splicing of PAX6 on 
beta cell stress response. This gene was selected due to the earlier work which 
showed it’s splicing was dysregulated in response to the cell stresses and its 
importance in the maintenance of mature beta cell differentiation status(195-197). 
Our group were also aware that the AKT pathway, and its downstream effector 
FOXO1, have been implicated in regulation of splicing and is also important to 
pancreatic plasticity(104, 198). We hypothesized that altered FOXO1 expression 
may influence regulation of splicing and investigated this using SH6 small 
molecule inhibition of the AKT pathway. 
 
1.8.3 Chapter 5: Cellular stress responses may be coordinated by microRNAs 
 
Summary 
 
In Chapter 5 I aimed to investigate the fine control of gene regulation by 
assessing altered microRNA expression in response to the cell stresses. To 
identify targets for further investigation, I performed a global high throughput 
assay of the expression of 757 microRNAs using the EndoC H1 cell model. 
From this, I aimed to validate the altered expression of selected microRNAs 
known to target relevant beta cell genes and compared this to changes in the 
expression of their targets.  Along with this, I aimed to select the most altered 
microRNAs from the global screen for validation and use these results for gene 
enrichment analysis. Having identified the pathways and gene targets implicated 
 
 
 
67 
in EndoC H1 responses to these cellular stresses, I aimed to validate these 
targets to determine whether they showed changes in expression in response to 
the cell stresses. 
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Chapter 2: 
 
Methods 
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2.1 Tissue culture  
 
2.1.1 General Culture conditions for EndoC-βH1 cells  
 
Throughout this study EndoC-βH1 cells were used, obtained from EndoCells, 
INSERM in France. They are a human beta cell line developed by transducing 
human pancreatic foetal buds with a lentivirus that is then grafted into severe 
combined immune-deficient mice (SCID)(199). As a result, the cells express the 
Simian Virus 40 large T antigen (SV40LT) oncogene(199). Following this, they 
were then expanded in culture to create cell lines(199). The cells are stable for up 
to 80 passages(183), however, in this study all of the cell treatment assays were 
carried out <P25. Here, the cells were cultured for 7 days between passages in 
T25 flasks and were fed once per week by removing half of the old culture media 
and replacing it with fresh media. Coating medium was prepared in, as described 
below, and the flasks were incubated for minimum of 5 hours prior to passage. 
The coating medium was then removed and immediately replaced with culture 
medium to prevent the matrix from drying out. The cells were passaged and 
seeded into the prepared T25 flasks at a density of 1.75 x 106/ μL and showed 
mean population doubling times of 19hrs.  
 
2.1.2 Standard culture conditions for EndoC-βH1 cell microenvironment using 
animal derived reagents 
 
EndoC βH1 cells (Endo Cells, INSERM, France) were cultured in accordance 
with the published guidelines(182, 183, 199). Cells were seeded  onto  an ECM coat 
consisting of DMEM 4.5 g/ L (Thermo Fisher, Waltham, MA USA), matrigel 
(100 μg/ mL) fibronectin from bovine plasma 2 μg/ mL coat (both from Sigma-
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Aldrich, Steinheim, Germany), and cultured in DMEM 1 g/ L glucose (Thermo 
Fisher, Waltham, MA, USA) 2% BSA fraction V (Merck Chemicals, 
Darmstadt, Germany), 10 mM nicotinamide (Sigma-Aldrich, Steinheim, 
Germany) 50 μM      β-2-Mercaptoethanol,  5.5 μg/ mL transferrin,  6.7 ng/mL 
sodium  selenite, and 100 U/ mL penicillin and 100 μg/ mL streptomycin (Sigma 
Aldrich, Steinheim,  Germany) 
 
2.1.3 Modified culture conditions for EndoC βH1 cell microenvironment using 
human derived reagents 
 
EndoC-βH1 cells were cultured on Maxgel ECM mixture liquid (Sigma 
Aldritch, Steinheim, Germany) containing fibronectin from human plasma 
(Sigma-Aldritch, Steinheim, Germany). Culture medium (DMEM 1 g/ L 
glucose, Thermo Fisher Waltham, MA USA) contained 2% human serum 
albumin fraction V (Merck Chemicals, Darmstadt, Germany), 100 U/ mL 
Penicillin and 100 μg/ mL streptomycin, 50 μM β-2-Mercaptoethanol (Sigma- 
Aldrich, Steinheim, Germany), 10 mM nicotinamide (Sigma Aldritch 
Steinheim, Germany), 5.5 μg/ mL human transferrin (Sigma Aldritch, 
Steinheim, Germany) and 6.7 ng/ mL of sodium selenite  (Sigma  Aldritch,  
Steinheim,  Germany).  Cells were passaged using TRYPLE 1x (Thermo 
Fisher, Waltham, MA, USA) and neutralised with heat inactivated human 
serum from human male AB plasma (Sigma Aldritch, Steinheim, Germany). 
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2.1.4 Glucose-stimulated insulin secretion 
 
The insulin enzyme linked immunoassay (ELISA) kit used in the study was 
a sandwich ELISA for insulin which utilizes an antibody that is immobilized 
onto the microplate wells along with a horse radish peroxidase (HRP) 
enzyme. Sandwich ELISAs have sample bound between two primary 
antibodies, one of which is a reporter and are considered to be the most 
sensitive assays for quantitatively determining the amount of analyte in 
samples(200). In this instance, the sample was incubated in the ELISA 
microplate along with the HRP labelled reported antibody and then washed 
after the 2 hr incubation period to remove the unbound antibody. The 
substrate solution was then added and incubated for 15 minutes before the 
reaction was stopped. 
 
To ensure parity of cell number, cell counts were used to ensure equal 
numbers of cells were plated in each well, with. EndoC-βH1 cells seeded 
onto 24 well plates at 4 × 105 per well and cultured for 72 hrs in separate 
cultures. Cells were then transferred to a culture medium containing 2.8 mM 
glucose as a starvation medium and cultured overnight, before being 
incubated for 1 hr in a starvation medium containing 0.5 mM glucose in 
HEPES Krebs Ringer Buffer (KRB) at  pH 7.4 containing: 116 mM/ L NaCl, 
5 mM/ L KCl, 1 mM/ L CaCl2, 1 mM/ L MgCl2, 1.2 mM/ L KH2PO4, 24 mM/ L 
NaHCO3, 10 mM/ L HEPEs, 0.2% Human Serum Albumin (HSA). After 1 hr, 
the 0.5 mM glucose starvation HEPES KRB starvation buffer was removed and 
replaced with HEPES KRB containing 20 mM glucose and cells incubated for 
1 hr. Media was removed from each sample, spun at 1000 g for 5 min to 
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remove protein debris and supernatant harvested for comparison with 
controls using the ELISA against fully processed human insulin. (Human 
Insulin ELISA, Crystal Chem, Downers Grove, IL, USA, assay range 0.9 - 
220 mU/ L, analytical sensitivity 0.25 mU/ L, precision CV < 10%, 1.2% 
cross reactivity with pro insulin). Absorbance was measured using a plate 
reader and measured A450 values, subtracting A630 values. Insulin levels 
were normalized to total protein. 
 
2.1.5 EndoC-βH1 insult assays to mimic diabetic microenvironment 
 
2.1.5.1 Hyperglycaemia and Hypoglycaemia 
 
For all assays the cells were seeded at 1.00 x 106/ μL in 6 well plates and cultured 
for 72 hours prior to treatment. In line with published hyperglycaemia 
methodologies, media containing 25 mM glucose was used to mimic 
hyperglycaemia across 24 hr, 36 hr and 48 hr time points in three separate 
cultures (n=3 for each time period)(46, 201).  This method was duplicated for 
hypoglycaemia but cells were treated with media containing 2.5 mM glucose 
across the same time periods (n=3 for each time period). Controls were cultured 
in media containing 1g/ L glucose across the same time periods (n=3 for each 
time period).  
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2.1.5.2 Hypoxia 
 
Cells were seeded at 1.00 x 106/ μL in 6 well plates and cultured for 72 hrs prior 
to treatment. To investigate the effects of hypoxia, separate cell cultures were 
placed in New Brunswick Galaxy 170R nitrogen fed, oxygen controlled, hypoxia 
incubators and exposed to 3% and 1% oxygen respectively across 4 hr, 12 hr 
and 24 hr time points (n=3 for each condition and each time point)(51, 202). Controls 
were maintained at usual cell culture protocols of 19% oxygen(203). 
 
2.1.5.3 Lipotoxicity 
 
Cells were seeded as previously described and cultured for 72 hrs prior to 
treatment. The effects of lipotoxicity were assessed by treatment with 0.5 mM 
Palmitic Acid conjugated to BSA as an ethanol carrier over 12 hrs, 24 hrs and 48 
hrs (n=3 for each time point)(29, 54, 204). Controls and BSA only controls were 
cultured in standard culture media with the addition of ethanol to account for its 
use as a carrier in treated cells (n=3 for each time point).  
 
2.1.5.4 Inflammatory cytokines 
 
Cells were seeded as previously described and cultured for 72 hrs prior to 
treatment. Inflammation was induced using the pro-inflammatory cytokines TNF𝛼 
at 1000 U/ mL, INF at 750 U/ mL and IL1 at 75 U/ mL over 12hrs, 24hrs and 
36hrs (n=3 for each time point)(39, 56, 205). Controls were cultured in standard 
culture media for the same time periods (n=3 for each time point).  
  
 
 
 
74 
2.1.5.5 Induced Endoplasmic Reticulum stress 
 
Endoplasmic Reticulum (ER) stress was induced using 0.5 mM Tunicamycin.(38, 
206) Cells were seeded as previously described and cultured for 72 hrs prior to 
treatment with Tunicamycin for 24hrs. For rescue from ER stress, after 24 hrs 
treatment cells were restored to normal culture media for a further 72 hrs (n=3 for 
each condition including controls).  
 
2.1.5.6 Palmitate and oleate test of metabolic response 
 
Metabolic response to cell treatments was tested via administration of 0.5 mM 
palmitic acid versus 0.5 mM oleic acid, as oleic acid is known to not cause beta 
cell stress(207). Cells were seeded as previously described and initially cultured 
for 72 hrs prior to treatment with either palmitic acid or oleic acid. A further 
treatment combining both 0.5 mM palmitic acid with 0.5 mM oleic acid was carried 
out for the same time points (n=3 for all conditions and controls) Controls were 
treated with the empty EtOH carrier. 
 
2.1.5.7 Phenotype rescue 
 
As previously, cells were seeded at 1.00 x106 / μL in 6 well plates. Determination 
of phenotype ‘rescue’ was investigated by culturing cells for 48 hours prior to 
treatment with 25 mM glucose for 24 hrs. It was not possible to culture the cells 
for 72 hrs prior to treatment as this would not have allowed sufficient time to 
‘rescue’ in 5 mM glucose, euglycaemic, media before the cells became overly 
confluent. After 24hrs of exposure to 25 mM glucose cells were restored to normal 
culture media containing 5 mM glucose for a further 72hr (n=3 for each condition 
including controls).  
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2.2 Immunofluorescent cytochemistry. 
 
Immunofluorescence staining was used to determine the expression of mature 
beta cell markers, as well as islet cell hormones, in EndoC-βH1 cells grown in 
conditions mimicking a diabetic microenvironment. Cells were fixed with 4% 
paraformaldehyde for 15 minutes at 4oC. Primary antibodies for PDX1 (Abcam 
Ab47267, rabbit polyclonal, 1/400), NEUROD1 (Abcam Ab60704, mouse 
monoclonal, 1/400), PAX6 (Abcam Ab195045, rabbit monoclonal, 1/350), 
Somatostatin (SST) (Abcam Ab30788, rat monoclonal, 1/200) and Glucagon 
(GCG) (Abcam Ab10988, mouse monoclonal, 1/2000) were diluted in phosphate 
buffered saline (PBS) with 0.1M Lysine, 10% donor calf serum, 0.02% sodium 
azide and 0.02% Triton (ADST), to permeabilise the cell membranes and 
incubated overnight. Primary antibodies were visualised using highly cross-
absorbed secondary antibodies (Life Technologies) diluted in ADST at 1/400: 
goat anti-rabbit Alexa Fluor 555 for PDX1 and PAX6 at 1/400, goat anti-mouse 
Alex Fluor 555 for NEUROD1 at 1/400, goat anti-rat Alex Fluor 488 for SST at 
1/400 and goat anti-mouse Alexa Fluor 488 for GCG at 1/400 and incubated for 
1 hour. Coverslips were then sequentially stained with insulin antisera (80564, 
LN10088287 Dako) and diluted in ADST at a concentration of 1/400 and 
incubated for 1 hour. Coverslips were then incubated with an appropriate 
secondary goat anti guinea-pig Alex Fluor (dependent on the Alexa Fluor utilised 
to recognise the first antisera) along with DAPI (Sigma-Aldritch D9542), were 
diluted in ADST at respective concentrations of 1/400 and 1μg/ ml. Slides were 
visualised using a LEICA DM4000 B-LED fluorescence microscope using LAS X 
image software. For fluophore filters details please refer to table 2. Due to 
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constraints on the use of animals, antibodies were not validated in knock out 
tissue.  
2.2.1 Image analysis 
 
Quantification of the proportion of somatostatin positive cells within the culture 
was achieved by cell count from images taken blinded to the somatostatin 488 
nm wavelength. Ten randomly selected images from 3 treated and 3 controls 
were taken for each assay. Images were visualised and analysed using Image J 
software and were normalised to the same settings for brightness and 
contrast(208). 
 
Table 2 Fluophore filter excitation and emission details 
 
Fluophore Colour Excitation/ 
Emission 
Excitation 
filter 
Emission 
Filter 
Platinum bright 
405 
Dark 
Blue 
410/455 405/10 460/36 
Platinum bright 
495 
Green 495/517 495/25 537/29 
Platinum bright 
550 
Red 550/580 546/22 590/23 
Platinum bright 
647 
Far red 587/612 580/25 625/30 
 
 
2.3 Immunofluorescent characterisation of pancreatic tissue sections 
from patients with T1D and T2D  
 
Immunofluorescence staining was used to determine the expression of islet cell 
hormones in pancreatic sections from individuals with no diabetes (n=7), patients 
with Type 1 Diabetes (T1D) (n=7) and also patients with T2D (n=7). Tissue 
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sections were utilised from two pancreatic biobanks, the Exeter Archival Diabetes 
Biobank (EADB, UK) and the JDRF network of Pancreatic Organ Donors with 
Diabetes (nPOD, USA) that contain both organ donor and post mortem tissue, 
please refer to supplementary table S2 for patient data.  Tissue sections were 
soaked for 2 x 5 minute washes in Histoclear to remove the HgCl2 or BF fixation 
and rehydrated using 1 min incubations in 100% EtOH, 90% EtOH, 70% EtOH, 
100%MeOH, with a final 5 minutes incubation in ddH2O. Heat induced epitope 
retrieval (HIER) using a citrate pH6 buffer was carried out for 20 minutes.   
Following a block in 5% normal goat serum tissue sections were incubated with 
the following primary antibodies against SST (Abcam Ab30788, rat monoclonal, 
1/200) and GCG (Abcam Ab10988, mouse monoclonal, 1/2000) were diluted in 
DAKO antibody diluent (Dako SO809) and incubated for 1 hour. The primary 
antibodies were visualised using highly cross-absorbed secondary antibodies 
(Life Technologies) diluted in Dako antibody at 1/400: goat anti-rat Alexa Fluor 
488 for SST and goat anti-mouse Alexa Fluor 555 for GCG and incubated for 1 
hour. This was followed by sequential staining with insulin antisera (80564, 
LN10088287 Dako) diluted in Dako antibody diluent at a concentration of 1/360 
and incubated for 1 hour. This was visualised using a secondary goat anti guinea-
pig Alexa Fluor 647 along with DAPI (Sigma-Aldritch D9542), that were diluted in 
Dako antibody diluent at respective concentrations of 1/400 and 1 μg/ μL and 
incubated for 1 hour. Slides were visualised using a LEICA DM4000 B-LED 
fluorescence microscope using LAS X image software. For fluophore filters 
details please refer to table 2   
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2.3.1 Image analysis 
 
Quantification of pancreatic endocrine cells types within the islet was achieved 
by assessing the comparative number of cells as a percentage of total islet area 
between T1D/ T2D patients and controls. Images from 10 randomly selected 
islets from 7 cases and controls were taken. Areas of somatostatin, insulin and 
glucagon staining were selected and measured using Image J(208). 
 
2.4 Candidate genes for expression analysis 
 
Target genes were selected for their roles in beta cell fate, maturity and function. 
Transcription factors with roles in the regulation of beta cell fate were also 
selected, including: PAX4, PAX6, PDX1, NEUROD1, FOXO1, NKX6.1, and 
NKX2.2 as well as the tumour suppressor STK11 (LKB1)(42, 43, 57, 90, 94, 107, 196, 197). 
Key genes to beta cell function genes were also chosen, including: INS, GCK, 
MAFA, MAFB, PTPN1, SLC2A2, SLC2A4 and SYP(58, 85, 107, 144, 209-211). To 
investigate cellular plasticity, genes with roles in beta cell differentiation were 
selected, including: NGN3, SOX9, NANOG, POU5F1 and HES1(61, 86, 103, 212-215). 
Selection also included SLC16A1 and LDHA, genes that are typically disallowed 
in beta cells due to their roles in inappropriate insulin release as a result of lactate 
and pyruvate metabolism in response to exercise (91, 171, 216). Alongside these, the 
target panel included genes associated with cell stress and apoptosis, including 
MYC, ARNT, HIF1a and DDIT3(39, 45, 51, 103, 217-219). Finally, genes that are markers 
for other endocrine pancreatic islet cell identity were selected, ARX and GCG as 
alpha cell markers, as well as SST and HHEX, the delta cell associated gene for 
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the hormone Somatostatin(62, 92, 96, 99, 113, 220). For gene names, roles and assay 
IDs please refer to table 3. 
 
Table 3 Gene assay IDs.  
 
Target panel of genes selected for their roles in beta cell fate and function, markers for 
increased plasticity and cell stress and markers for other pancreatic endocrine cell types. 
 
 
Gene 
Symbol 
Assay ID Role in beta cells 
GUSB Hs00939627_m1 Housekeeper 
PPIA Hs04194521_s1 Housekeeper 
HPRT1 Hs02800695_m1 Housekeeper 
STK11 Hs00176092_m1 Beta cell function 
FOXO1 Hs01054576_m1 Beta cell differentiation and beta cell function 
PAX6 Hs00240871_m1 Beta cell differentiation and beta cell function 
GCK Hs01564555_m1 Beta cell function 
MAFA Hs01651425_s1 Beta cell function 
NKX6-1 Hs00232355_m1 Beta cell differentiation and beta cell function 
NEUROD1 Hs01922995_s1 Beta cell differentiation and beta cell function 
NKX2-2 Hs00159616_m1 Beta cell differentiation and beta cell function 
INS Hs00355773_m1 Beta cell function 
PDX1 Hs00236830_m1 Beta cell differentiation and beta cell function 
PTPN1 Hs00942477_m1 Beta cell function 
SLC16A1 Hs01560299_m1 Lactate/ pyruvate solute carrier – disallowed in beta cells 
SYP Hs00300531_m1 Beta cell function 
LDHA Hs01378790_g1 Lactate/ pyruvate solute carrier – disallowed in beta cells 
PAX4 Hs00173014_m1 Beta cell differentiation and beta cell function 
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Gene 
Symbol 
Assay ID Role in beta cells 
MAFB Hs00271378_s1 Beta cell function 
SLC2A2 Hs01096908_m1 Beta cell function 
ARX Hs00292465_m1 Alpha cell differentiation and function 
GCG Hs01031536_m1 Alpha cell function 
SST Hs00356144_m1 Delta cell function 
HHEX Hs00242160_m1 Delta cell marker 
SOX9 Hs01001343_g1 Beta cell progenitor marker 
NEUROG3 Hs01875204_s1 Beta cell progenitor marker 
HES1 Hs00172878_m1 Beta cell progenitor marker 
POU5F1 Hs04260367_gH Beta cell progenitor marker 
NANOG Hs04399610_g1 Beta cell progenitor marker 
HIF1A Hs00153153_m1 Hypoxia marker 
ARNT Hs01121918_m1 Cellular stress and hypoxia marker 
MYCL Hs00420495_m1 Cellular stress and proliferation marker 
DDIT3 Hs00358796_g1 Cellular stress and apoptosis marker 
 
2.5 Alternatively spliced genes candidate selection 
 
Five genes were investigated for the effects of microenvironment on alternative 
splicing. The genes were selected from the existing target panel based on three 
criteria: it was possible to design probes that differentiate between the isoforms, 
there are known functional differences between the isoforms, and isoform 
differences are relevant to the pancreas. Please refer to table 4 for assay IDs. 
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2.5.1 Insulin 
 
Human Insulin (INS) contains 3 exons. Exon 1, intron 1 and the first section of 
exon 2 contain the 5’ untranslated region (UTR) and so are likely to be 
regulatory(142, 221). Exon 2 encodes the signal peptide, the B chain and part of the 
c-peptide. Exon 3 encodes the rest of the C-peptide and the A chain. Both of the 
2 introns are flanked by canonical splice sites and encode the consensus 
sequences of GT(U)-AG introns(142, 221). Despite the small number of exons, there 
are two functionally distinct isoforms: the canonical variant excises intron 1. 
However, there is also a 5’ cryptic splice site which creates an isoform that retains 
the first 26bp of the first intron. This isoform is known to make up about 10% of 
all insulin transcripts and is highly regulated by glucose, conferring increased 
translational efficiency(142, 221).  Glucose enhances translational efficiency by 
inducing binding of the polypyrimidine tract binding protein (PTB) to its 3’ UTR. 
Here, Taqman® custom assays (Thermo Fisher, Waltham, MA, USA) were 
designed to distinguish between the isoform containing the 26bp intron inclusion 
and the other variants. In-silico splicing was used to be able to identify exon 
boundaries that contained the target sequence 
 GTGGGCTCAGGATTCCAGGGTGGCTG for the 26bp intron inclusion, termed 
variant 1, that detects human gene INS refseq NM_001185098, from Human 
genome assembly December 2013 (GRCh38/hg38).  The same process was 
used to detect exon boundary sequences that would only distinguish the other 
variants, termed variant 2. The resulting sequences were used to design custom 
Taqman gene assays that detect human gene INS refseq NM_001185097 and 
NM_000207, from the same genome assembly.  
 
 
 
 
82 
2.5.2 Paired box protein 6 (PAX6)  
 
Alternative splicing generates two PAX6 isoforms, referred to as PAX6 and 
PAX6(5a), which differ by the inclusion of 14 amino acids (aa) encoded by the 
additional exon 5a(222-224). The 14‐aa insertion profoundly alters the DNA‐binding 
activity of the Pax6 paired domain(225). The paired domain of Pax6 depends on 
both subdomains for DNA sequence recognition, similar to all members of the 
Pax2/5/8 family(223, 225). As these insertions severely restrict the sequence 
recognition of the paired domain, they may almost entirely switch the DNA‐
binding mode of certain Pax proteins [such as Pax6(5a)] from the paired domain 
to the homeodomain. The transcriptional function of the two isoforms is 
influenced by the ratio of PAX6:PAX6(5a); depending on cell type and 
developmental stage(197, 226).  In this way it has been suggested that exon 5a 
functions as a molecular switch which specifies target genes(227). 
 
Studies have also shown that the PAX6(5a) isoform is associated with pancreatic 
cancer(197, 226, 228). Pax6 is known to regulate the expression, via binding of the 
promoters, of INS, PDX1,MAFA, NKX6-1 and SLC2A2 (GLUT2), indicating it’s 
critical role in beta cellfunction(197, 226). Studies have also shown that it is important 
for glucagon synthesis in alpha cells via regulation of the glucagon gene GCG. 
In alpha cells it also regulates MAFB and NEUROD1, which are also critical for 
GCG expression and maintenance of alpha cell fate.  
 
Taqman® custom assays (Thermo Fisher, Waltham, MA, USA) were designed to 
distinguish between canonical PAX6 and PAX6(5a). In-silico splicing was used 
to be able to identify exon boundaries that contained the target sequence for the 
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14aa exon 5 inclusion which detects human gene PAX6 refseqs 
NM_001258462.1, NM_001258463.1, NM_001310158.1, NM_ 001310160.1, 
NM_001310161.1 and NM_001604.5 from Human genome assembly December 
2013 (GRCh38/hg38).  The same process was used to detect exon boundary 
sequences that would only distinguish the canonical variants. The resulting 
sequences were used to design custom Taqman gene assays that detects 
human gene PAX6 refseqs NM_001258463.1, NM_001258464, NM_001258465, 
NM_000280 from the same genome assembly. 
 
2.5.3 POU class 5 homeobox 1 (POU5F1 (OCT4)) 
 
There are three main isoforms of human POU5F1, also known as OCT4, which 
are categorised as OCT 4A, OCT4B and OCT4B1. Previous studies have 
established that OCT4A is associated with stemness properties, where as 
OCT4B and OCT4B1 appear to be responsive to cellular stress(229). The cellular 
localisation of the OCT4 isoforms has also been previously characterised, with 
OCT4A exclusively localised to the nucleus where it acts as a transcription 
factor(229, 230). However, OCT4B and OCT4B1 are localised to both the cytoplasm 
and the nucleus(229). Localisation changes are known to be associated with 
response to cellular stress. Here, Taqman® custom assays (Thermo Fisher, 
Waltham, MA, USA) were designed to differentiate between the OCT4A and 
OCT4B/ B1 isoforms. Again, in-silico splicing was used to identify sequence 
differences across the exon 2 and 3 boundary for the OCT4A isoform refseqs 
NM_002701 from Human genome assembly December 2013 (GRCh38/hg38).  
The same process was used to detect exon boundary sequences that would only 
distinguish the OCT4B/B1 variants and these were used to design custom 
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Taqman® gene assays to detect refseqs NM_001285987, NM_001285986.1 and 
NM_203289.5 from the same genome assembly. 
 
2.5.4 Nanog homeobox (NANOG) 
 
NANOG has two isoforms resulting from alternative splicing(231, 232). The long 
variant is known to be more highly expressed in ES cells than the shorter isoform. 
However, in multipotent adult progenitor cells the shorter isoform shows much 
higher expression than is seen in ES cells, hence expression level is considered 
an important determining factor for pluripotency(231, 232). It has been suggested 
that the increase in ratio of short to long form variants is indicative of a role in the 
regulation and control of differentiation(233). To differentiate between the long and 
short form NANOG variants, Taqman® custom assays (Thermo Fisher, Waltham, 
MA, USA) were designed. The technique of in-silico splicing was again used to 
identify sequence differences in exon 4 between the long and short isoforms. 
Termed NANOG exon 4 long, this assays identified the refseq variant 
NM_024865.3 from Human genome assembly December 2013 (GRCh38/hg38). 
The other assay, called exon 4 truncated, detected the NM_001298698.1 from 
the same genome assembly. 
 
2.5.5 Protein tyrosine phosphate PTPN1 
 
PTPN1 (PTP1B) is known to negatively regulate insulin and leptin signalling via 
dephosphorylation of the activating phosphor-tyrosines on the insulin receptor(234, 
235). There are two variants resulting from alternative splicing: a long transcript 
which includes intron 9 and a shorter form where intron 9 is excised. Studies have 
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shown that the long isoform is associated with body fat percentage and fasting 
insulin scores and has been suggested as a biomarker for hyperinsulinaemia in 
Diabetes(145, 234, 235). To distinguish between the long and short form PTPN1 
variants, Taqman® custom assays (Thermo Fisher, Waltham, MA, USA) were 
designed by in-silico splicing to identify sequence differences in exon 2. PTPN1 
‘long’ detected the refseq variant NM_002827.3 from Human genome assembly 
December 2013 (GRCh38/hg38). The other assay, PTPN1 ‘short’, identified 
refseq NM_001278618.1 from the same genome assembly.  
 
Table 4 Alternatively spliced gene assay IDs.  
Custom assays were designed using in silico splicing to distinguish between isoforms. 
 
 
Assay Name Forward Primer Seq. Reverse Primer Seq. Reporter 1 Sequence 
INS_EX1 CCATCAAGCAGGTCTGTTCCAA GGGCCATGGCAGAAGGA CCTTTGCGTCAGATCACT 
PTPN1_EX2DEL AGTTCGAGCAGATCGACAAGTC GCGTTGATATAGTCATTATCTTCTTGATGTAGT CTATGGTCAACTGGTAAATG 
INS_EX1DEL GGCTTCTTCTACACACCCAAGAC CCTCCAGGGCCAAGGG CTGCAGGGCAGCCTG 
NANOG1_EX4LNG TGGCCGAAGAATAGCAATGGT CATCCCTGGTGGTAGGAAGAGTA ACGCAGAAGGCCTCAGC 
PAX6_EX5DEL CGTGCGACATTTCCCGAATT GTCTCGTAATACCTGCCCAGAATTT ATCCGTTGGACACCTGC 
NANOG_EX4TRU TGGCCGAAGAATAGCAATGGT GGTTCCCAGTCGGGTTCAC ACGCAGGGATGCCTG 
INS_EX1LNG GGACAGGCTGCATCAGAAGAG GGGCCATGGCAGAAGGA CCATCAAGCAGATCACTG 
POU5F1_EX3 GAAGAGGATCACCCTGGGATATACA TGGCTGAATACCTTCCCAAATAGAAC CAGGCCGATGTGGCTC 
 
 
2.6 RNA extraction 
 
 
RNA was extracted from EndoC βH1 cells for each of the cell assays using the 
TRI®reagent/ chloroform method. TRI®reagent, or TRIzol, is a solution of phenol 
and guanidium isothiocyanate which lyses the cells, denatures protein and has 
the advantage of eradicating RNases which would otherwise degrade the 
sample. The addition of chloroform causes phase separation, where RNA 
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remains in the aqueous phase, DNA is at the interface and protein is in the 
organic phase. This method is useful in that it allows the isolation of RNA, DNA 
and protein from the same sample(236-238).  The addition of MgCl2 was used to 
protect against the loss of miRNAs during the extraction process. It has been 
shown that TRI®reagent can lead to the loss of small RNAs with a low GC 
content(239). MgCL2 is thought to stabilise the phosphate backbone of small RNAs, 
allowing them to survive this method of extraction(239).  
 
For the extraction, cells were washed in Dulbecco’s phosphate buffered saline 
(D-PBS). TRI® reagent (Sigma-Aldrich, Steinheim, Germany), was used to 
harvest RNA, 10 μL of MgCl2 to stabilise short RNAs, such as microRNAs with 
low GC content (Thermo Fisher, Waltham, MA, USA) and 200 μL of Chloroform 
(Thermo Fisher, Waltham, MA, USA)added(239). Samples were centrifuged at 
14800 rpm, 4 oC for 20 mins, the clear aqueous layer removed and 500 μL of 
isopropanol (Thermo Fisher, Waltham, MA, USA) added for overnight 
precipitation. Samples were centrifuged at 14800 rpm, 4 oC for 45 minutes to form 
RNA pellet. The pellet was then repeatedly washed using 75% molecular grade 
ethanol (Thermo Fisher, Waltham, MA, USA), air dried and then re-suspended in 
20 μL RNase-free water. 
 
2.7 Reverse transcription 
 
Reverse transcription is the process by which single stranded complementary 
(cDNA) is synthesized. It uses RNA as the template and a reverse transcriptase 
enzyme to synthesise the cDNA molecule. The reaction amplifies the product for 
use in quantitative polymerase chain reaction (qPCR) studies. Here we used 
three different methods for reverse transcription, using RNA extracted from 
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EndoC βH1 cells from each of the cell treatment assays. Superscript® VILO™ 
was used for all of the gene expression assays in Chapter’s 3 and 4. However, 
for the siRNA gene modification and SH6 AKT pathway inhibition assays 
EvoScript Universal cDNA synthesis kits were used. Taqman® Advanced miRNA 
cDNA kits were used for the microRNA expression assays in Chapter 5. Finally, 
we again used EvoScript Universal cDNA synthesis kits for the target gene 
expression assays in Chapter 5. 
 
2.7.1 Superscript™ VILO™ cDNA synthesis.  
 
For the total gene expression, alternative splicing, splicing factor expression, 
rescue of phenotype and ER stress assays, cDNA synthesis was carried out 
using Superscript® VILO™ cDNA synthesis kit (Thermo Fisher, Waltham, MA 
USA). Samples were normalised to 100 ng/ μL RNA prior to reverse transcription. 
This enzyme mix has good thermostability which is required since the reaction 
includes a high temperature denaturing step. It also contains an inhibitor which 
eliminates RNase H activity and increases the yield of cDNA. The reaction mix 
contains random primers, dNTPs and MgCL2 for phosphodiester bond formation. 
Cycling conditions were incubation at room temperature (25 oC) for 10 minutes, 
42 oC for 60 minutes and 85 oC for 5 minutes.  
 
2.7.2 Taqman™ Advanced microRNA cDNA synthesis. 
 
For the microRNA (miRNA) open array and miRNA expression assays, cDNA 
synthesis was carried out using the Taqman® Advanced miRNA Assay kit 
(Thermo Fisher, Waltham, MA USA). Samples were normalised to 10 ng/ μL prior 
 
 
 
88 
to reverse transcription. The first stage of the reaction adds a polyA tail to the 3’ 
end, cycling at 37 oC for 45 minutes and then a 10 minute cycle at 65 oC to stop 
the reaction. The second step is 5’ adapter ligation to extend the mature miRNAs 
present in the sample, at 16 oC for 60 minutes. Following these preliminary 
reactions, the reverse transcription reaction is performed using universal primers 
that recognize the universal sequences on the 5’ and 3’ ends of the miRNAs. The 
cycling conditions for this reaction are 42 oC for 15 minutes and the reaction is 
stopped by a 5 minute cycle at 85 oC. To increase detection of lowly expressed 
miRNA targets, the product of the reverse transcription reaction is then amplified 
in the miR-Amp reaction, with enzyme activation and denaturing at 95 oC for 5 
minutes, and 14 cycles of annealing at 60 oC before the reaction is stopped by a 
10 minute cycle at 99 oC for 10 minutes. The resulting product is then ready for 
qPCR reactions.  
 
2.7.3 EvoScript Universal cDNA Master cDNA synthesis. 
 
For the siRNA PAX6(5a) knockdown, SH6 AKT pathway inhibition and miRNA 
pathway target gene validation assays, cDNA synthesis was performed using 
EvoScript Universal cDNA master (Roche life science, Burgess Hill, UK). 
Samples were normalised to 100 ng/ μL RNA prior to reverse transcription. 
Similarly to the VILO kit, this enzyme mix is also thermostable during the high 
temperature denaturing step.  However, the enzyme mix does have RNase 
activity and therefore the enzyme is added last to avoid digestion of the sample. 
Cycling conditions were 42 oC for 30 minutes, 85 oC for 5 minutes and 65 oC for 
15 minutes.  
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2.8 Quantitative real-time Polymerase Chain reaction (qRT PCR) 
assessment of gene expression 
 
The polymerase chain reaction (PCR) is a method for amplifying regions of DNA 
and utilises a reaction where DNA polymerase copies a DNA template to 
generate a new DNA strand. To detect gene expression, RNA is extracted from 
samples and reverse transcription is used to synthesize cDNA. An 
oligonucleotide probe, designed against the region of interest, hybridises to the 
cDNA and initiates a reaction that allows the DNA polymerase enzyme to add 
nucleotides. Reaction mixtures incorporate dNTPs, a buffer solution and MgCl2, 
which acts as a cofactor for the Taq polymerase enzyme. It is necessary for the 
removal of the phosphate from dNTPs, breaking them down to dNMPs and the 
formation of a phosphodiester bond between the 3’ OH of the adjacent nucleotide 
and the 5’ phosphate of the next nucleotide. Adjusting the concentration of MgCl2 
is therefore important to primer annealing as increased concentrations improve 
annealing but at the risk of reducing specificity.  
 
Cycling temperature changes facilitate the exponential reaction and amplification 
of the cDNA. High temperatures at the beginning of the reaction denature the 
double stranded cDNA molecule before reducing temperature to allow the 
oligonucleotide probe to anneal to the template and extension of the primer 
sequence. At each cycle the PCR reaction increases the number of template 
copies exponentially until there are either insufficient reagents and template or 
accumulation of phosphates and primer-dimerisation, which causes the reaction 
to enter the stationary phase. Quantitative PCR (qPCR) allows for the 
determination of the amount of starting template during the exponential phase. 
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Real time q-PCR (RT-PCR) allows quantification to be determined at each cycle 
of the reaction. 
 
Taqman chemistry uses an oligonucleotide probe which contains a fluorescent 
fluorophore reporter, FAM™, at the 5’ end and a quencher fluorophore at the 3’ 
end. In this state the quencher fluorophore is sufficiently close to the FAM™ 
fluorophore that no fluorescence can be detected. Once the reaction is initiated, 
the Taq polymerase, which has 5’ activity, digests the oligonucleotide probe and, 
at completion of the cDNA replication, it cleaves the quencher from the 3’ end. 
This allows fluorescence from the FAM™ reporter to be emitted so that it can be 
detected. This chemistry allows calculation of the cycle at which fluorescence 
exceeds the baseline threshold, which will be discussed in more detail below.    
 
Here, we measured gene expression levels by quantitative real-time PCR. 
Endogenous control genes were PPIA, UBC, HPRT1, GUSB, B2M and IDH3B. 
Reaction mix included 2.5 μL Taqman® Universal PCR mastermix II (no 
AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL 
cDNA and 0.25 μL Taqman® gene assay (Thermo Fisher, Waltham, MA, USA) in 
a 5 μL reaction volume. The reaction mixes were spun, vortexed and re-spun at 
3000 rpm to ensure reagents were well mixed before being added to a 384 well 
qRT-PCR plate. Cycling conditions were: 50 °C for 2 min, 95 °C for 10 min and 
50 cycles of 15 seconds at 95°C for 30 s and 1 minute at 60°C. Reactions were 
carried out in 3 biological replicates and 3 technical replicates. Expression levels 
were normalised to the median level of expression seen in unstimulated EndoC-
βH1 cell controls. Using the Ct method for relative quantification, described 
below, differences in gene expression levels between EndoC-βH1 cells subjected 
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to each separate diabetogenic stimulus were compared to the same time point 
controls for each assay and investigated by student independent t-test carried 
out using SPSS version 23 (IBM, North Castle, NY, USA). Data were presented 
as means ± S.E.M.  
 
2.8.1 Relative Quantification 
 
There are a number of different approaches to determining gene expression. Of 
these, relative quantification(240, 241), which is expressed as fold change, can be 
performed either by the Ct method, the Pfaffl method or the sigmoidal curve 
fitting method(240). The Pfaffl approach is particularly useful for when primer sets 
have different efficiencies as this uses standard curves and corrects for 
differences in efficiencies(242). Relative expression is calculated from the 
amplification efficiencies and the crossing point of an unknown sample versus a 
control(242).  The sigmoidal curve fitting approach also precludes the need to know 
amplification efficiencies and is therefore useful for analysing high throughput 
data. It uses mathematical modelling of amplification reactions to assess relative 
quantification(243, 244).  For all of the gene expression and miRNA expression 
assays in this study, the relative expression of each test transcript was calculated 
by the Ct comparative Ct method(240, 241). This method uses the Ct value, which 
is the PCR cycle at which fluorescence goes above the background threshold. 
Although this approach is easy to use, it assumes that the transcript amplification 
efficiency is 100%. To address this issue, Taqman and IDT gene expression 
assays were used in this study as they have been validated at essentially 100% 
efficiency.  For determination of threshold, background fluorescence threshold 
values are set at 10 standard deviations above the baseline fluorescence. 
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Replication is exponential and lower Ct values equate to higher levels of cDNA. 
Expression was assessed relative to global mean of each test transcript, or 
miRNA, and normalized back to the median level of expression of each individual 
transcript.  
 
2.8.3 Other Statistical approaches 
 
Data was log transformed to ensure normal distribution. and was analysed using 
SPSS version 23 (IBM, North Castle, NY, USA). However normality tests, such 
as Kolmogorov-Smirnov and Shapiro-Wilks which compare the sample values to 
a set of normally distributed values, were not applied due to the unreliable nature 
of such tests in small sample sizes or where there is large variation(245). Data 
were presented as p value and mean difference. ANOVA tests were used for 
analysis. This compares the means between two independent groups against the 
same dependent variable to see if there is a statistically significant difference 
between the two groups. It can be used to determine the difference in means 
between treatments and controls and was selected for this purpose by this study. 
A Bonferroni correction was applied to take into account multiple testing to ensure 
no reporting of false positives, or type one errors. The Bonferroni correction 
accounts for the problem of high numbers of tests increasing the likelihood that 
the p value might be due to pure chance. It divides the standard p = 0.05 value 
by the number of tests applied. However, as this correction can increase the risk 
of a type two error, failing to reject the null hypothesis, standard p = 0.05 values 
have been reported. It has been clearly stated throughout where a Bonferroni 
correction has been applied and the number of multiple tests that have been 
considered.  
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2.9 Splicing factor expression 
 
Splicing factor expression was quantified using using Taqman® Low Density 
Array (TLDA). This method allows the quantification of gene expression for 
multiple genes on one array. TLDA plates comprise 384 wells that are connected 
by microfluidic channels and which contain the gene expression assays and each 
plate accommodates 8 samples. The reaction mixes included 50 μL Taqman® 
Fast Universal PCR Mastermix (Life Technologies, Foster City, USA), 30 μL 
dH2O and 20 μL cDNA template. The 100 μL reaction mixture was dispensed 
into the TLDA card chamber and centrifuged twice, for 1 min, at 1000 rpm to 
ensure correct distribution of solution to each well and removal of bubbles. 
Cycling conditions were 1 cycle each of 50 °C for 2 min, 94.5 °C for 10 min and 
then 40 cycles of 97 °C for 30 s and 57.9 °C for 1 min. Expression was again 
assessed by the Comparative Ct approach, relative to the IDH3B, GUSB and 
PPIA endogenous control genes, selected on the basis of empirical evidence for 
stability in beta cells. Changes in expression were expressed relative to the level 
of splicing factor expression in the control cells. 
 
2.10 Modification of gene expression using and siRNA to knock down the 
expression of PAX6 isoform, PAX6(5a). 
 
To investigate whether the PAX6(5a) isoform of the PAX6 gene was important 
for changes in beta cell differentiation status during cell stress, a custom select 
siRNA was designed (assay ID 1THO, Thermo Fisher, Waltham, MA, USA). 
Effective candidate sequences were selected using siDIRECT2. Cells were 
cultured in 1 mL penicillin and streptomycin free culture media with 250 μL from 
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a master mix of siRNA containing 300 μL Optim-MEM® (Life Technologies, Foster 
City, USA) , 9 μL Lipofectamine® (Life Technologies, Foster City, USA) and 3 μL 
siRNA at 10 μM, made up according to the manufacturer’s instructions. Cells 
were cultured for 72 hrs prior to the administration of siRNA and were then 
incubated for a further 48 hours. At this point RNA was harvested using the 
protocol previously described. Reverse transcription and qPCR was performed 
to ascertain whether the PAX6(5a) knock down was successful. Following siRNA 
validation, cells were cultured in 24 well plates for 72 hrs before the addition of 
the siRNA mastermix at the concentration specified in the manufacturer’s 
protocol. The siRNA was incubated for 48 hrs, before treating relevant wells with 
25 mM glucose for 24 hrs. After treatment cells were fixed with 4% 
paraformaldehyde for 15 minutes at 4oC. 
 
2.11 High throughput global microRNA screen by open array 
 
The Taqman® open arrays have 3072 reactions on each plate and up to 4 plates 
can be run at once, allowing for high throughput expression profiling. Each plate 
contains 48 subarrays with 64 x 300 μM holes. The holes are 300 μM deep and 
are treated with hydrophilic and hydrophobic coatings. which retain the reaction 
mix due to surface tension. The reaction mix is loaded into the plates by robot 
and the plate immediately sealed with a mineral oil-like material to prevent 
evaporation of the very small volumes. Here we used inventoried Taqman® 
Advanced microRNA (miRNAs) open arrays, containing 757 miRNA targets, to 
investigate all diabetic microenvironment treatment conditions and selection of 
miRNAs for further study, please refer to supplementary table S11 for assay IDs. 
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The resulting data was analysed using Thermo Fisher cloud software to identify 
the ten most altered miRNAs, across all assays, for pathways analysis.  
 
2.11.1 miRNA enrichment analysis 
 
To assess what the likely pathway and gene targets were for miRNAs found to 
be dysregulated in response to the cellular stress assays, we used the DNA 
intelligent analysis (DIANA) mirPath v3.0 database and the DIANA-micro-T-CDS 
v 5.0 algorithm(246, 247). The DIANA mirPath database focuses on the identification 
of miRNA targeted cell pathways and operates by allowing the selection of single 
or multiple miRNAs(246, 247). The algorithm then performs gene set enrichment 
analysis (GSEA) using a Fisher’s exact test to determine the statistical 
significance of microRNA gene targets in KEGG pathways(246, 247). Following 
identification of the significant pathways from the multiple miRNA effect analysis, 
it is then possible to access DIANA microT-CDS entries to determine which target 
genes within those pathways are predicted by this pattern of altered miRNA 
expression(248). Each gene has an MITG score which predicts the probability of 
the microRNA targeting that gene(248). Here, we used this platform to carry out 
GSEA using miRNAs differentially regulated across several treatment regimes to 
determine whether any were overrepresented in gene ontology or functional 
category pathways derived from KEGG. The p value was set to 0.050 and MicroT 
threshold to 0.8.  
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2.11.2 Validation of dysregulated miRNAs 
 
miRs selected from the large-scale analysis were validated by qRT PCR using 
Taqman® advanced miRNA assays (Thermo Fisher, Waltham, MA USA). Three 
miRNAs (miRNA 106b-3p, miR-191-3p and miR103-3p) were empirically 
selected from the large dataset for stability in response to treatment for use as 
endogenous control genes. qRT PCR reaction mixes included 2.5 μL Taqman® 
Universal PCR mastermix II (no AmpErase® UNG) (Thermo Fisher, Waltham, 
MA, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene assay 
(Thermo Fisher, Foster City USA) in a 5 μL reaction volume. Cycling conditions 
were: 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 seconds at 95 °C for 
30 s and 1 minute at 60 °C. Reactions were carried out in 3 biological replicates 
and 3 technical replicates. MicroRNA assay Identifiers are given in table 5. The 
relative expression of each was determined by the comparative Ct approach. 
Expression levels were calculated relative to the geometric mean of the 
empirically-determined endogenous control genes, but also to the global mean of 
expression across all transcripts tested which provided a robust baseline. 
Expression levels were then normalised to the median level of expression seen 
in untreated EndoC-βH1 cell controls. Differences in gene expression levels 
between mock-treated and treated EndoC-βH1 cells were compared to the same 
time point controls for each condition and investigated for statistical significance 
by student independent t-test carried out using SPSS version 23 (IBM, North 
Castle, NY, USA). Data were presented as means ± S.E.M. 
 
  
 
 
 
97 
Table 5 MicroRNA assay IDs for most altered miRs selected from large 
global screen. 
 
Assay name Assay IDID Assay name Assay ID 
hsa-miR-576-5p  478165_mir  hsa-miR-148b-5p  478719_mir  
hsa-miR-376a-3p  478240_mir  hsa-miR-454-5p  478919_mir  
hsa-miR-9-5p  478214_mir  hsa-miR-30c-2-3p  479401_mir  
hsa-miR-101-3p  477863_mir  hsa-miR-27b-3p  478270_mir  
hsa-miR-365a-3p  478065_mir  hsa-miR-186-3p  479544_mir  
hsa-miR-202-5p  478755_mir  hsa-miR-34a-5p  478048_mir  
hsa-miR-34a-5p  478048_mir  hsa-miR-195-3p  478744_mir  
hsa-miR-93-5p  478210_mir  hsa-miR-593-5p  479077_mir  
hsa-miR-23a-3p  478532_mir  hsa-miR-106b-3p  477866_mir  
hsa-miR-34b-3p  478049_mir  hsa-miR-577  479057_mir  
hsa-miR-34c-5p  478052_mir  hsa-miR-299-5p  478793_mir  
hsa-miR-30c-1-3p  479412_mir  hsa-miR-199a-3p  477961_mir  
hsa-miR-27a-3p  478384_mir  hsa-miR-99a-3p  479224_mir  
hsa-miR-92b-5p  479207_mir  hsa-miR-124-3p  477879_mir  
hsa-miR-30a-5p  479448_mir  hsa-miR-29a-3p  478587_mir  
hsa-miR-185-3p  478732_mir  hsa-miR-136-5p  478307_mir  
hsa-miR-885-5p  478207_mir  hsa-miR-152-3p 477921_mir  
hsa-miR-374b-3p  479421_mir  hsa-miR-21-3p  477973_mir  
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2.11.3 Validation of miRNA target gene mRNA levels 
 
Target genes for validation were based on the MITG scores from the DIANA-
microT-CDS v5.0 algorithm, table 6. A panel of 10 miRNAs were selected on the 
basis of highest MITG score, most statistically significant p value, number of 
genes predicted and number of miRNAs targeting the top 5 pathways; Lysine 
degradation, FOXO signalling pathway, HIPPO signalling pathway, TGF - 
estrogen signalling and Pathways in Cancer. MITG score is the predictive score, 
where the higher the score the higher the target probability(248).  
 
The expression levels of predicted target genes was measured using quantitative 
RT-PCR performed using IDT mini primetime gene expression assays 
(Integrated DNA Technologies, Skokie, Illinois, USA) as detailed in table 6. 
Reactions were run in triplicate on 384 well plates, using one assay per plate 
containing all samples. Each reaction included 2.5 μL Taqman® Universal PCR 
mastermix II (no AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 
μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene assay (Thermo Fisher, Foster 
City USA) in a 5 μL reaction volume. Cycling conditions were: 50 °C for 2 min, 
95 °C for 10 min and 50 cycles of 15 seconds at 95 °C for 30 s and 1 minute at 
60 °C. Associations between miRNA and mRNA target expression were 
assessed using independent t-tests carried out using SPSS v23 (IBM, North 
Castle, NY, USA). 
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Table 6 Targets from DIANA pathways analysis.  
Genes selected from DIANA-microT-CDS v5.0 algorithm based on highest MITG scores, 
most statistically significant p value, the numbers of genes predicted and number of 
microRNAs targeting the top 5 pathways. 
 
GENE Pathway Pathway 
p-value 
MITG 
score 
ASSAYS 
KMT2C Lysine 
degradation 
3.00 x 10-3 0.97/0.9
2/0.80 
All assays 
BCL2L11 FOXO 0.02 0.99/ 
0.89 
Glycaemia and Palmitic 
acid 
DLG2 Hippo 5.84 x 10-5 0.92/0.8
1 
Glycaemia, Palmitic acid 
and pro-inflammatory 
cytokines 
SP1 TGF and 
Estrogen 
0.02 0.99 Glycaemia and Hypoxia 
SOD FOXO 0.02 0.98 Glycaemia and Palmitic 
acid 
MAPK1 FOXO 0.02 0.9 Glycaemia and Palmitic 
acid 
TEAD1 Hippo 5.84 x 10-5 0.85 Glycaemia and Hypoxia 
SERPINE1 Hippo 5.84 x 10-5 0.82 Glycaemia 
MOB1A Hippo 5.84 x 10-5 0.82 Glycaemia 
PDK1 Central carbon 
cancer 
3.00 x 10-3 0.82 Glycaemia and Hypoxia 
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Chapter 3: 
Data chapter.  
The species origin of the 
cellular microenvironment 
influences markers of beta cell 
fate and function in EndoC-βH1 
cells 
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3.1 Introduction 
 
Communication between pancreatic beta cells and other endocrine cell types is 
important for the maintenance of beta cell fate and function(249-251). Within islets, 
beta cells interact intimately with the micro-environment, critical for glucose 
sensing and the regulation of islet cell function(249-251). The cellular 
microenvironment of beta cells is also known to influence cell behaviour and 
survival(65, 66, 68) and can influence aspects of growth morphology, such as cell 
density, which is vital to beta cell survival as well as influencing differentiation, 
cell-cell signalling and function(69, 70). Differences in pancreatic islet architecture, 
between humans and other species such as rodents, have also been shown to 
have implications for cell-to-cell crosstalk and beta cell function(19, 20, 199). 
 
Accordingly, several features of beta cell function and behaviour also differ 
between species. Glucose sensitivity and transport are different between human 
and rodent beta cells, with the major glucose transporter being GLUT2 (encoded 
by the solute carrier family 2 member 2 (slc2a2) gene) in rodents and GLUT1 and 
GLUT3 (encoded by the SLC2A1 and SLC2A3 genes) in humans(20, 22, 83, 199). 
Proliferation rate and expression of cyclin dependent kinases also vary between 
rodents and man, as do responses to cellular stress, pancreatic beta cell injury 
and inflammation(20, 39, 48, 58, 199, 252, 253). There are also important transcriptomic 
distinctions between species, with insulin being coded for by one gene (INS) in 
humans but two genes (Ins1 and Ins2) in rodents(84, 85, 182, 183, 199). Gene 
expression differences, especially in relation to stress response, are also seen in 
human beta cells compared with rodent cells, most notably in neurogenin3 
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(NGN3), NANOG homeobox (NANOG), POU class 5 homeobox 1 (POU5F1 
(Oct4)), L-Myc-1 proto oncogene (MYCL1), paired box 4 (PAX4) and MAF BZIP 
transcription factor B (MAFB) expression(58). 
 
Given the importance of cellular microenvironment to beta cell fate and 
function, it follows that the nature of the microenvironment may influence these 
features in in vitro culture systems. Model systems to investigate the effect of a 
non-human cellular microenvironment have been difficult to source until recently 
since fully functional human beta cell lines have been few and far between. The 
creation of EndoC-βH1, a human cell line derived from fetal pancreata, has 
provided a new and physiologically-relevant model system for the investigation 
of beta cell function in vitro.(182, 199, 252) These cells demonstrate stable insulin 
gene expression across multiple passages and are responsive to glucose(182, 183, 
199, 252). Like many other differentiated cell lines, EndoC-βH1 cells require an 
extracellular matrix (ECM) coat containing fibronectin and other components 
such as Fraction V for culture(183). This requirement allows investigation of the 
effects of different components of the cellular microenvironment on aspects of 
beta cell behaviour. 
 
In this work, we have compared the effects of a non-human culture 
microenvironment with those of a culture system containing only human 
components on aspects of cell morphology and culture dynamics, beta cell 
function (insulin content, insulin processing and glucose-stimulated insulin 
secretion), and on the transcriptional output of genes involved in beta cell 
differentiation status and beta cell identity. Cells cultured according to these 
modified protocols grow reliably in pseudo islet-like structures, and can be 
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propagated for long periods of time without compromise to beta cell survival, 
function or phenotype. Cells also show evidence of a more consolidated beta cell 
phenotype at the transcriptional level, with increased expression of mature beta 
cell markers and decreased expression of markers associated with other islet 
subtypes. These data highlight the potential advantages of propagating human 
beta cell lines in a microenvironment more reminiscent of human physiology, 
when considering aspects of islet biology in experimental systems. 
 
3.2 Methods 
 
3.2.1 Standard culture protocol: non-human microenvironment 
 
Cells were cultured in accordance with the guidelines for EndoC βH1 cells from 
the manufacturers Endo Cells, INSERM, France. Flasks or plates were coated, 
at least 6 hours in advance of seeding, with an ECM consisting of DMEM 4.5 g/ 
L (Thermo Fisher, Waltham, MA USA), matrigel (100 μg/ mL) fibronectin from 
bovine plasma 2 μg/ mL coat (both from Sigma-Aldrich, Steinheim, Germany). At 
seeding the ECM coat was replaced with culture medium containing: DMEM 1 g/ 
L glucose (Thermo Fisher, Waltham, MA, USA) 2% BSA fraction V (Merck 
Chemicals, Darmstadt, Germany), 10 mM nicotinamide (Sigma-Aldrich, 
Steinheim, Germany) 50 μM β-2-Mercaptoethanol, 5.5 μg/ mL transferrin, 6.7 ng/ 
mL sodium selenite, and 100 U/mL penicillin and 100 μg/ mL streptomycin (Sigma 
Aldrich, Steinheim, Germany). 
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3.2.2 Human microenvironment 
 
Culture reagents were replaced with human equivalents. Here, flasks were again 
coated at least 6 hours prior to seeding with coating medium consisting of: Maxgel 
ECM mixture liquid (Sigma Aldritch, Steinheim, Germany) and fibronectin from 
human plasma (Sigma-Aldritch, Steinheim, Germany). The ECM was replaced at 
seeding with a modified culture medium consisting of: DMEM 1 g/ L glucose, 
(Thermo Fisher Waltham, MA USA), 2% human serum albumin fraction V (Merck 
Chemicals, Darmstadt, Germany), 100 U/ mL Penicillin and 100 μg/ mL 
streptomycin, 50 μM β-2-Mercaptoethanol (Sigma- Aldrich, Steinheim, 
Germany), 10 mM nicotinamide (Sigma Aldritch Steinheim, Germany), 5.5 μg/ 
mL human transferrin (Sigma Aldritch, Steinheim, Germany) and 6.7 ng/ mL of 
sodium  selenite  (Sigma  Aldritch,  Steinheim,  Germany). Cells were passaged 
using TRYPLE 1x (Thermo Fisher, Waltham, MA, USA) and neutralised with heat 
inactivated human serum from human male AB plasma (Sigma Aldritch, 
Steinheim, Germany).  
 
3.2.3 Immunofluorescence characterisation of EndoC-βH1 cells cultured in 
human microenvironment 
 
Immunofluorescence staining was used to determine expression of mature beta 
cell markers in EndoC-βH1 cells grown in conditions to mimic a more human 
microenvironment, compared with cells grown using the standard non-human 
culture reagent protocol. EndoC-βH1 cells were cultured on coverslips for 72 hrs 
before fixing with 4% paraformaldehyde for 15 min at 4 °C. Primary antibodies 
for PDX1 (Abcam Ab47267, rabbit polyclonal) and NEUROD1 (Abcam Ab60704, 
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mouse monoclonal) were diluted in phosphate buffered saline (PBS) with .1 M 
Lysine, 10% donor calf serum, .02% sodium azide and .02% Triton (ADST), to 
permeabilise the cell membranes, at concentrations of 1/500 and 1/400 
respectively and incubated overnight. Primary antibodies were visualised using 
highly cross-absorbed secondary antibodies (Life Technologies) also diluted in 
ADST at 1/400: goat anti-rabbit for PDX1 at 1/400 (555 nm) and goat anti-mouse 
for NEUROD1 at 1/400 (555 nm) and incubated for 1 hr. Insulin antibody (80564, 
LN10088287 Dako) was diluted in ADST at a concentration of 1/700  and 
incubated for 1 hr. Secondary goat anti guinea-pig insulin along with DAPI 
(Sigma- Aldritch D9542), were diluted in ADST at respective concentrations of 
1/400 and 1 μg/ mL. Slides (n= 3 separate cultures) were visualised using a 
LEICA DM4000 B-LED fluorescence microscope using LAS X image software. 
 
3.2.4 Assessment of glucose-stimulated insulin secretion 
 
EndoC-βH1 cells were seeded onto 24 well plates at 4 x 105 per well and cultured 
for 72 hrs in separate cultures. Cells were then transferred to a culture medium 
containing 2.8 mM glucose as a starvation medium and cultured overnight, before 
being incubated for 1 hr in a starvation medium containing 0.5 mM glucose in 
HEPES Krebs Ringer Buffer (KRB) at pH 7.4 containing: 116 mM/L NaCl, 5 mM/L 
KCl, 1 mM/L CaCl2, 1 mM/L MgCl2, 1.2 mM/L KH2PO4, 24 mM/L NaHCO3, 10 
mM/L HEPEs, 0.2% Human Serum Albumin (HSA). After 1 hr the 0.5 mM glucose 
starvation HEPES KRB starvation buffer was removed and replaced with HEPES 
KRB containing 20 mM glucose and cells incubated for 1 hr. This concentration 
of glucose was selected as representative of a high glucose environment and 
from previous documented studies in the literature, including those on EndoC 
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βH1 cells(182). Media was removed from each sample (n=10), spun at 1000 g for 
5 min to remove protein debris and supernatant harvested for comparison with 
controls using an ELISA against fully processed human insulin. (Human Insulin 
ELISA, Crystal Chem, Downers Grove, IL, USA, assay range 0.9 - 220 mU/ L, 
analytical sensitivity 0.25 mU/ L, precision CV < 10%, 1.2% cross reactivity with 
pro insulin). Absorbance was measured using a plate reader and measured A450 
values, subtracting A630 values. 
 
3.2.5 Candidate genes for expression analysis 
 
As previously described, the panel of target genes were selected for their roles 
in beta cell fate, maturity and function. Markers of other pancreatic endocrine cell 
types and also genes associated with cell stress were also included.  
 
3.2.6 Quantitative real-time polymerase chain reaction (qRT PCR) assessment 
of gene expression 
 
RNA was extracted using the TRI®reagent (Sigma-Aldrich, Steinheim, 
Germany), chloroform (Thermo Fisher, Waltham, MA, USA) method. Cells were 
washed in Dulbecco's phosphate buffered saline (D-PBS). TRI® reagent was 
used to harvest RNA, 10 μL of MgCl2 (Thermo Fisher, Waltham, MA, USA) and 
200 μL of Chloroform added. Samples were centrifuged at 14,800 rpm, 4 °C for 
20 mins, the clear aqueous layer removed and 500 μL of isopropanol (Thermo 
Fisher, Waltham, MA, USA) added for overnight precipitation. Samples were 
centrifuged at 14,800 rpm, 4 °C for 45 min to form RNA pellet. The pellet was 
then repeatedly washed using 75% molecular grade ethanol (Thermo Fisher, 
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Waltham, MA, USA), air dried and then re-suspended in 20 μL RNase- free water. 
cDNA synthesis was carried out using Superscript® VILO™ cDNA synthesis kit 
(Thermo Fisher, Waltham, MA USA). Samples were normalised to 100 ng/ μL 
RNA prior to reverse transcription. 
We measured the expression levels of 31 target genes by quantitative 
real-time PCR. Endogenous control genes were PPIA, UBC, HPRT1, GUSB, 
B2M and IDH3B Reaction mix included 2.5 μL Taqman® Universal PCR 
mastermix II (no AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 
μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene assay (Thermo Fisher, 
Waltham, MA, USA) in a 5 μL reaction volume. The reaction mixes were spun, 
vortexed and re-spun at 3000 rpm to ensure reagents were well mixed before 
being added to a 384 well qRT-PCR plate. Cycling conditions were: 50 °C for 2 
min, 95 °C for 10 min and 50 cycles of 15 s at 95 °C for 30 s and 1 min at 60 °C. 
Reactions were carried out in 3 biological replicates and 3 technical 
replicates. The relative expression of each test transcript was calculated by the 
comparative Ct technique which was used to calculate the expression of each 
test transcript. Expression was assessed relative to the global mean of 
expression across all transcripts which was empirically determined not to vary 
across test conditions. Expression levels were normalised to expression levels 
as seen in unstimulated EndoC-βH1 cells cultured in a non-human 
microenvironment. The data were log transformed to ensure normal distribution 
and differences in gene expression levels were then investigated by student 
independent t-test carried out using SPSS version 23 (IBM, North Castle, NY, 
USA). Data were presented as means ± S.E.M. 
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3.3 Results 
 
3.3.1 EndoC-βH1 cells show morphological changes when cultured in a more 
‘human-like’ microenvironment 
 
EndoC-βH1 cells cultured in a cellular microenvironment containing only human 
components showed no observational change in replication rate compared with 
cultures grown according to standard protocols, and this remained stable over 
eight passages. Population doubling (PD) showed no differences between 
culture methodologies (p = 0.975, mean difference 0.023). Culture in human 
reagents showed population doubling values of (mean PD = 18.98 hrs, n = 3) 
while those cultured using non-human reagents had values of (mean PD = 19.0 
hrs, n = 3). The cells showed an increased tendency to form three-dimensional 
structures resembling pseudo-islets under human culture conditions, which were 
visible under fluorescence microscopy, whereas cells cultured in a non-human 
microenvironment, grew as a flat confluent monolayer (Figure. 8, images C and 
D). EndoC-βH1 cells grown in the ‘human’ microenvironment, analysed and 
quantified, appeared smaller and more rounded compared with cells grown in a 
non-human microenvironment; the median area in μM for cells cultured in non-
human reagents was 81.2 μM compared with 77.6 μM for cells in human 
reagents, although this was not quite statistically significant (p = .070). However, 
despite this difference in area, there was no increased evidence of nuclear 
blebbing when cells were visualised using a nuclear dye (Figure 8). Nuclear size 
is considered to be linked to cell function and integrity(254), with cell cycle 
progression potentially dependent upon changes in the ratio between 
cytoplasmic and nuclear volume(255). Levels of transcription also correlate with 
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increased nuclear size and larger nuclei can also indicate the loss of nuclear 
lamina structural integrity(254). Such findings may therefore be an indication of 
altered cell function. 
 
Figure 8 Culture morphology and pseudo islet structure of EndoC-βH1 cells 
grown in different species microenvironments. 
1) Morphological differences between EndoC-βH1 cells grown in a human 
microenvironment compared with the same cells grown in a non-human 
microenvironment. A. Cells cultured in human derived culture reagents. B. Cells 
cultured in non-human derived culture reagents. C. DAPI nuclear stain in blue cells 
cultured in human derived reagents. No increase in nuclear blebbing. D. DAPI 
nuclear stain. Cells cultured in non-human derived reagents. No increase in nuclear 
blebbing. 
2) Bar graph showing number of pseudoislet structures. Cells cultured in human 
reagents showed significantly increased tendency to form three dimensional 
structures resembling beta cell only pseudo islets (p = 0.0005). Those cultured in 
non-human reagents form a confluent monolayer (p=0.004). 
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3.3.2 EndoC-βH1 cells cultured in a more human microenvironment demonstrate 
no alteration in insulin secretion, insulin processing or protein expression of 
mature beta cell markers 
 
We measured insulin secretion, insulin processing and expression of the mature 
beta cell proteins Pdx-1 and NeuroD1 in EndoC-βH1 cells cultured in a human-
like microenvironment by immunofluorescence (IF). EndoC-βH1 cells stained 
positively with antibodies against both insulin and pro-insulin, suggesting that 
they contain both pro-insulin and processed ‘free’ insulin, and there was no 
discernible difference in localisation or intensity of the insulin or pro-insulin 
staining between the two conditions (Figure 9). However, no area measurement 
was taken for proinsulin and therefore ratios have been based solely upon cell 
positivity. EndoC-βH1 cells cultured in both systems were also assessed for 
expression of the mature beta cell markers NeuroD1 (p = 0.335; mean difference 
− 2.72, standard error 2.79; Figure 10) and Pdx-1 (p = .164, mean difference 
3.91, standard error 2.76; Figure 10). No difference in the level of protein 
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expression of either marker was identified in EndoC-βH1 cells cultured using 
either methodology. 
 
Figure 9 Proinsulin and insulin expression in EndoC-βH1 cells grown in 
human vs non-human microenvironments. 
1A–1D: EndoC-βH1 cells cultured in human reagents (n = 6). 1A. DAPI stain. 1B. 
Proinsulin stain. 1C. Insulin Stain. 1D. Overlay image of 1A-C showing co-localisation of 
proinsulin with insulin as well as ‘free’ processed insulin indicating proper insulin 
processing in the cells cultured in human derived reagents.  
 
2A-D: EndoC-βH1 cells cultured in non-human reagents (n = 6) 2A. DAPI stain. 2B. Pro-
insulin stain. 2C. Insulin stain. 2D Overlay image of 2A-C showing co-localisation of 
proinsulin with insulin as well as ‘free’ processed insulin indicating proper insulin 
processing in the cells cultured in non-human reagents. This experiment was carried out 
in 6 replicates.  
 
3 Bar graph showing number of cells expressing proinsulin, free insulin and colocalised 
proinsulin and insulin compared to total cell counts from 5 representative images. 
 
 
  
1 2 
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Figure 10 NEUROD1 and PDX1 expression in EndoC-βH1 cells grown in 
different species microenvironments.  
1 A-D: EndoC-βH1 cells cultured in human reagents (n = 6). 1A. DAPI stain. 1B 
NEUROD1 stain. 1C. Insulin Stain. 1D. Overlay image of 1A-C showing co-localisation 
of NEUROD1 with DAPI. 2 A-D. EndoC-βH1 cells cultured in non-human reagents (n = 
6). 2A. DAPI stain. 2B. NEUROD1 stain. 2C. Insulin stain. 2D Overlay image of 2A-C 
showing co-localisation of NEUROD1 with DAPI.  
 
3 E-H: EndoC-βH1 cells cultured in human reagents (n = 6). 1E. DAPI stain. 1F PDX1 
stain. 1G. Insulin Stain. 1H. Overlay image of 1E-G showing co-localisation of PDX1 with 
DAPI.4 E-H. EndoC-βH1 cells cultured in non-human reagents (n= 6). 2E. DAPI stain. 
2F. PDX1 stain. 2G. Insulin stain. 2H Overlay image of 2E-G showing co-localisation of 
PDX1 with DAPI. 
 
5 Bar graph showing the number of NEUROD1 and PDX1 positive cells from cells 
cultured in both human and non-human culture conditions. 
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3.3.3 EndoC-βH1 cells cultured in a more human microenvironment exhibit 
enhanced glucose stimulated insulin secretion (GSIS) compared with those 
cultured in a non-human microenvironment 
 
We assessed basal insulin release and glucose-stimulated insulin secretion 
(GSIS) in cells cultured in non-human or human-like microenvironments by 
ELISA. Cells cultured in a non-human microenvironment stimulated with 20 mM 
glucose showed a doubling in insulin secretion compared to unstimulated 
controls which reproduces results found by Anderson et al. (0.13–0.24, n = 10, p 
= 0.047; SD = 0.015; Figure 11A).[19] However, we used a Bonferonni correction 
to take into account multiple testing and under these conditions (p = < 0.016) the 
cells cultured in a non-human environment did not show a statistically significant 
increase in insulin secretion following glucose stimulation. In contrast, the cells 
cultured in a human-like microenvironment showed a much stronger response, 
demonstrating a 4-fold increase in insulin secretion compared to unstimulated 
cells following glucose stimulation (0.11–0.47 p = 0.006; SD = 0.03; Figure 11A). 
A significant difference in insulin release in glucose-stimulated cells cultured in a 
human microenvironment (0.471 mU/ L) was detected compared with those 
cultured in a non-human microenvironment (0.239 mU/ L; p = 0.0003). 
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Figure 11 (A) Assessment of glucose stimulated insulin secretion and 
insulin content in EndoC-βH1 cells grown in different species 
microenvironments. (B) Change in gene expression in EndoC-βH1 cells 
grown in different species microenvironments. 
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3.3.4 EndoC-βH1 cells cultured in human reagents have an increase in key genes 
involved in beta cell fate 
 
We compared the expression of a panel of candidate genes involved in beta cell 
function or maintenance of beta cell differentiation status in EndoC-βH1 cells 
cultured in a more human microenvironment compared with those cultured in a 
non-human microenvironment. The genes assessed are described in Table 7. 
Although overall there was little difference in the gene expression profile between 
the two different culture methodologies, we did identify some changes in genes 
relating to alpha cell-like phenotypes. We identified a decrease in the alpha cell 
marker aristaless related homeobox (ARX) in a human-like microenvironment 
compared with cells cultured in a non-human microenvironment; (mean 
difference − 0.623, standard error 0.072, p =0.003; Figure 11B). Expression of 
transcripts encoding glucagon (GCG) showed lower expression in EndoC-βH1 
cells cultured in a more human microenvironment compared with cells cultured 
in a non-human microenvironment (RQ mean difference − 0.577, standard error 
0.064, p= 0.001; Figure 11B). There was a concomitant increase in PAX4 
expression in a human-like microenvironment compared with in cells cultured in 
a non-human microenvironment (mean difference 0.349, standard error 0.092, p 
= 0.032; Figure 11B). Finally, we noted an increase in the expression of 
transcripts encoding the pancreatic glucose sensor glucokinase (GCK); mean 
expression in cells cultured in a human micro- environment when compared with 
cells cultured in a non-human microenvironment; (mean difference, 0.244, 
standard error 0.070 p = 0.028; Figure 11B). 
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Table 7 Expression of genes involved in beta cell differentiation, fate or 
function in EndoC ßH1 cells cultured in human versus non-human 
microenvironments. 
SE = standard error, 95% CI = 95% Confidence Intervals. Genes showing expression 
differences in cells grown in ‘human’ or ‘non-human’ microenvironments are indicated in 
bold italic type.  
 
t-test for equality of means 
Gene p value Mean diff. SED 95% CI 
lower upper 
ARNT 0.406 0.098 0.104 -0.203 0.399 
ARX 0.003 0.624 0.072 0.400 0.847 
DDIT3 0.795 0.031 0.107 -0.358 0.419 
FOXO1 0.540 -0.145 0.213 -0.783 0.493 
GCG 0.001 0.578 0.065 0.398 0.757 
GCK 0.028 -0.244 0.071 -0.445 -0.043 
HES1 0.192 0.166 0.096 -0.159 0.491 
HIF1A 0.241 0.124 0.088 -0.136 0.384 
INS 0.107 0.193 0.093 -0.067 0.453 
LDHA 0.173 0.134 0.080 -0.093 0.362 
MAFA 0.960 -0.011 0.205 -0.580 0.558 
MAFB 0.462 -0.124 0.152 -0.554 0.306 
MYC 0.930 0.019 0.193 -0.790 0.828 
NANOG 0.238 -0.149 0.107 -0.448 0.149 
NEUROD1 0.221 -0.190 0.131 -0.555 0.174 
NKX2-2 0.575 -0.083 0.135 -0.464 0.298 
NKX6-1 0.870 -0.031 0.180 -0.532 0.469 
PAX6 0.056 -0.250 0.093 -0.510 0.010 
PAX4 0.032 -0.349 0.093 -0.643 -0.055 
PDX1 0.605 -0.089 0.158 -0.533 0.356 
POU5F1 0.079 -0.127 0.052 -0.279 0.025 
PTPN1 0.244 0.104 0.071 -0.130 0.337 
SLC16A1 0.285 0.139 0.109 -0.190 0.468 
SLC2A2 0.936 0.010 0.113 -0.338 0.358 
SLC2A4 0.385 0.132 0.124 -0.343 0.608 
SOX9 0.090 0.346 0.129 -0.111 0.802 
SST 0.275 -0.426 0.337 -1.362 0.510 
STK11 0.176 -0.060 0.036 -0.163 0.043 
SYP 0.339 0.111 0.091 -0.253 0.475 
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3.4 Discussion 
 
Beta cells are known to interact with their immediate extracellular 
microenvironment, and cell-cell communication has been shown to be important 
for regulation of beta cell function and cell identity(249-251). There are major 
differences between rodent and human beta cells in relation to cellular signalling, 
glucose transport and transcriptomic output, which have consequences for beta 
cell fate and beta cell function(19, 22, 83, 85). It follows, therefore, that the composition 
of the cellular microenvironment may influence studies of beta cell biology in 
human cells in vitro. Here, we assess differences in beta cell growth, glucose 
sensitivity and the expression of genes associated with beta cell function or 
differentiation in the human beta cell line EndoC-βH1 cultured in human and non-
human cellular microenvironments. We demonstrate that EndoC-βH1 cells 
demonstrate altered cellular morphology and enhanced response to glucose 
when cultured in a more human microenvironment. However, it is acknowledged 
that the data presented here represents only measurements of insulin, with first 
and second phase insulin release combined, and no other functional 
measurements, such as calcium imaging and electrophysiology, were performed. 
These features are accompanied by changes in the expression of genes 
associated with beta cell differentiation or beta cell function consistent with a 
more consolidated beta cell phenotype. 
 
The cellular microenvironment is known to influence cell fate and differentiation 
status for many types of cells(256-259). Fibronectin, in particular, is known to 
mediate mesodermal cell fate decisions(260). The extracellular matrix has 
particular importance in determining the functionality and survival of pancreatic 
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beta cells(249-251). Species differences in characteristics of extracellular matrix 
have previously been reported in relation to extracellular matrix components(261). 
Given these observations, it is perhaps unsurprising that cells may behave 
differently when cultured in cellular microenvironments derived from different 
species. The increased tendency of the cells to form beta cell only pseudo islet 
structures when cultured in human derived reagents may improve cell-cell 
communication and previous studies have shown its importance for insulin 
secretion in islets(262, 263). Whilst basal insulin secretion was similar in EndoC-βH1 
cells cultured in human and non-human cellular microenvironments, cells 
maintained in a more human-like microenvironment demonstrated an enhanced 
response to glucose in terms of combined first and second phase insulin 
secretion. Human beta cell lines typically exhibit 2–3 fold increases in insulin 
secretion in response to a glucose stimulus, representing a release of 
approximately 10% of their insulin content(46, 182, 264) and our results are consistent 
with this. Since the cells were seeded at the same density and have equivalent 
PD times, it is not thought that the differences in insulin secretion were caused 
by differences in cell numbers in culture. Our data suggest that the glucose 
sensing and secretion machinery remains intact in EndoC-βH1 cells cultured 
according to our protocols, and that these responses may perhaps be more 
physiologically representative of primary human beta cells when these cells are 
cultured in a more human microenvironment. We also assessed the effects of 
human and non-human cellular microenvironments on the expression of genes 
involved in beta cell function or beta cell identity in EndoC-βH1 cells. Although 
we saw little change in expression levels of the majority of genes expressed, 
changes in markers of alpha cell function (GCG, ARX, which were down-
regulated) and some genes involved in maintenance of beta cell state (PAX4, 
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which was upregulated) were noted. This finding is consistent with models in the 
literature which describe a regulatory feedback axis between ARX and PAX4, 
where the latter downregulates ARX expression to maintain beta cell fate(62, 92, 97, 
98). However, a recent study comparing rodent and human beta cell 
transcriptomes noted that in the mice, while Pax4 is required for Arx repression, 
it was undetectable in mature mouse beta cells(265). Total somatostatin RNA 
levels were lower in cells cultured in human reagents, but this did not reach 
statistical significance (Table 7). This is consistent with a more consolidated beta 
cell phenotype through repression of delta cell characteristics. We also identified 
an increase in the expression of glucokinase (GCK) transcripts in EndoC-βH1 
cells cultured in a more human-like microenvironment. Glucokinase is a 
metabolic sensor which is involved in the regulated secretion of insulin(266), and 
is also a MODY gene (MODY subtype 2)(267). The changes in gene expression 
that we note in our work are probably not confined to the genes we have tested, 
and emphasise the importance for transcriptomic studies to be carried out using 
the most physiologically-relevant model systems(41, 42, 72, 85, 90). 
 
The existence of a human cell model such as EndoC-βH1 is a great advantage 
for characterising disease in humans, but there are inevitably some limitations. 
EndoC-βH1 cells have been reported to express some disallowed genes(182). 
These are genes which are typically not expressed in human beta cells, due their 
roles in pyruvate and lactate metabolism, as this is imperative to protect against 
exercise induced insulin secretion. In primary beta cells the lactate 
dehydrogenase A (LDHA) and solute carrier family 15 member 1 (SLC16A1) 
genes are typically expressed at minimal levels(91). We identified that regardless 
of the culture microenvironment, EndoC-βH1 cells express the LDHA and 
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SLC16A1 genes at relatively high levels. LDHA and SLC16A1 code for proteins 
involved with pyruvate metabolism. They are disallowed in beta cells to prevent 
both inefficient processing of glycolytic products negatively impacting insulin 
secretion as well as exercise induced insulin release due to inappropriate 
pyruvate metabolism(91). 
 
The strengths of this study are the creation of a fully human in vitro model system 
for the study of beta cell biology in the context of human disease. Although islets 
remain the gold standard for analysis of human disease, EndoC-βH1 represent 
a good step forward and offer an acceptable, and tractable, substitute, 
comparable to newly developed Def-PANC IPSC cell lines. Although the findings 
of this study show that the use of human derived reagents provides a culture 
environment which is equivalent to the standard culture methodology for EndoC-
βH1 cells, there have been some challenges in developing the new protocol. This 
was particularly relevant for replacing the non-human ECM with a human 
equivalent and took some time to optimise. Further there are greater cost 
implications for sourcing human derived reagents. Despite such limitations, it is 
clear that the novel culture methodology described here can potentially improve 
the physiological relevance of the cellular microenvironment and provides a more 
human-like in vitro model system. We have shown that the species origin of the 
cellular microenvironment has affects and needs to be considered. Furthermore, 
our findings suggest that for EndoC-βH1 cells, this improves combined first and 
second phase GSIS response and potentially consolidates mature beta cell 
status in this cell line. This study also represents the most comprehensive gene 
expression profile to date for genes involved with beta cell differentiation status 
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and function, demonstrating the usefulness of this model for studies of islet 
function in man. 
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Chapter 4: 
Data Chapter. 
Cellular stressors may 
influence the 
differentiation status of 
human beta cells by 
moderation of 
alternative splicing 
patterns. 
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4.1 Introduction 
 
A reduction in beta cell mass occurs during the progression of Type 2 diabetes 
(T2D) and has been attributed to net enhancement of the rate of beta cell death(76, 
268). It is increasingly apparent, however, that changes in the differentiation status 
of beta cells may also be a contributory factor(61, 71). Studies in mice have 
described a gradual process of trans-differentiation from beta cells to alpha cells 
in type 2 diabetes models(47, 269), but dedifferentiation to earlier progenitor cell 
types has also been reported(71, 86).  Indeed, beta cell to delta cell 
transdifferentiation in response to immunological stimuli with specific relevance 
to type 1 diabetes, has also been reported by lineage tracing in mouse islets(270). 
Data from human pancreas is scarce, but the limited information available 
suggests that similar changes in differentiation status may also occur in 
humans(80, 96) .  
 
Maintenance of beta cell identity is determined by a tightly-regulated 
transcriptional network, consisting of proteins encoded by the Pancreatic and 
Duodenal Homeobox 1 (PDX1), Forkhead Box O1 (FOXO1), NK2 Homeobox 2 
(NKX2-2), MAF BZIP Transcription Factor A (MAFA), NK6 Homeobox 1 (NKX6-
1) and Paired Box 6 (PAX6) genes amongst others. Most of these do not display 
specific expression in beta cells but are also expressed in other pancreatic islet 
cell types(181, 271) and their role in cell identity definition is likely to involve the 
relative balance of expression(47, 107, 272). Among these, the FOXO1 gene, a 
downstream effector of AKT signalling in beta cells(273) has been demonstrated 
to play a specific role in the maintenance of beta cell differentiation status in 
mice(61). Indeed, in addition to its role in regulation of beta cell plasticity(104) and 
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diabetes induced stress responses(274), FOXO1 also regulates alternative 
splicing(275) a process which occurs in over 95% of human genes(276)  and allows 
for the generation of multiple mRNAs from a single coding unit as a means to 
provide a powerful interface between cell identity and cell stress(277-279). 
 
The cellular microenvironment created by diabetes is considered to be intensely 
stressful for beta cells(31) and elevated glucose levels (leading to glucotoxicity) 
have been linked to reduced expression of nodal genes within the transcriptional 
network that controls beta cell identity at the level of total gene expression(197). 
Changes to beta cell differentiation status also occur in response to chronic 
hyperglycaemia(82, 86). In addition, exposure of beta cells to certain lipids (such as 
the lipotoxic saturated fatty acid, palmitate) or to pro-inflammatory cytokines, has 
also been shown to induce widespread changes to the beta cell transcriptome(36, 
280).  
 
It has been suggested that altered beta cell identity may occur as a protective 
mechanism in response to a stressful extracellular milieu, with cellular plasticity 
serving to protect beta cells which might, otherwise, be lost via apoptosis. As 
such, this reversible plasticity allows for later re-differentiation should the 
extracellular environment become more conducive(86). Such effects could be 
relevant to all beta cells but they may be particularly important for “hub cells” 
within islets, which are known to be more sensitive to insult than other beta cell 
subsets, resulting in beta cell failure (79, 281).   
 
We hypothesised that exposure to the cellular stressors that accompany the 
development of diabetes may cause disrupted regulation of key genes involved 
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in the maintenance of beta cell identity, leading to changes in beta cell fate. 
Therefore, we exposed human EndoC-βH1 beta cells in culture to diabetes-
related cellular stressors (including elevated glucose and fatty acid levels, 
hypoxia or pro-inflammatory cytokines) and observed that a small population of 
cells adopted a delta cell-like phenotype. Elevated numbers of delta cells were 
also noted in pancreatic sections from individuals with T1D or T2D by 
immunofluorescence using an antibody to somatostatin, suggesting that such 
changes may also occur in vivo, as has been suggested recently by others(270). 
In EndoC H1 cells, these changes were accompanied by alterations in the 
expression patterns of several key beta genes involved in the control of cell fate 
and cell identity. Dysregulation of genes controlling alternative splicing and 
attendant changes in the splicing patterns of key beta cell genes were also seen. 
These changes were reversible upon removal of the stressful stimulus suggesting 
that targeting of the processes controlling alternative splicing patterns may offer 
a tractable modality for therapeutic intervention to maintain beta cell 
differentiation in diabetes. 
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4.2 Research Design and Methods 
 
4.2.1 Culture and treatment of EndoC-βH1 cells 
 
EndoC-βH1 cells at P<25 were seeded in 24-well plates at a density of 6.0 x 105 
cells/ ml and maintained according to a modified humanised culture protocol as 
previously described(282) for 72 hrs prior to treatment. For assessment of the 
effects of altered glycaemia, cells were treated with 2.5 mM and 25 mM D- or L-
glucose for 24, 36 or 48 hrs. For assessment of the effects of oxygen levels, cells 
were grown in 1%, 3% or 21% O2 for a period of 24, 36 or 48 hrs. For assessment 
of the effects of altered lipids, cells were treated with 0.5 mM palmitic acid, 0.5mM 
oleic acid or 0.5mM palmitic acid/0.5mM oleic acid for 12, 24 and 48 hrs, 
according to concentrations described in the literature(29, 207). To determine the 
effects of pro-inflammatory cytokines, cells were treated with TNF𝛼 (1000 U/ mL, 
INF𝛾 (750 U/ mL) and IL1𝛽 (75 U/ mL) for 12, 24 and 36 hrs. Cytokines and 
concentrations selected were based upon those reported in previous studies(39, 
205). For assessment of the effects of ER stress, cells were treated with 0.5 mM 
Tunicamycin for 24 hrs. Each treatment was carried out in 3 biological replicates, 
along with vehicle-only controls. Where cells were being used for subsequent 
immunofluorescence experiments they were cultured on 12 mm diameter 
coverslips and treated according to the conditions described above before being 
fixed with 4% paraformaldehyde.  
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4.2.2 Immunofluorescent characterisation of EndoC-βH1 cells in vitro 
 
The expression of mature beta cell markers, as well as islet cell hormones in 
EndoC-βH1 cells grown as described above was assessed using co-
immunofluorescent microscopy. Briefly, following treatment, cells were fixed with 
4% paraformaldehyde for 15 minutes at 4oC. Primary antibodies to PDX-1, PAX-
6, SST, GCG and HHEX were diluted in phosphate buffered saline (PBS) with 
0.1M Lysine, 10% donor calf serum, 0.02% sodium azide and 0.02% Triton X100 
(ADST), to permeabilise the cell membranes and incubated overnight at 4oC. 
HHEX was selected as a delta cell specific marker as it was not possible to use 
an antibody against the ghrelin receptor, which would have otherwise been a 
preferred choice for establishing a delta cell phenotype(283). Primary antibodies 
were visualised using species specific highly cross-absorbed secondary 
antibodies (Invitrogen, Paisley) diluted in ADST at 1/400 and incubated for 1 hr 
at room temperature. Sequential staining was then performed with an antisera 
raised against insulin (Supplementary Table S1) diluted in ADST for 1 hr, followed 
by a goat anti guinea-pig Alexa Fluor 647 along with DAPI (Sigma-Aldrich; 
1μg/ml) for 1 hr. Slides were visualised using a Leica AF6000 microscope (Leica, 
Milton Keynes, UK) and processed using the standard LASX Leica software 
platform. Ten randomly selected images were taken for each of the three 
biological replicates. Details of all antibodies are provided in Supplementary table 
S1. 
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4.2.3 Immunofluorescent characterisation of human pancreatic tissue sections 
from patients with Type 1 or Type 2 Diabetes 
 
Immunofluorescence staining was used to determine the expression of islet cell 
hormones in formalin-fixed paraffin embedded (FFPE) pancreatic sections from 
individuals with Type 1 diabetes (T1D), Type 2 Diabetes (T2D) and individuals 
without diabetes from the Exeter Archival Diabetes Biobank (EADB; 
http://foulis.vub.ac.be/) (Supplementary Table S2). All samples were studied with 
ethical approval (WoSREC4; 15/WS/0258).  Following dewaxing and rehydration, 
pancreas sections were subjected to heat–induced epitope retrieval (HIER) in 10 
mmol/ L citrate buffer (pH 6). The sections were then sequentially probed with 
antisera to somatostatin, glucagon and insulin (Supplementary Table S1) which 
were detected using species specific highly cross-absorbed secondary 
antibodies conjugated with fluorescent dyes (Invitrogen, Paisley, UK; 
Supplementary Table S1). Cell nuclei were stained with DAPI.  Slides were 
visualised using a Leica AF6000 microscope (Leica, Milton Keynes, UK) and 
processed using the standard LASX Leica software platform. Quantification of 
pancreatic endocrine cells types within the islet was achieved by assessing the 
comparative number of cells as a percentage of total islet area between T1D/ 
T2D patients and controls. Ten randomly selected images from 7 cases and 
controls were taken. Areas of somatostatin, insulin and glucagon staining were 
selected and measured using Image J(208).  
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4.2.4 RNA extraction, reverse transcription and assessment of total gene 
expression in EndoC-βH1 cells 
 
EndoC-βH1 cells were washed in Dulbecco’s phosphate buffered saline (D-PBS) 
before RNA extraction using TRI® reagent to harvest RNA (Sigma-Aldrich, 
Steinheim, Germany). RNA concentrations were adjusted to 100 ng/ μL prior to 
reverse transcription. Synthesis of cDNA was carried out using Superscript® 
VILO™ cDNA synthesis kit (Thermo Fisher, Foster City USA) according to 
manufacturer’s instructions. Gene expression levels were measured in treated 
and untreated EndoC-βH1 cells by quantitative real-time PCR. A panel of 30 á 
priori target genes was selected on the basis that they had known roles in either 
beta cell fate or function, were markers of cell stress or were markers of other 
pancreatic endocrine cell types (genes are listed in supplementary table S3). 
Endogenous control genes (PPIA, UBC, HPRT1, GUSB, B2M and IDH3B) were 
empirically selected for stability in response to treatment. qRTPCR reaction 
mixes included 2.5 μL Taqman® Universal PCR mastermix II (no AmpErase® 
UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL cDNA and 
0.25 μL Taqman® gene assay (Thermo Fisher, Foster City USA) in a 5 μL 
reaction volume. Cycling conditions were: 50°C for 2 min, 95°C for 10 min and 
50 cycles of 15 seconds at 95°C for 30 s and 1 minute at 60°C. Reactions were 
carried out in 3 biological replicates and 3 technical replicates. Assay Identifiers 
are given in Supplementary table S3. The relative expression of each test 
transcript was determined by the comparative Ct approach. Expression levels 
were calculated relative to the geometric mean of the endogenous controls, but 
also to the global mean of expression across all transcripts tested, (as one would 
with an array) which was empirically determined not to vary across test conditions 
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to provide a robust baseline. Expression levels were normalised to the median 
level of expression seen in untreated EndoC-βH1 cell controls. Differences in 
gene expression levels between mock-treated and treated EndoC-βH1 cells were 
compared to the same time point controls for each condition and investigated for 
statistical significance by student independent t-test carried out using SPSS 
version 23 (IBM, North Castle, NY, USA). Data were presented as means ± 
S.E.M. 
 
4.2.5 Determination of Splicing Factor expression in EndoC-βH1 cells 
 
Splice site usage and thus patterns of alternative splicing are determined by the 
relative balance of serine-arginine rich RNA binding proteins (SRSFs; splice site 
activators) and heterogeneous nuclear ribonucleoprotein particles (hnRNPs; 
splice site inhibitors) at each splice site(284). Splicing factor Assay Ids are given in 
Supplementary Table S4. Splicing factor expression was quantified in EndoC-
βH1 cells using Taqman® Low Density Array (TLDA) on the Quantstudio 12K 
Flex system. Cycling conditions were 1 cycle each of 50 oC for 2 minutes, 94.5 
oC for 10 minutes and then 40 cycles of 97 oC for 30 seconds and 57.9 oC for 1 
minute. The reaction mixes included 50 μL Taqman® Fast Universal PCR 
Mastermix (Life Technologies, Foster City, USA), 30 μL dH2O and 20 μL cDNA 
template. The 100 μL reaction mix was dispensed into the TLDA card chamber 
and centrifuged twice for 1 minute at 1000 rpm to ensure the correct distribution 
of solution to each well and removal of bubbles. Transcript expression was 
assessed the by the comparative Ct approach relative to the endogenous control 
genes IDH3B, GUSB and PPIA which were selected based upon empirical 
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evidence for stability in response to treatment and normalised to transcript 
expression in the untreated cells.  
 
4.2.6 Assessment of alternative splicing in EndoC-βH1 cells 
 
Of the panel of 30 genes selected for total gene expression, 17 were known to 
exhibit alternative splicing.  Of these, 5 were chosen for further analysis in EndoC-
βH1 cells according to three criteria: i) unique, isoform-specific exon boundaries, 
ii) known functional differences between the isoforms, and iii) relevance of 
isoform differences to beta cell differentiation status or islet function. Isoforms of 
the INS, PAX6, POU5F1 (OCT4), NANOG and PTPN1 genes fulfilled these 
criteria. Isoform-specific Taqman custom assays (Thermo Fisher, Waltham, MA, 
USA) were designed across unique splice boundaries that distinguish between 
the functionally distinct isoforms, please refer to figure 12 . Probe and primer 
sequences are given in Supplementary Table S5.  
 
To investigate whether the PAX6(5a) isoform of the PAX6 gene was important 
for changes in beta cell differentiation status during cell stress, a custom select 
siRNA was designed (assay ID 1THO, Thermo Fisher, Waltham, MA, USA). 
Effective candidate sequences were selected using siDIRECT2. Cells were 
cultured in 1 mL penicillin and streptomycin free culture media with 250 μL from 
a master mix of siRNA containing 300 μL Optim-MEM® (Life Technologies, Foster 
City, USA) , 9 μL Lipofectamine® (Life Technologies, Foster City, USA) and 3 μL 
siRNA at 10 μM, made up according to the manufacturer’s instructions. Cells 
were cultured for 72 hrs prior to the administration of siRNA and were then 
incubated for a further 48 hrs. qPCR was performed to ascertain whether the 
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PAX6(5a) knock down was successful. Following siRNA validation, cells were 
cultured in 24 well plates for 72 hours before the addition of the siRNA mastermix 
at the concentration specified in the manufacturer’s protocol. The siRNA was 
incubated for 48 hrs, before treating relevant wells with 25 mM glucose for 24 hrs. 
After treatment cells were fixed with 4% paraformaldehyde for 15 minutes at 4 
oC. 
 
Figure 12. Schematic diagram showing regions where isoforms probes 
were designed. 
 
1) Insulin gene. Schematic showing exon boundary and region of probe design to 
distinguish intronic inclusion 
2) POU5F1. Schematic showing exon boundary to distinguish between OCT4A and 
OCT4B/B1 variants. 
3) NANOG. Schematic showing exon boundary to distinguish between long and short 
variants. 
4) PTPN1. Schematic showing exon boundary to distinguish between long and short 
variants and exon inclusion. 
5) PAX6. Schematic showing exon boundary to distinguish between PAX6(5a) family 
with exon 5 inclusion and PAX6 canonical family. 
 
 
 
 
 
 
 
 
 
 
134 
 
 
4.2.7 Reversal of delta cell phenotype in EndoC-βH1 cells by restoration of 
homeostasis 
 
To test for reversibility of effect in our system, cells were first treated with 25 mM 
glucose or 0.5 mM Tunicamycin for 24 hrs as described above. Immediately 
following this, cells were restored to normal culture conditions for 72 hrs prior to 
assessment of cell identity, total gene expression and splicing patterns.  
 
4.2.8 Reversal of delta cell phenotype in EndoC-βH1 cells by restoration of 
homeostasis or by small molecule inhibition of AKT pathway 
 
Previous reports suggest that changes to beta cell identity can be reversed upon 
removal of cellular stress(274). Reports have suggested that the AKT pathway, one 
of the signalling mechanisms whereby cells can communicate signals from stimuli 
such as cellular stress stimuli from the exterior of the cell is involved with 
regulation of splicing decisions and has also been linked with changes in beta 
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cell plasticity(31, 285, 286). To test for reversibility of effect in our system, cells were 
first treated with 25 mM glucose or 0.5 mM Tunicamycin for 24 hrs as described 
above. Immediately following this, cells were restored to normal culture 
conditions for 72 hrs prior to assessment of cell identity, total gene expression 
and splicing patterns. To assess the effect of AKT inhibition on response to 
hyperglycaemia, cells were treated with 25 mM glucose alone, 1 μM of the AKT 
inhibitor SH-6 alone, or 25 mM glucose in combination with 1 μM SH-6 for 24 hrs 
prior to assessment of splicing patterns and cell identity as described above. 
 
4.3 Results 
 
4.3.1 Metabolic and ER stress is associated with beta cell to delta cell-like trans-
differentiation in EndoC-βH1 cells 
 
We quantified the effect of treatments designed to mimic the islet milieu in 
diabetes on cell identity in EndoC-βH1 cells cultured in vitro. A small (~5%) but 
consistent and statistically robust increase in the number of somatostatin-positive 
cells was noted in EndoC-βH1 cell cultures in response to incubation with 
elevated glucose levels (both D- and L-glucose) for 24 hrs. Control cells, 
incubated in 5.5mM D-glucose showed no evidence of somatostatin 
immunopositivity (p=9.1 x 10-5, figure 13A). The proportion of somatostatin 
positive cells remained stable over longer periods of culture and no evidence of 
increased rates of cell death was seen in cells incubated under hyperglycaemic 
conditions (figure 13B). An increase in somatostatin positive cells was also noted 
in response to palmitic acid, hypoxia, pro-inflammatory cytokines, and 
tunicamycin (p = 5.2 x 10-5, p= 4.2 x 10-5, p=4.0 x 10-3, and p = 5.0 x 10-3 
respectively; figure 13C). Conversely, no such increase was seen in response to 
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oleic acid (p=0.343), although cells exposed to both palmitic acid and oleic acids 
concurrently responded in a similar manner to those treated with palmitate alone 
(p=0.003).  No evidence of increased glucagon expression was noted in control 
or treated EndoC-βH1 cells at the protein level although a rise in GCG mRNA 
(and that encoding the transcription factor ARX) was evident in response to some 
treatment conditions. Despite the increase in somatostatin immunopositivity, we 
were unable to detect any change in the expression of HHEX mRNA transcripts.  
Figure 13. The effects of cell stressors on hormone expression.  
A) Immunofluorescence cytochemistry showing gain of somatostatin expression in cells 
treated with 25 mM high glucose. Cells were treated for 24, 36 and 48 hours and showed 
gains of somatostatin expression at all time points. There was no increase in the 
proportion of cells gaining somatostatin expression at later time points.  Representative 
image panels from 36 hour time point.  Image 1. 25 mM glucose, DAPI staining. Image2. 
25 mM glucose overlay of DAPI, somatostatin (green). Image 3. 25 mM high glucose. 
DAPI and insulin (red). Image 4. 25 mM high glucose overlay of DAPI, somatostatin 
(green) and insulin (red).  
B) Timecourse of somatostatin positivity in cultures of EndoC-βH1cells treated with high 
glucose (25mM). C)The number of Somatostatin positive cells in cultures of EndoC-
βH1cells treated with high glucose (25mM), Palmitic Acid (PI) 0.5mM, Hypoxia (3% O2), 
Cytokines (TNFα [1000 U/ mL], INFγ [750 U/ mL] and IL1β [75 U/ mL]), Tunicamycin 
(0.5mM) or oleic acid (0.5mM). 
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4.3.2 Pancreatic sections from donors with T1D or T2D demonstrate increased 
numbers of delta cells 
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To determine if the effects we had noted in EndoC-βH1 cells vitro were also 
recapitulated in human pancreas, we determined the proportion of different 
endocrine cell types in islet preparations from donors with T1D or T2D, and in 
control islets. We identified a significant increase in somatostatin-positive (delta) 
cell area in tissue sections from patients with either T1D or T2D compared to 
control islets. The total somatostatin positive area in in situ islets from T1D or 
T2D donors compared to control islets was 17069.9 μM (3%) v/s 6166.24 μM 
(1%) for T2D (p= 2.47 x 10-9) and 31713 μM (9.3%) v/s 7360  μM (1% of islet 
area) for T1D (p= 2.1 x 10-6) (figure 14A and 2B; n=10 images for 5 cases and 5 
controls).  
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Figure 14 Hormone staining patterns of donor islets from controls or 
individuals with T2D.  
A) Immunofluorescence on human donor pancreatic tissue showing increases in the 
staining area of delta cells in cases of T1D compared to controls. Representative image 
panels from cases and controls.  Image 1. DAPI and somatostatin (green) staining. 
Image 2. Overlay of DAPI, somatostatin (green), glucagon (red) and insulin (turquoise). 
Image 3. DAPI and somatostatin (green) staining. Image 4. Overlay of DAPI, 
somatostatin (green), glucagon (red), no evidence of insulin (turquoise) in T1D islet.  
B) Immunofluorescence on human donor pancreatic tissue showing increases in the 
staining area of delta cells in cases of T2D compared to controls.  Representative image 
panels from cases and controls.  Image 5. DAPI and somatostatin (green) staining. 
Image 6. Overlay of DAPI, somatostatin (green), glucagon (red) and insulin (turquoise). 
Image 7. DAPI and somatostatin (green) staining. Image 8. Overlay of DAPI, 
somatostatin (green), glucagon (red) and insulin (turquoise) in T2D islet. 
C) Graph showing increase in delta cells in T1D and T2D case versus controls. 
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4.3.3 Key beta cell fate and function genes show disrupted expression in 
response to cell stress stimuli in EndoC-βH1 cells 
 
We tested the total expression levels of 31 genes comprising markers of 
endocrine cell types, genes with roles in determination of beta cell identity or 
those acting as markers of cell stress in response to treatments designed to 
mimic aspects of diabetic pathophysiology. Large scale changes in the 
expression of the majority of these genes were noted in response to all treatments 
across all timepoints (supplementary table S6). Representative data for the 24 hr 
timepoint are given in figure 15. We also noted treatment-responsive differences 
in the expression of a core set of transcription factors known to be important for 
maintenance of beta cell fate and function (figure 15; supplementary table S6). 
Notable amongst these were MAFA, PAX6, NEUROD1, NKX2-2, PDX1, NKX6-
1 and PAX4 which are known to form an interacting network. All of these were 
responsive to either 25mM D-glucose or 0.5 mM palmitic acid. PAX6, NKX2-2, 
PDX1, NKX6-1 and PAX4 were similarly responsive to hypoxia. Differences in 
expression were also evident for HES1, SOX9, NGN3 NANOG and POU5F1 
genes which are markers for cellular plasticity (figure 15; supplementary table 
S6). Markers of cellular stress including DDIT3, ARNT, and MYC also showed 
altered expression patterns across all of the assays (figure 15; supplementary 
table S6).  
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4.3.4 Changes to the expression of splicing factors and beta cell splicing patterns 
in response to cell stress stimuli in EndoC-βH1 cells 
 
We assessed the responses of genes encoding splicing factor genes, given their 
role in mediating the relationships between cell and environment(285, 286). Several 
splicing factors, notably the genes encoding HNRNPA2B1, AKAP17A, PNSIR, 
SRSF1, SRSF2, SRSF3, SRSF6 and LSM14A demonstrated dysregulated 
expression in response to treatment with cytokines, hypoxia high/low glucose or 
altered lipids (figure 16; supplementary table S7). 
 
To determine whether these changes had functional significance, we also 
assessed the splicing patterns of key beta cell genes. Genes were included for 
analysis where they were known to produce alternatively-spliced isoforms with 
functionally different roles in beta cell function or differentiation status that we 
could identify uniquely. 3/5 genes fitting these criteria (PAX6, PTPN1 and 
POU5F1/OCT4) demonstrated changes in the ratio of alternatively-expressed 
isoforms in response to treatment (figure 17; supplementary table S8). However, 
in contrast to what we observed at total gene expression levels, there was only 
dysregulation of insulin isoforms at the splicing level following exposure to an 
Hypoxic environment (figure 17, supplementary table S8). Following validation of 
the siRNA PAX6(5a) knockdown, siRNA and 25 mM glucose treated cells 
showed no change in the proportion of somatostatin positive cells compared to 
cells treated with 25 mM glucose alone. 
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Figure 15 Effects of cell stresses on gene expression of genes with roles in 
beta cell differentiation or function. 
Volcano Plot demonstrating the most dysregulated genes in response to 24 hours 
treatment with cellular stressors associated with a type 2 diabetic microenvironment. 
Volcano plots are illustrative of the numbers of genes dysregulated by cell stresses, for 
specific information regarding individual genes at later time points please refer to 
supplementary data table S6. Y axis shows -log10 of p value. Upper line infers the 
Bonferroni multiple testing limit. The lower dotted line gives nominal significance.  
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Figure 16 Effects of cell stresses on splicing factor expression. 
Modified Manhattan plot showing the effects of cellular stressors on splicing factor 
expression. Y axis shows -log10 of p value. Upper line infers the Bonferroni multiple 
testing limit. The lower dotted line gives nominal significance. Blue circles 25 mM high 
glucose. Green squares: 2.5mM low glucose.  Red diamonds: <3% O2.   Purple 
triangles: 0.5 mM Palmitic Acid. Orange triangles: Cytokines. Upper line infers the 
Bonferroni multiple testing limit. The lower dotted line gives nominal significance. 
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Figure 17 Effects of cell insult treatments on alternatively spliced gene 
expression. 
 
X axis refs to the ratio of alternatively expressed isoforms at each locus. Isoform variants 
were divided by canonical variants.  Y axis shows -log10 of p value. Upper line infers the 
Bonferroni multiple testing limit. The lower dotted line gives nominal significance. Blue 
circles: 25 mM glucose. Green squares: 2.5mM glucose.  Red diamonds: <3% 
O2.   Purple triangles: 0.5 mM Palmitic Acid. Pink inverse triangles: Cytokines. Orange 
hexagons: 0.5 mM.  
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4.3.5 Changes in beta cell identity and beta cell expression patterns are 
reversible upon restoration of homeostatic conditions in EndoC-βH1 cells 
 
To determine whether the changes in cell identity and gene expression patterns 
we have observed were permanent or reversible, we exposed EndoC-βH1 cells 
to cellular stressors for 24 hrs but then returned the cells to control conditions for 
72 hrs prior to assessment. Following treatment with either high glucose or 
tunicamycin, we noted an increase in the number of somatostatin positive cells 
compared to controls (p=3.69 x 10-9 and p=1.3 x 10-4), and dysregulation of 
splicing ratios of candidate alternatively-spliced genes (figure 18; supplementary 
table S9). Following return to control conditions, the number of somatostatin 
positive cells was indistinguishable from zero time point controls, (figure 18a; 
p=0.568 and p=0.643), and patterns of alternative splicing were restored (figure 
18, supplementary table S9) indicating that the treatment induced changes we 
noted were reversible.  
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Figure 18 Rescue of phenotype by restoration to normal culture conditions. 
Figures show rescue of beta cell phenotype by restoration to 5 mM euglycaemic culture 
conditions for 72 hrs. A). Immunofluorescence image panel. Images 1, 3, 5: DAPI and 
Somatostatin (green). Images 2, 4, 6: Overlay, DAPI, Somatostatin (green), Insulin (red). 
Panels 1 – 2: representative cells from control. Panels 3 – 4: 25 mM glucose.  Panels 5 
– 6: 24 hr treatment with 25 mM glucose and restoration to normal culture conditions for 
72 hrs. B). Graph. Total gene expression 25 mM glucose for 24 hrs versus 25 mM 
glucose treatment followed by 72 hrs rescue in 5 mM glucose media. C). Alternative 
splicing patterns 25 mM glucose 24 hrs versus 25 mM glucose treatment followed by 72 
hrs rescue in 5 mM glucose media. 
 
 
 
  
Control 24 hrs 25 mM Glucose Rescue 
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4.3.6 Restoration of splicing patterns and splicing factor activity with the AKT 
inhibitor SH-6 renders cells immune to transdifferentiation in EndoC-βH1 cells. 
 
The AKT pathway has previously been suggested to have a role in regulation of 
splicing and splicing factor activity(285). Treatment with low concentrations of the 
AKT inhibitor SH-6 alone had no impact on the number of cells staining positively 
for somatostatin expression, whereas cells treated with 25 mM glucose 
demonstrated an increase in SST positivity similar to that we observed previously 
(p = 0.0004). EndoC-H1 cells treated with SH-6 and subsequently exposed to 
25 mM glucose for 24 hrs however showed no increase in the number of 
somatostatin positive cells compared to controls; figure 19). This effect was also 
noted at the level of splicing factor expression and alternative splicing 
(supplementary table S10). 
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Figure 19 EndoC  H1 cells treated with the AKT pathway inhibitor SH6 and 
exposed to 25 mM glucose. 
Cells showed no increase in the number of somatostatin cells compared with both 
controls and cells treated with 25 mM glucose alone.  
1) Panels A-D Cells treated with SH6 alone. Panels E-H Cells treated with SH6 and 25 
mM high glucose. Panels I-L Control cells no treatment. Panels M-P Cells treated 
with 25 mM high glucose alone. 
2) Graph showing the number of somatostatin positive cells counted from 10 separate 
images. 
 
 
 
 
 
 
 
 
  
Blue: DAPI. Green: Somatostatin. Red: Insulin.  
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4.4 Discussion 
 
Loss of beta cell mass over the disease course is characteristic of both T1D and 
T2D. Studies using rodent models have suggested that some of the change may 
be due to alteration in beta cell differentiation status in response to cellular 
stresses(57, 96, 113), but this phenomenon has not been explored extensively in 
humans. In the work described here, we demonstrate that when EndoC-H1 beta 
cells are treated with cell stressors designed to mimic aspects of the islet milieu 
in diabetes (hyperglycaemia, pro-inflammatory cytokines or palmitic acid) or with 
the ER stress inducer tunicamycin, a small proportion of the cells cease to 
produce insulin and begin to synthesise somatostatin, suggesting a change in 
phenotype. Similar effects were also noted when cells were exposed to L-
glucose, suggesting that the response may occur in response to an osmotic 
stress and also that changes to beta cell differentiation status are independent of 
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metabolism. Conversely, the monounsaturated fatty acid oleate, a fatty acid that 
is not known to induce metabolic stress in human beta cells(287) elicits no such 
response. Increased somatostatin positive staining area was also evident in islet 
preparations from donors with T1D and T2D, suggesting that these changes may 
also occur in vivo. 
 
The change in differentiation status of EndoC-H1 cells was accompanied by 
large-scale alterations in the pattern of expression of key transcription factors 
involved in the control of beta cell identity, as well as in genes responsible for 
beta cell identity and function when assessed as an á priori candidate gene set. 
Beta cell differentiation status is known to be influenced by a transcriptional 
network of genes including: PAX6, PDX1, NEUROD1, NKX2-2, NKX6-1, MAFA, 
PAX4 and FOXO1(196, 288) and notably the expression of these genes was 
significantly disrupted across multiple time points in response to each of the 
insults employed in the present work. The pattern of expression of serine arginine 
rich (SR) and heterogeneous ribonucleoprotein particle (HNRNP) genes, which 
encode positive and negative regulators of alternative splicing, was also 
dysregulated, as were patterns of alternative splicing for the majority of 
functionally-relevant candidate genes tested. However, the knock down of the 
PAX6 isoform PAX6(5a) did not affect the cells responses to high glucose. We 
hypothesise that these alterations in splicing patterns may be affected by 
changes in the expression of FOXO1 in response to each treatment. FOXO1 
plays a role in the regulation of splicing factors in human primary fibroblasts(275), 
as well as having well-known roles in cellular stress(289) and in regulation of beta 
cell plasticity(273). Alternative splicing of multiple gene targets has been well 
documented as a response to cellular stress(277). FOXO1 is a downstream 
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effector of AKT signalling, and accordingly, inhibition of AKT in our system 
restored splicing factor expression and patterns of alternative splicing to those 
seen in euglycaemia and prevented changes to differentiation status. These 
observations are consistent with previous reports that stress-related changes in 
beta cell differentiation are modifiable once the noxious stimuli is removed(197, 274). 
 
We noted some interesting differences in the responses measured here 
compared to those noted previously in other species. For example, studies in 
murine models of T2D have revealed both beta cell de-differentiation and trans-
differentiation, but in these cases the change in phenotype was from beta to alpha 
cells(47, 269), rather than from beta to delta cells as we  observe. Interestingly, we 
did find an increase in the expression of transcripts encoding both ARX and 
glucagon, which are known alpha cell markers, in EndoC-H1cells but we did not 
detect the expression of glucagon at the protein level. The factors underlying 
apparent species differences may arise because of differences in islet 
architecture, gene expression and glucose sensing between rodent and 
human(290), but may also reflect profound differences in mRNA processing 
between these species since only 30% of splicing events are conserved between 
mice and humans(291).  
 
We acknowledge that our study has limitations. Firstly, the changes in cell identity 
were observed in only a small proportion of the total cell population. The reasons 
for this are unclear but appear to be unrelated to the time of incubation since the 
response occurred very quickly (within 24 hrs) and was then stable for several 
days in the continued presence of the stressor. One possibility is that the cultures 
are heterogeneous and that a small population of cells are more susceptible to 
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stress-induced plasticity than the majority. It would be interesting to determine 
whether this putatively ‘plastic’ cell population shares features with cells such as 
those identified as ‘hubs’ in intact islets since these also display a greater degree 
of plasticity than other beta cell sub populations(79). However, it may also be that 
the EndoC βH1 cell line is contaminated with progenitor like cells although the 
data from the rescue experiments might suggest that this is not the case, given 
the absence of somatostatin positivity during normal culture conditions.   
 
We also acknowledge that we have not conducted an exhaustive survey of 
splicing changes in the treated cells. The heterogenous nature of the treated 
cultures means that only the largest effects would have been revealed by our 
transcriptome-wide analysis. In particular, we focused on those genes known to 
be responsible for beta cell identity decisions. Importantly, some of the effects on 
gene expression had not been detected at the level of total gene expression, 
highlighting the need to undertake an investigation of splicing changes when 
considering transcriptomic profiling.  
Our data are consistent with a model in which beta cell trans-
differentiation, or dedifferentiation to a progenitor like state followed by re-
differentiation into a delta cell like state, can occur in response to the imposition 
of cellular stress and we postulate that this may reflect the dysregulation of 
splicing factor genes mediated by altered expression of FOXO1. This work is, to 
our knowledge the first demonstration that dedifferentiation and/ or trans-
differentiation in human endocrine cells may be specifically associated with 
changes in the regulation of mRNA splicing. Without lineage tracing experiments, 
which are not currently possible when using human model systems, it is not 
possible to infer that these changes are beta to delta cell transdifferentiation. 
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However, the consequence of the changes we observed may, at the molecular 
level, result in the altered expression of key genes involved in cell fate decisions. 
Targeting splicing patterns for therapeutic benefit is now a very real possibility 
with several approaches already in clinical trials(292). We have shown that 
differentiation status in beta cells can be influenced by targeting splicing 
decisions, and a deeper understanding of the specific points at which such 
interventions could be focused might confer benefits for diabetes therapy in the 
future. 
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Supplementary table S1. Details of antibodies and experimental 
conditions 
 
 
Ab Supplier Cat # Lot number Species Conc used: 
PDX1 Abcam Ab47267 GR238480-
1 
Rabbit 
polyclonal 
IgG 
1/500 
NEUROD1 Abcam Ab60704 GR249997-
1 
Mouse 
monoclonal 
IgG2A 
1/400 
PAX6 Abcam Ab195045 GR313146-
6 
Rabbit 
monoclonal 
IgG 
1/350 
Insulin DAKO 80564 10088287 Guinea-pig 
polyclonal 
1/363 
Glucagon Abcam Ab10988 GR260160-
1 
Mouse 
monoclonal 
IgG1 
1/2000 
Somatostatin Abcam Ab30788 GR213035-
1 
Rat 
monoclonal 
IgG2b 
1/200 
HHEX LSBIO LS-
B11570 
Clone 3F4 Mouse 
monoclonal 
IgG2b 
1/500 
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Supplementary table S2. Patient data table. 
 
Disease status Case ID Age (years) Duration (years) 
T1D SC107 18 5 
T1D SC109 20 6 
T1D E557 22 4 
T1D SC112 22 9 
T1D SC116 35 15 
T1D nPOD6038-01PB 37.5 20 
T1D nPOD6086-02PB 78 74 
Control 12142 17 - 
Control 146/66 18 - 
Control PAN1 22 - 
Control 329/72 24 - 
Control 447/71 32 - 
Control nPOD6095-06PB 40 - 
Control nPOD6012-4PT 68 - 
T2D 38/66 56 0.25 
T2D 386/66 unknown unknown 
T2D 184/66 60 unknown 
T2D 192/71 65 unknown 
T2D 192/69 66 unknown 
Control 110/96 58 - 
Control 202/75 60 - 
Control 224/66 67 - 
Control 44/66 60 - 
control 244/66 63 - 
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Supplementary table S3. Assay details of total gene expression 
 
Gene 
Symbol 
Assay ID Gene Symbol Assay ID 
STK11 Hs00176092_m1 HES1 Hs00172878_m1 
FOXO1 Hs01054576_m1 GCG Hs01031536_m1 
PAX6 Hs00240871_m1 PTPN1 Hs00942477_m1 
GCK Hs01564555_m1 POU5F1 Hs04260367_gH 
GUSB Hs00939627_m1 NKX2-2 Hs00159616_m1 
SLC16A1 Hs01560299_m1 INS Hs00355773_m1 
MAFA Hs01651425_s1 HIF1A Hs00153153_m1 
NKX6-1 Hs00232355_m1 NANOG Hs04399610_g1 
ARX Hs00292465_m1 PAX4 Hs00173014_m1 
PPIA Hs04194521_s1 SST Hs00356144_m1 
LDHA Hs01378790_g1 ARNT Hs01121918_m1 
NEUROD1 Hs01922995_s1 MYCL Hs00420495_m1 
SOX9 Hs01001343_g1 PDX1 Hs00236830_m1 
PTF1A Hs00603586_g1 SLC2A2 Hs01096908_m1 
HPRT1 Hs02800695_m1 DDIT3 Hs00358796_g1 
PDGFRA Hs00998026_m1 MAFB Hs00271378_s1 
SYP Hs00300531_m1 HHEX Hs00242160_m1 
VIM Hs00958111_m1 NEUROG3 Hs01875204_s1 
ONECUT1 Hs00413554_m1   
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Supplementary table S4. Assay Ids for splicing factors quantified in this 
study. 
 
 
Gene symbol Assay ID 
AKAP17A Hs00946624_m1 
HNRNPA0 Hs00246543_s1 
HNRNPA1 Hs01656228_s1 
HNRNPA2B1 Hs00955384_m1 
HNRNPD Hs01086912_m1 
HNRNPH3 Hs01032113_g1 
HNRNPK Hs03989611_gH 
HNRNPM Hs00246018_m1 
HNRNPUL2 Hs01398726_g1 
IMP3 Hs00251000_s1 
18s rRNA Hs99999901_s1 
LSM14A Hs00385941_m1 
LSM2 Hs01061967_g1 
PNISR Hs00369090_m1 
SF3B1 Hs00961640_g1 
SRSF1 Hs00199471_m1 
SRSF2 Hs00427515_g1 
SRSF3 Hs00751507_s1 
SRSF6 Hs00740177_g1 
SRSF7 Hs01032695_m1 
TRA2B Hs00190210_m1 
IDH3B Hs00199382_m1 
PPIA Hs04194521_s1 
GUSB Hs00939627_m1 
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Supplementary table S5. Sequences of isoform specific probes and 
primers used in this study 
 
 
 
 
 
 
 
 
 
  
Assay 
Name 
Assay IDs Forward Primer Seq. Reverse Primer Seq. Reporter 1 
Sequence 
INS_EX1 NM_0011
85097 
CCATCAAGCAGGTC
TGTTCCAA 
GGGCCATGGCAGAAGGA CCTTTGCGTCA
GATCACT 
INS_EX1D
EL 
NM_0002
07 
GGCTTCTTCTACACA
CCCAAGAC 
CCTCCAGGGCCAAGGG CTGCAGGGCAG
CCTG 
INS_EX1L
NG 
NM_0011
85098 
GGACAGGCTGCATC
AGAAGAG 
GGGCCATGGCAGAAGGA CCATCAAGCAG
ATCACTG 
PTPN1_EX
2DEL 
NM_0012
78618.1 
AGTTCGAGCAGATC
GACAAGTC 
GCGTTGATATAGTCATTAT
CTTCTTGATGTAGT 
CTATGGTCAAC
TGGTAAATG 
NANOG1_
EX4LNG 
NM_0248
65.3 
TGGCCGAAGAATAG
CAATGGT 
CATCCCTGGTGGTAGGAA
GAGTA 
ACGCAGAAGGC
CTCAGC 
PAX6_EX5
DEL 
NM_0012
58462.1  
NM_0012
58463.1  
NM_0013
10158.1 
NM_0013
10160.1 
NM_0013
10161.1 
NM_0016
04.5  
CGTGCGACATTTCC
CGAATT 
GTCTCGTAATACCTGCCC
AGAATTT 
ATCCGTTGGAC
ACCTGC 
NANOG_E
X4TRU 
NM_0012
97698 
TGGCCGAAGAATAG
CAATGGT 
GGTTCCCAGTCGGGTTCA
C 
ACGCAGGGATG
CCTG 
POU5F1_E
X3 
 GAAGAGGATCACCC
TGGGATATACA 
TGGCTGAATACCTTCCCA
AATAGAAC 
CAGGCCGATGT
GGCTC 
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Supplementary table S6: Effects of cell insult treatments on total gene expression. 
The p values for statistical significance as determined by independent t-test, Mean difference, Standard errors of measurement (SED) and the 95% 
confidence intervals are given below. Bold italic p<0.016 Bonferroni correction for 3 tests: 1st, 2nd and 3rd time-points. Gene list is á priori  so no further 
corrections. Italic underlined p<0.050. No correction for multiple testing. Tunicamycin table Bold italic p=<0.025. Bonferroni correction for 2 tests: 
treatment and rescue. Gene list is á priori  so no further corrections. Italic underlined p=<0.050. No correction for multiple testing 
 
Hyperglycaemia 25mM glucose assay Independent t-test p = 0.016 
24 hours 36 hours 48 hours 
Gene P 
valu
e 
Mean 
Diff. 
SED 95% C I Gene P 
value 
Mean diff. SED 95% C I Gene P 
value 
Mean 
diff. 
SED 95% C I 
Lower Upper Lower Upper Lower Upper 
INS 0.001 0.338 0.072 0.178 0.498 INS 0.229 0.087 0.07 -0.06 -0.24 INS 0.035 -0.223 0.09 0.43 0.02 
PDX1 0.210 0.047 0.035 -0.031 0.125 PDX1 0.732 0.016 0.04 -0.08 -0.11 PDX1 0.277 -0.205 0.14 0.79 -0.38 
PAX6 0.002 -0.172 0.040 -0.262 -0.081 PAX6 0.496 -0.034 0.05 -0.14 -0.07 PAX6 0.168 -0.274 0.13 0.82 -0.27 
FOXO1 0.166 -0.444 0.126 -1.860 0.972 FOXO1 0.628 -0.292 0.51 -2.5 -1.92 FOXO1 0.195 0.292 0.15 0.35 -0.94 
NEUROD1 0.000 -0.533 0.045 -0.635 -0.430 NEUROD1 0.639 -0.304 0.56 -2.69 -2.08 NEUROD1 0.231 0.216 0.13 0.32 -0.75 
NKX2-2 0.003 -0.471 0.116 -0.734 -0.207 NKX2-2 0.487 -0.483 0.57 -2.91 -1.95 NKX2-2 0.255 0.387 0.25 0.63 -1.40 
MAFA 0.004 0.109 0.030 0.043 0.175 MAFA 0.007 0.120 0.04 -0.04 -0.20 MAFA 0.856 0.014 0.07 0.25 -0.28 
MAFB 0.055 -0.056 0.026 -0.114 0.001 MAFB 0.619 -0.036 0.06 0.29 -0.22 MAFB 0.886 0.015 0.09 0.38 -0.41 
GCK 0.573 -0.030 0.051 -0.144 0.084 GCK 0.083 -0.085 0.04 0.18 -0.01 GCK 0.315 0.049 0.05 0.05 -0.15 
SYP 0.086 -0.581 0.091 -1.542 0.380 SYP 0.598 -0.334 0.54 2.64 -1.97 SYP 0.305 0.303 0.22 0.64 -1.25 
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Hyperglycaemia 25mM glucose assay Independent t-test p = 0.016 
24 hours 36 hours 48 hours 
SLC2A2 0.547 0.033 0.053 -0.085 0.150 SLC2A2 0.562 0.033 0.06 0.09 -0.16 SLC2A2 0.198 0.084 0.06 0.05 -0.22 
PTPN1 0.026 -0.072 0.028 -0.133 -0.011 PTPN1 0.943 0.005 0.06 0.22 -0.23 PTPN1 0.385 -0.079 0.07 0.37 -0.21 
PAX4 0.465 0.068 0.077 -0.235 0.370 PAX4 0.002 0.145 0.03 -0.07 -0.22 PAX4 0.243 -0.192 0.12 0.68 -0.30 
STK11 0.198 -0.042 0.031 -0.110 0.026 STK11 0.025 -0.107 0.04 0.2 0.02 STK11 0.132 -0.059 0.04 0.14 -0.02 
SLC16A1 0.663 -0.019 0.042 -0.112 0.074 SLC16A1 0.120 -0.087 0.05 0.2 -0.03 SLC16A1 0.308 -0.159 0.12 0.64 -0.32 
LDHA 0.001 0.108 0.024 0.053 0.162 LDHA 0.175 0.039 0.03 0.02 -0.10 LDHA 0.003 0.125 0.03 -0.05 -0.20 
GCG 0.307 -0.067 0.062 -0.204 0.071 GCG 0.409 -0.060 0.07 -0.21 0.09 GCG 0.012 0.224 0.07 0.06 0.39 
SST 0.260 0.060 0.050 -0.052 0.171 SST 0.269 0.060 0.05 -0.05 0.17 SST 0.004 0.211 0.06 0.08 0.34 
ARX 0.944 0.006 0.088 -0.189 0.202 ARX 0.309 0.091 0.08 -0.1 0.28 ARX 0.480 0.058 0.08 -0.12 0.23 
ARNT 0.013 0.107 0.033 0.030 0.184 ARNT 0.723 0.022 0.06 -0.14 0.18 ARNT 0.144 0.148 0.08 -0.09 0.39 
DDIT3 0.142 0.069 0.043 -0.028 0.166 DDIT3 0.386 0.055 0.06 -0.08 0.19 DDIT3 0.062 0.113 0.05 -0.01 0.23 
HIF1A 0.416 0.070 0.082 -0.113 0.253 HIF1A 0.701 0.035 0.09 -0.16 0.23 HIF1A 0.051 0.208 0.09 0 0.42 
MYC 0.959 -0.008 0.140 -0.590 0.574 MYC 0.001 -0.183 0.04 -0.27 0.10 MYC 0.000 0.313 0.04 0.23 0.40 
SOX9 0.613 -0.053 0.101 -0.277 0.172 SOX9 0.033 0.269 0.11 0.03 0.51 SOX9 0.001 0.277 0.06 0.15 0.41 
POU5F1 0.032 -0.072 0.029 -0.137 -0.008 POU5F1 0.215 -0.057 0.04 -0.15 0.04 POU5F1 0.333 -0.096 0.08 -0.4 0.21 
NANOG 0.176 0.067 0.046 -0.036 0.169 NANOG 0.194 0.076 0.05 -0.05 0.20 NANOG 0.008 0.165 0.05 0.05 0.28 
HES1 0.002 -0.161 0.040 -0.250 -0.073 HES1 0.000 0.243 0.05 0.14 0.34 HES1 0.003 -0.149 0.04 -0.24 -0.06 
NGN3 0.365 -0.045 0.047 -0.151 0.061 NGN3 0.193 -0.062 0.04 -0.16 0.04 NGN3 0.375 -0.052 0.06 -0.18 0.07 
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Hypoglycaemia 2.5mM glucose assay Independent t-test p=0016 
24 hours 36 hours 48 hours 
Gene P 
valu
e 
Mean 
diff. 
SED 95% C I Gene P 
value 
Mean diff SED 95% C I Gene P 
value 
Mean diff SED 95% C I 
Lower Upper Lower Upper Lower Upper 
INS 0.038 0.183 0.08 0.01 0.35 INS 0.994 0.001 0.06 -0.14 0.14 INS 0.015 -0.284 0.10 -0.5 -0.07 
PDX1 0.003 -0.148 0.04 -0.23 -0.06 PDX1 0.000 -0.191 0.04 0.27 -0.11 PDX1 0.001 -0.224 0.05 -0.33 -0.12 
PAX6 0.058 -0.415 0.11 -0.86 0.03 PAX6 0.000 0.269 0.04 0.35 -0.19 PAX6 0.000 -0.239 0.04 -0.34 -0.14 
FOXO1 0.000 0.303 0.04 0.21 0.39 FOXO1 0.000 0.372 0.04 -0.28 0.46 FOXO1 0.000 0.427 0.05 0.32 0.54 
NEUROD1 0.000 0.301 0.03 0.22 0.38 NEUROD1 0.000 0.348 0.04 -0.26 0.43 NEUROD1 0.000 0.299 0.05 0.19 0.41 
NKX2-2 0.000 0.580 0.08 0.39 0.77 NKX2-2 0.002 0.386 0.09 -0.17 0.60 NKX2-2 0.001 0.409 0.09 0.21 0.61 
MAFA 0.983 0.002 0.07 -0.29 0.3 MAFA 0.001 -0.161 0.03 0.24 -0.08 MAFA 0.067 -0.292 0.08 -0.63 0.05 
MAFB 0.084 0.044 0.02 -0.01 0.1 MAFB 0.816 -0.016 0.06 0.25 0.22 MAFB 0.635 -0.038 0.07 -0.32 0.25 
GCK 0.037 0.121 0.05 0.01 0.23 GCK 0.063 0.102 0.05 0.01 0.21 GCK 0.857 0.030 0.13 -1.43 1.49 
SYP 0.000 0.427 0.03 0.35 0.5 SYP 0.000 0.420 0.04 -0.34 0.50 SYP 0.000 0.421 0.04 0.33 0.51 
SLC2A2 0.024 0.145 0.05 0.02 0.27 SLC2A2 0.005 0.183 0.05 -0.07 0.30 SLC2A2 0.757 0.019 0.06 -0.12 0.16 
PTPN1 0.000 -0.190 0.03 0.26 -0.12 PTPN1 0.032 -0.082 0.03 -0.16 -0.01 PTPN1 0.001 -0.184 0.04 -0.27 -0.09 
PAX4 0.382 -0.042 0.05 0.14 0.06 PAX4 0.063 0.069 0.03 0 0.14 PAX4 0.000 -0.211 0.04 -0.3 -0.12 
STK11 0.001 -0.154 0.03 0.23 -0.08 STK11 0.312 -0.043 0.04 -0.13 0.05 STK11 0.000 -0.206 0.04 -0.29 -0.12 
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Hypoglycaemia 2.5mM glucose assay Independent t-test p=0016 
24 hours 36 hours 48 hours 
SLC16A1 0.000 -0.307 0.05 0.42 -0.19 SLC16A1 0.000 -0.301 0.04 -0.39 -0.21 SLC16A1 0.000 -0.361 0.05 -0.48 -0.24 
LDHA 0.159 0.155 0.07 -0.14 0.45 LDHA 0.485 -0.057 0.07 -0.33 0.22 LDHA 0.249 0.189 0.12 -0.31 0.69 
GCG 0.518 -0.036 0.05 -0.16 0.08 GCG 0.468 -0.053 0.07 -0.21 0.10 GCG 0.001 0.311 0.07 0.16 0.46 
SST 0.559 0.030 0.05 -0.08 0.14 SST 0.189 0.078 0.06 -0.05 0.20 SST 0.000 0.259 0.05 0.15 0.36 
ARX 0.831 0.018 0.08 -0.16 0.2 ARX 0.625 0.041 0.08 -0.14 0.22 ARX 0.020 -0.241 0.09 -0.44 -0.05 
ARNT 0.000 0.185 0.04 0.11 0.26 ARNT 0.062 0.135 0.06 -0.01 0.28 ARNT 0.311 0.066 0.06 -0.07 0.20 
DDIT3 0.001 0.195 0.04 0.11 0.28 DDIT3 0.004 0.165 0.04 0.07 0.26 DDIT3 0.269 0.197 0.13 -0.34 0.74 
HIF1A 0.091 0.153 0.08 -0.03 0.34 HIF1A 0.355 0.080 0.08 -0.1 0.26 HIF1A 0.501 -0.804 0.99 -5.04 3.43 
MYC 0.004 0.136 0.04 0.05 0.22 MYC 0.262 0.238 0.16 -0.41 0.89 MYC 0.657 0.019 0.04 -0.08 0.11 
SOX9 0.059 0.221 0.10 -0.01 0.45 SOX9 0.005 0.421 0.12 0.16 0.68 SOX9 0.015 0.371 0.12 0.09 0.65 
POU5F1 0.000 -0.208 0.04 -0.29 -0.12 POU5F1 0.001 -0.152 0.03 -0.22 -0.08 POU5F1 0.001 -0.220 0.04 -0.32 -0.12 
NANOG 0.060 0.106 0.05 -0.01 0.22 NANOG 0.186 -0.081 0.06 -0.21 -0.05 NANOG 0.426 0.119 0.12 -0.37 0.61 
HES1 0.120 -0.095 0.06 -0.22 0.03 HES1 0.024 0.119 0.04 -0.02 -0.22 HES1 0.714 -0.053 0.13 -0.58 0.47 
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Hypoxia 3% O2 assay Independent t-test p = 0.016 
4hrs 12 hrs 24hrs 
Gene P 
valu
e 
Mean 
diff. 
SED 95% CI Gene P 
value 
Mean diff. SED 95% CI Gene P 
value 
Mean 
diff. 
SED 95% CI 
Lower Upper Lower Upper Lower Upper 
NGN3 0.715 -0.024 0.058 -0.255 0.207 NGN3 0.125 -0.137 0.056 -0.360 0.086 NGN3 0.031 0.082 0.033 0.009 0.155 
NANOG 0.819 0.012 0.051 -0.101 0.125 NANOG 0.130 -0.085 0.052 -0.201 0.03 NANOG 0.763 0.013 0.043 -0.082 0.109 
POU5F1 0.261 -0.064 0.053 -0.182 0.055 POU5F1 0.004 -0.194 0.053 -0.312 -0.075 POU5F1 0.015 -0.160 0.054 -0.280 -0.039 
INS 0.561 -0.042 0.071 -0.200 0.115 INS 0.053 -0.154 0.070 -0.309 0.002 INS 0.002 -0.296 0.072 -0.457 -0.135 
PDX1 0.134 -0.303 0.128 -0.821 0.216 PDX1 0.000 -0.332 0.047 -0.437 -0.227 PDX1 0.000 -0.261 0.042 -0.354 -0.168 
PAX6 0.037 -0.092 0.038 -0.178 -0.007 PAX6 0.000 -0.328 0.048 -0.434 -0.222 PAX6 0.000 -0.379 0.040 -0.467 -0.291 
SLC16A1 0.000 -0.139 0.025 -0.196 -0.083 SLC16A1 0.005 -0.201 0.057 -0.328 -0.075 SLC16A1 0.023 -0.114 0.042 -0.209 -0.02 
FOXO1 0.936 -0.005 0.065 -0.151 0.141 FOXO1 0.281 0.075 0.066 -0.071 0.221 FOXO1 0.048 -0.148 0.066 -0.294 -0.002 
NEUROD1 0.488 -0.048 0.066 -0.195 0.1 NEUROD1 0.355 0.067 0.069 -0.087 0.221 NEUROD1 0.479 -0.049 0.067 -0.198 0.1 
NKX2-2 0.040 0.125 0.052 0.007 0.243 NKX2-2 0.015 0.165 0.055 0.040 0.29 NKX2-2 0.192 -0.075 0.053 -0.196 0.045 
SYP 0.231 0.065 0.050 -0.049 0.179 SYP 0.031 0.153 0.060 0.017 0.29 SYP 0.036 0.122 0.050 0.010 0.234 
NKX6-1 0.997 0.000 0.100 -0.223 0.222 NKX6-1 0.004 0.446 0.118 0.183 0.708 NKX6-1 0.005 0.369 0.102 0.142 0.596 
MAFA 0.891 0.007 0.052 -0.123 0.109 MAFA 0.272 0.057 0.049 -0.052 0.166 MAFA 0.801 0.012 0.046 -0.091 0.115 
LDHA 0.000 0.163 0.026 0.104 0.222 LDHA 0.000 0.346 0.025 0.289 0.402 LDHA 0.000 0.412 0.025 0.357 0.467 
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Hypoxia 3% O2 assay Independent t-test p = 0.016 
4hrs 12 hrs 24hrs 
MAFB 0.711 0.014 0.037 -0.068 0.096 MAFB 0.959 -0.002 0.037 -0.084 0.08 MAFB 0.373 -0.034 0.037 -0.117 0.048 
GCG 0.722 0.076 0.208 -0.387 0.539 GCG 0.098 0.380 0.208 -0.083 0.843 GCG 0.653 -0.096 0.208 -0.559 0.367 
SST 0.000 0.096 0.018 0.056 0.137 SST 0.249 0.025 0.021 -0.021 0.071 SST 0.000 0.139 0.018 0.099 0.178 
ARNT 0.899 0.003 0.021 -0.044 0.049 ARNT 0.246 0.027 0.022 -0.022 0.076 ARNT 0.844 0.004 0.022 -0.044 0.053 
DDIT3 0.458 0.029 0.038 -0.055 0.113 DDIT3 0.805 -0.010 0.040 -0.100 0.08 DDIT3 0.248 -0.054 0.044 -0.151 0.044 
ARX 0.118 0.057 0.033 -0.017 0.132 ARX 0.018 -0.102 0.036 -0.183 -0.022 ARX 0.383 -0.035 0.039 -0.122 0.051 
GCK 0.001 0.159 0.036 0.079 0.239 GCK 0.000 0.360 0.019 0.316 0.405 GCK 0.000 0.415 0.030 0.349 0.482 
HIF1A 0.245 0.036 0.029 -0.029 0.1 HIF1A 0.314 -0.032 0.030 -0.099 0.035 HIF1A 0.008 -0.108 0.032 -0.181 -0.036 
MYC 0.004 0.170 0.044 0.071 0.268 MYC 0.689 0.019 0.045 -0.083 0.121 MYC 0.918 0.008 0.077 -0.163 0.18 
SLC2A2 0.002 0.088 0.022 0.040 0.137 SLC2A2 0.001 0.092 0.020 0.048 0.135 SLC2A2 0.063 -0.159 0.046 -0.338 0.019 
SOX9 0.335 0.126 0.125 -0.152 0.404 SOX9 0.453 0.120 0.153 -0.222 0.462 SOX9 0.000 0.659 0.123 0.386 0.933 
PTPN1 0.049 -0.065 0.029 -0.130 0.001 PTPN1 0.070 -0.203 0.062 -0.442 0.036 PTPN1 0.315 -0.255 0.193 -1.074 0.563 
PAX4 0.001 -0.097 0.021 -0.144 -0.05 PAX4 0.151 -0.106 0.049 -0.297 0.086 PAX4 0.057 -0.196 0.053 -0.407 0.014 
STK11 0.145 -0.334 0.144 -0.948 0.28 STK11 0.121 -0.119 0.052 -0.336 0.078 STK11 0.000 -0.341 0.021 -0.244 -0.149 
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Hypoxia 1% O2 assay Independent Samples Test p= 0.016 
4hrs 12hrs 24 hours 
Gene P 
valu
e 
Mean 
diff. 
SED 95% CI Gene P 
value 
Mean diff.  SED 95% CI Gene P 
value 
Mean 
diff.  
SED 95% CI 
Lower Upper Lower Upper Lower Upper 
NGN3 0.017 -0.080 0.028 -0.143 -0.017 NGN3 0.555 -0.080 0.653 -2.350 3.268 NGN3 0.566 -0.077 0.096 -1.212 1.058 
NANOG 0.145 -0.072 0.046 -0.175 0.03 NANOG 0.001 -0.072 0.051 -0.343 -0.115 NANOG 0.799 -0.015 0.056 -0.140 0.111 
POU5F1 0.044 -0.120 0.052 -0.237 -0.004 POU5F1 0.001 -0.120 0.066 -0.466 -0.174 POU5F1 0.225 -0.083 0.063 -0.226 0.061 
INS 0.007 -0.299 0.088 -0.495 -0.104 INS 0.094 -0.299 0.087 -0.353 0.033 INS 0.045 -0.202 0.087 -0.400 -0.005 
PDX1 0.000 -0.375 0.046 -0.479 -0.272 PDX1 0.000 -0.375 0.059 -0.464 -0.201 PDX1 0.001 -0.271 0.051 -0.388 -0.155 
PAX6 0.001 -0.204 0.044 -0.303 -0.105 PAX6 0.000 -0.204 0.046 -0.637 -0.434 PAX6 0.000 -0.371 0.050 -0.484 -0.258 
SLC16A1 0.000 -0.251 0.044 -0.349 -0.152 SLC16A1 0.000 -0.251 0.045 -0.611 -0.41 SLC16A1 0.007 -0.178 0.052 -0.295 -0.061 
FOXO1 0.017 0.196 0.068 0.044 0.348 FOXO1 0.566 0.196 0.064 -0.181 0.105 FOXO1 0.041 -0.217 0.091 -0.424 -0.011 
NEUROD1 0.483 0.048 0.066 -0.100 0.196 NEUROD1 0.895 0.048 0.072 -0.170 0.151 NEUROD1 0.111 -0.159 0.090 -0.363 0.044 
NKX2-2 0.161 0.105 0.069 -0.050 0.26 NKX2-2 0.502 0.105 0.117 -0.354 0.539 NKX2-2 0.155 -0.114 0.073 -0.282 0.053 
SYP 0.011 0.175 0.055 0.050 0.299 SYP 0.831 0.175 0.077 -0.158 0.191 SYP 0.757 0.020 0.063 -0.165 0.125 
NKX6-1 0.011 0.302 0.098 0.085 0.519 NKX6-1 0.440 0.302 0.113 -0.343 0.161 NKX6-1 0.365 -0.114 0.119 -0.384 0.156 
MAFA 0.347 0.045 0.046 -0.057 0.147 MAFA 0.306 0.045 0.453 -1.322 2.557 MAFA 0.453 1.090 0.939 -10.80 12.98 
LDHA 0.000 0.253 0.027 0.193 0.312 LDHA 0.000 0.253 0.053 0.335 0.572 LDHA 0.000 0.539 0.031 0.469 0.609 
MAFB 0.643 0.021 0.043 -0.117 0.076 MAFB 0.016 0.021 0.054 -0.275 -0.036 MAFB 0.186 0.069 0.049 -0.180 0.04 
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Hypoxia 1% O2 assay Independent Samples Test p= 0.016 
4hrs 12hrs 24 hours 
GCG 0.827 0.047 0.210 -0.422 0.516 GCG 0.402 0.047 0.209 -0.283 0.648 GCG 0.117 -0.445 0.257 -1.027 0.136 
SST 0.088 0.134 0.045 -0.047 0.315 SST 0.928 0.134 0.097 -0.398 0.418 SST 0.029 0.057 0.022 0.007 0.108 
ARNT 0.649 0.014 0.029 -0.051 0.079 ARNT 0.535 0.014 0.085 -0.414 0.289 ARNT 0.856 0.021 0.093 -1.073 1.116 
DDIT3 0.029 0.101 0.040 0.013 0.189 DDIT3 0.000 0.101 0.052 0.240 0.47 DDIT3 0.026 0.122 0.046 0.018 0.227 
ARX 0.090 -0.102 0.055 -0.225 0.019 ARX 0.099 -0.102 0.081 -0.542 0.095 ARX 0.000 -0.270 0.051 -0.386 -0.155 
GCK 0.000 0.272 0.029 0.208 0.338 GCK 0.034 0.272 0.088 0.079 0.792 GCK 0.000 0.337 0.017 0.300 0.375 
HIF1A 0.311 0.046 0.043 -0.050 0.143 HIF1A 0.005 0.046 0.041 -0.240 -0.057 HIF1A 0.000 0.301 0.037 -0.385 -0.219 
MYC 0.757 0.051 0.147 -0.518 0.621 MYC 0.185 0.051 0.076 -0.061 0.277 MYC 0.000 0.528 0.083 0.341 0.715 
SLC2A2 0.369 0.069 0.062 -0.181 0.321 SLC2A2 0.244 0.069 0.123 -0.721 0.321 SLC2A2 0.000 -0.232 0.025 -0.288 -0.177 
SOX9 0.757 0.041 0.129 -0.246 0.328 SOX9 0.002 0.041 0.147 0.324 0.987 SOX9 0.000 1.090 0.145 0.763 1.418 
PTPN1 0.000 -0.146 0.029 -0.210 -0.082 PTPN1 0.024 -0.146 0.084 -0.826 -0.152 PTPN1 0.000 -0.289 0.037 -0.373 -0.207 
PAX4 0.000 -0.144 0.025 -0.200 -0.089 PAX4 0.050 -0.144 0.094 -0.786 -0.001 PAX4 0.077 -0.665 0.086 -1.673 0.342 
STK11 0.004 -0.109 0.029 -0.174 -0.044 STK11 0.079 -0.109 0.075 -0.556 0.067 STK11 0.000 -0.156 0.023 -0.209 -0.104 
 
 
  
 
 
 
168 
 
Lipotoxicity 0.5 mM Independent Samples Test p = 0.016 
12hrs 24hrs 48hrs 
Gene P 
valu
e 
Mean 
diff. 
SED 95% CI Gene P 
value 
Mean diff. SED 95% CI Gene P 
value 
Mean. 
Diff. 
SED 
 
95% CI 
Lower Upper Lower Upper Lower 
 
Upper 
FOXO1 0.909 -0.005 0.049 -0.114 0.103 FOXO1    0.077 -0.104 0.053 -0.222 0.013 FOXO1 0.492 -0.036 0.051 -0.078 0.151 
INS 0.591 0.049 0.089 -0.150 0.249 INS 0.001 0.412 0.094 0.203 0.623 INS 0.531 0.072 0.112 -0.176 0.321 
PDX1 0.014 -0.199 0.067 -0.349 -0.050 PDX1 0.017 0.158 0.055 0.035 0.282 PDX1 0.464 0.044 0.057 -0.084 0.171 
NEUROD
1 
0.652 0.016 0.035 -0.061 0.094 NEUROD1 0.583 -0.021 0.037 -0.103 0.061 NEUROD1 0.000 0.357 0.032 0.285 0.429 
SLC16A1 0.000 0.162 0.023 0.112 0.212 SLC16A1 0.189 -0.040 0.029 -0.104 0.023 SLC16A1 0.08 -0.047 0.024 -0.100 0.007 
SYP 0.984 -0.015 0.737 -1.658 1.627 SYP 0.944 0.052 0.738 -1.591 1.696 SYP 0.047 1.668 0.738 0.024 3.313 
GCK 0.285 -0.056 0.050 -0.167 0.055 GCK 0.007 -0.166 0.050 -0.277 -0.056 GCK 0.000 0.787 0.050 0.676 0.898 
MAFA 0.065 -0.085 0.041 -0.178 0.006 MAFA 0.185 -0.064 0.045 -0.165 0.036 MAFA 0.000 0.636 0.039 0.550 0.724 
NKX2.2 0.090 -0.106 0.057 -0.233 0.020 NKX2.2 0.818 0.013 0.057 -0.114 0.141 NKX2.2 0.003 -0.224 0.058 -0.353 -0.096 
LDHA 0.837 -0.008 0.039 -0.095 0.079 LDHA 0.347 0.037 0.038 -0.048 0.123 LDHA 0.000 -0.295 0.037 -0.378 -0.214 
MAFB 0.085 -0.203 0.068 -0.470 0.063 MAFB 0.008 -0.096 0.029 -0.161 -0.031 MAFB 0.225 0.123 0.073 -0.170 0.416 
NKX6.1 0.010 -0.149 0.047 -0.254 -0.044 NKX6.1 0.044 0.108 0.047 0.004 0.214 NKX6.1 0.000 -0.347 0.049 -0.455 -0.239 
ARNT 0.010 0.102 0.032 0.031 0.175 ARNT 0.055 -0.071 0.033 -0.144 0.002 ARNT 0.000 -0.165 0.032 -0.237 -0.095 
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Lipotoxicity 0.5 mM Independent Samples Test p = 0.016 
12hrs 24hrs 48hrs 
PAX4 0.431 0.057 0.070 -0.098 0.212 PAX4 0.213 0.099 0.075 -0.067 0.265 PAX4 0.000 1.251 0.068 1.100 1.404 
SST 0.001 0.183 0.041 0.093 0.274 SST 0.021 0.117 0.043 0.022 0.213 SST 0.000 -0.500 0.046 -0.603 -0.398 
DDIT3 0.893 -0.004 0.035 -0.083 0.074 DDIT3 0.000 -0.261 0.044 -0.359 -0.164 DDIT3 0.000 -1.320 0.042 -1.415 -1.226 
GCG 0.026 -0.173 0.066 -0.321 -0.026 GCG 0.000 -0.503 0.065 -0.649 -0.358 GCG 0.000 1.209 0.067 1.061 1.359 
PAX6 0.331 -0.049 0.048 -0.156 0.058 PAX6 0.047 -0.108 0.048 -0.215 -0.002 PAX6 0.009 0.176 0.055 0.054 0.300 
MYC 0.005 0.421 0.117 0.161 0.681 MYC 0.154 0.156 0.102 -0.070 0.384 MYC 0.001 -0.588 0.103 -0.739 -0.279 
NANOG 0.796 -0.020 0.077 -0.192 0.151 NANOG 0.374 -0.072 0.078 -0.246 0.101 NANOG 0.000 -0.669 0.084 -0.858 -0.482 
SLC2A2 0.014 -0.104 0.035 -0.183 -0.026 SLC2A2 0.440 0.106 0.113 -0.353 0.566 SLC2A2 0.000 -0.228 0.037 -0.311 -0.147 
HIF1A 0.023 -0.084 0.030 -0.154 -0.015 HIF1A 0.022 -0.205 0.076 -0.374 -0.037 HIF1A 0.301 -0.062 0.057 -0.190 0.065 
PTPN1 0.570 0.015 0.027 -0.044 0.075 PTPN1 0.089 -0.047 0.025 -0.104 0.009 PTPN1 0.004 0.111 0.030 0.045 0.177 
STK11 0.509 0.036 0.053 -0.081 0.153 STK11 0.534 -0.038 0.059 -0.170 0.094 STK11 0.211 -0.070 0.053 -0.188 0.047 
ARX 0.612 0.043 0.083 -0.142 0.229 ARX 0.053 0.176 0.080 -0.003 0.355 ARX 0.339 -0.075 0.075 -0.242 0.091 
SLC2A4 0.382 -0.113 0.124 -0.163 0.389 SLC2A4 0.197 0.158 0.115 -0.097 0.414 SLC2A4 0.288 0.136 0.122 -0.135 0.409 
SOX9 0.255 0.136 0.113 -0.115 0.387 SOX9 0.012 0.329 0.107 0.091 0.567 SOX9 0.000 -1.430 0.120 -1.699 -1.162 
HES1 0.013 -0.208 0.069 -0.363 -0.054 HES1 0.22 0.082 0.063 -0.058 0.223 HES1 0.019 -1.738 0.254 -2.801 -0.676 
NGN3 0.004 0.165 0.044 0.067 0.264 NGN3 0.001 0.212 0.044 0.115 0.310 NGN3 0.000 0.338 0.045 0.237 0.440 
POU5F1 0.024 0.165 0.062 0.026 0.304 POU5F1 0.015 -0.187 0.064 -0.331 -0.044 POU5F1 0.043 0.146 0.063 0.005 0.288 
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Cytokine assay TNF𝛂 INF𝛄 and IL1𝛃 Independent Samples Test p = 0.025 
12 hours 24 hours 36 hours 
Gene  P 
valu
e 
Mean 
diff. 
SED. 95% CI Gene  P 
value 
Mean 
diff. 
SED.  95% CI Gene P 
value 
  
Mean 
diff. 
SED 95% CI 
Lower Upper Lower Upper  Lower Upper 
FOXO1 0.244 -0.060 0.049 -0.168 0.048 FOXO1 0.021 -0.168 0.062 -0.305 -0.031 FOXO1 0.000 -0.258 0.050 -0.369 -0.146 
INS 0.014 0.149 0.050 0.037 0.262 INS 0.837 0.009 0.045 -0.090 0.109 INS 0.211 -0.162 0.093 -0.527 0.202 
PDX1 0.232 -0.058 0.046 -0.162 0.044 PDX1 0.045 0.109 0.048 0.003 0.217 PDX1 0.923 0.005 0.048 -0.102 0.112 
NEUROD1 0.173 0.099 0.067 -0.051 0.250 NEUROD1 0.697 -0.026 0.067 -0.176 0.123 NEUROD1 0.209 -0.154 0.115 -0.409 0.101 
SLC16A1 0.000 -0.166 0.021 -0.214 -0.120 SLC16A1 0.000 -0.354 0.022 -0.403 -0.305 SLC16A1 0.000 -0.278 0.046 -0.380 -0.176 
SYP 0.518 -0.051 0.077 -0.224 0.120 SYP 0.68 0.023 0.055 -0.099 0.146 SYP 0.067 0.115 0.056 -0.010 0.241 
GCK 0.034 0.304 0.124 0.029 0.580 GCK 0.62 -0.063 0.124 -0.340 0.213 GCK 0.793 -0.033 0.123 -0.308 0.242 
MAFA 0.275 -0.118 0.103 -0.347 0.110 MAFA 0.152 -0.158 0.103 -0.388 0.070 MAFA 0.181 -0.151 0.105 -0.384 0.083 
NKX2.2 0.004 -0.221 0.060 -0.355 -0.088 NKX2.2 0.042 -0.215 0.093 -0.423 -0.009 NKX2.2 0.253 -0.073 0.060 -0.208 0.061 
LDHA 0.028 -0.122 0.048 -0.229 -0.016 LDHA 0.334 0.048 0.047 -0.057 0.154 LDHA 0.994 0.000 0.057 -0.129 0.128 
MAFB 0.042 -0.093 0.040 -0.182 -0.004 MAFB 0.027 -0.105 0.041 -0.197 -0.015 MAFB 0.001 -0.179 0.040 -0.268 -0.091 
NKX6.1 0.003 -0.304 0.079 -0.480 -0.130 NKX6.1 0.62 0.041 0.082 -0.140 0.224 NKX6.1 0.714 -0.030 0.078 -0.204 0.145 
ARNT 0.086 -0.124 0.065 -0.269 0.021 ARNT 0.311 0.061 0.057 -0.067 0.189 ARNT 0.611 0.036 0.068 -0.116 0.187 
PAX4 0.021 0.368 0.134 0.069 0.667 PAX4 0.316 0.141 0.134 -0.157 0.439 PAX4 0.300 0.147 0.134 -0.152 0.446 
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Cytokine assay TNF𝛂 INF𝛄 and IL1𝛃 Independent Samples Test p = 0.025 
12 hours 24 hours 36 hours 
SST 0.182 -0.143 0.100 -0.366 0.079 SST 0.398 0.086 0.098 -0.132 0.305 SST 0.952 0.006 0.098 -0.212 0.224 
DDIT3 0.166 -0.318 0.206 -0.769 0.151 DDIT3 0.956 0.012 0.213 -0.463 0.487 DDIT3 0.219 0.270 0.206 -0.188 0.728 
GCG 0.135 0.412 0.254 -0.153 0.979 GCG 0.172 -0.372 0.253 -0.935 0.191 GCG 0.278 -0.291 0.254 -0.856 0.274 
PAX6 0.469 0.055 0.074 -0.109 0.220 PAX6 0.625 0.037 0.075 -0.129 0.205 PAX6 0.314 0.078 0.074 -0.086 0.242 
MYC 0.003 -0.452 0.118 -0.715 -0.189 MYC 0.84 0.028 0.136 -0.274 0.330 MYC 0.066 -0.252 0.122 -0.525 0.020 
NANOG 0.112 -0.183 0.105 -0.418 0.051 NANOG 0.379 0.097 0.106 -0.139 0.335 NANOG 0.372 0.100 0.107 -0.138 0.338 
SLC2A2 0.014 0.181 0.061 0.046 0.316 SLC2A2 0.41 0.061 0.072 -0.098 0.222 SLC2A2 0.031 0.163 0.065 0.018 0.307 
HIF1A 0.008 -0.097 0.030 -0.164 -0.031 HIF1A 0.024 -0.088 0.033 -0.162 -0.014 HIF1A 0.104 -0.158 0.060 -0.386 0.071 
PTPN1 0.007 0.121 0.035 0.042 0.201 PTPN1 0.162 0.055 0.037 -0.026 0.137 PTPN1 0.009 0.123 0.038 0.037 0.208 
STK11 0.346 -0.045 0.046 -0.147 0.057 STK11 0.229 -0.056 0.044 -0.154 0.042 STK11 0.145 0.066 0.042 -0.027 0.159 
ARX 0.194 -0.180 0.099 -0.561 0.199 ARX 0.001 -0.224 0.051 -0.337 -0.111 ARX 0.041 -0.125 0.053 -0.244 -0.006 
SLC2A4 0.336 0.119 0.118 -0.144 0.384 SLC2A4 0.984 -0.005 0.263 -1.033 1.022 SLC2A4 0.029 -0.369 0.144 -0.690 -0.047 
SOX9 0.086 -0.591 0.310 -1.282 0.100 SOX9 0.233 -0.396 0.312 -1.093 0.299 SOX9 0.974 0.011 0.317 -0.695 0.716 
HES1 0.238 -0.422 0.337 -1.173 0.328 HES1 0.611 0.177 0.338 -0.575 0.931 HES1 0.712 0.128 0.338 -0.624 0.880 
NGN3 0.14 -0.141 0.088 -0.338 0.055 NGN3 0.258 0.105 0.088 -0.090 0.301 NGN3 0.020 0.239 0.087 0.046 0.432 
POU5F1 0.102 0.093 0.052 -0.022 0.208 POU5F1 0.049 -0.072 0.032 -0.146 0.000 POU5F1 0.010 -0.096 0.030 -0.164 -0.029 
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Tunicamycin Induced ER stress. Independent Samples Test p=0.025 
24 hrs 0.5 mM tunicamycin 
Gene P value Mean diff. SED  95% CI 
Lower Upper 
ARNT 0.642 0.017 0.036 -0.081 0.117 
ARX 0.033 0.662 0.208 0.085 1.239 
DDIT3 0.033 0.387 0.121 0.052 0.722 
FOXO1 0.013 -0.216 0.051 -0.357 -0.075 
GCG 0.931 -0.025 0.272 -0.781 0.730 
GCK 0.081 -0.174 0.075 -0.384 0.035 
HHEX 0.115 0.499 0.248 -0.190 1.189 
INS 0.448 -0.041 0.05 -0.180 0.096 
LDHA 0.226 0.028 0.02 -0.027 0.083 
MAFA 0.050 -0.319 0.115 -0.640 0.001 
MAFB 0.085 -0.086 0.038 -0.193 0.019 
NANOG 0.274 -0.068 0.054 -0.217 0.081 
ND1 0.857 -0.008 0.044 -0.130 0.113 
NKX2-2 0.005 0.100 0.018 0.049 0.152 
NKX6-1 0.099 0.174 0.06 -0.080 0.429 
PAX4 0.049 -0.345 0.123 -0.689 -0.003 
PAX6 0.161 -0.144 0.084 -0.379 0.089 
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Tunicamycin Induced ER stress. Independent Samples Test p=0.025 
24 hrs 0.5 mM tunicamycin 
PDX1 0.058 -0.216 0.082 -0.444 0.012 
POU5F1 0.639 -0.068 0.136 -0.447 0.309 
SLC16A1 0.351 -0.053 0.051 -0.195 0.088 
SOX9 0.145 0.393 0.218 -0.211 0.998 
SST 0.111 0.325 0.16 -0.118 0.770 
STK11 0.165 -0.129 0.077 -0.343 0.083 
SYP 0.056 -0.110 0.041 -0.226 0.005 
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Supplementary table S7: Effects of cell insult treatments on splicing factor 
expression. 
The p values for statistical significance as determined by independent t-test, Mean 
difference, Standard errors of measurement (SED) and the 95% confidence intervals are 
given below. Bold italic p=<0.01 and p=<0.050  Bonferroni correction for 5 tests: Control 
vs high glucose, control vs low glucose, control versus <3% O2, control versus pro-
inflammatory cytokines and control versus ‘rescue’. Gene list is á priori  so no further 
corrections. A separate control for 0.5 mM Palmitic Acid was used to account for EtOH 
carrier. p value for this assay was 0.050 as no correction for multiple testing was 
required. Italic and underlined. P=<0.050 No correction for multiple testing 
 
25 mM high glucose Independent Samples Test p=0.01 
  P value Mean Difference Std. Error Difference 
95% CI 
Lower Upper 
AKAP17A 0.538 0.035 0.052 0.109 -0.179 
HNRNPA0 0.816 -0.016 0.063 -0.189 0.158 
HNRNPA1 0.872 0.004 0.021 -0.055 0.062 
HNRNPA2B1 0.006 0.176 0.033 0.084 0.268 
HNRNPD 0.667 0.083 0.180 -0.416 0.583 
HNRNPH3 0.243 0.086 0.063 -0.089 0.262 
HNRNPK 0.800 -0.014 0.054 -0.163 0.134 
HNRNPM 0.790 0.038 0.135 -0.337 0.414 
HNRNPUL2 0.586 0.030 0.050 -0.110 0.170 
IMP3 0.364 0.064 0.063 -0.110 0.239 
LSM14A 0.461 0.050 0.061 -0.120 0.219 
LSM2 0.503 -0.445 0.605 -2.124 1.234 
PNISR 0.062 0.114 0.044 -0.009 0.237 
SF3B1 0.444 0.069 0.081 -0.156 0.294 
SRSF1 0.537 0.025 0.037 -0.078 0.129 
SRSF2 0.052 0.142 0.052 -0.002 0.286 
SRSF3 0.117 0.090 0.045 -0.035 0.216 
SRSF6 0.653 -0.020 0.040 -0.132 0.093 
SRSF7 0.280 -0.079 0.063 -0.253 0.096 
TRA2B 0.154 0.135 0.077 -0.079 0.348 
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2.5 mM low glucose Independent Samples Test p=0.01 
  P value Mean Difference Std. Error Difference 
95% CI 
Lower Upper 
AKAP17A 0.029 0.159 0.048 0.026 0.291 
HNRNPA0 0.022 0.103 0.028 0.024 0.181 
HNRNPA1 0.242 0.159 0.098 -0.250 0.567 
HNRNPA2B1 0.004 0.179 0.030 0.097 0.262 
HNRNPD 0.047 -0.374 0.132 -0.741 -0.007 
HNRNPH3 0.154 0.105 0.060 -0.061 0.271 
HNRNPK 0.063 0.069 0.027 -0.006 0.144 
HNRNPM 0.879 0.022 0.128 -0.513 0.557 
HNRNPUL2 0.471 0.022 0.027 -0.054 0.097 
IMP3 0.217 0.028 0.019 -0.025 0.081 
LSM14A 0.004 0.109 0.019 0.057 0.160 
LSM2 0.290 -0.712 0.505 -2.812 1.388 
PNISR 0.005 0.202 0.036 0.100 0.303 
SF3B1 0.047 0.202 0.071 0.005 0.399 
SRSF1 0.001 0.107 0.012 0.072 0.141 
SRSF2 0.015 0.285 0.069 0.093 0.476 
SRSF3 0.009 0.141 0.030 0.059 0.223 
SRSF6 0.001 0.201 0.021 0.143 0.259 
SRSF7 0.667 0.026 0.055 -0.128 0.179 
TRA2B 0.776 0.016 0.052 -0.128 0.159 
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Hypoxia Independent Samples Test p=0.01 
  P value Mean Difference Std. Error Difference 
95% CI 
Lower Upper 
AKAP17A 0.034 0.190 0.060 0.023 0.357 
HNRNPA0 0.291 0.029 0.024 -0.038 0.096 
HNRNPA1 0.011 -0.098 0.022 -0.158 -0.038 
HNRNPA2B1 0.004 0.120 0.020 0.064 0.175 
HNRNPD 0.140 -0.367 0.200 -0.921 0.187 
HNRNPH3 0.098 0.126 0.059 -0.037 0.289 
HNRNPK 0.056 0.071 0.027 -0.003 0.146 
HNRNPM 0.884 0.021 0.132 -0.345 0.386 
HNRNPUL2 0.564 0.017 0.027 -0.058 0.092 
IMP3 0.274 0.021 0.016 -0.025 0.067 
LSM14A 0.004 0.139 0.023 0.076 0.201 
LSM2 0.252 -0.794 0.508 -2.861 1.274 
PNISR 0.007 0.234 0.046 0.107 0.362 
SF3B1 0.018 0.201 0.052 0.058 0.345 
SRSF1 0.024 0.056 0.016 0.012 0.100 
SRSF2 0.094 0.245 0.112 -0.066 0.555 
SRSF3 0.001 0.160 0.018 0.111 0.209 
SRSF6 0.003 0.190 0.030 0.106 0.275 
SRSF7 0.994 -0.000 0.054 -0.151 0.150 
TRA2B 0.715 -0.020 0.051 -0.162 0.122 
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Lipotoxicity Independent Samples Test p=0.01 
  P value Mean Difference Std. Error Difference 
95% CI 
Lower Upper 
AKAP17A 0.127 0.126 0.066 -0.056 0.309 
HNRNPA0 0.288 -0.051 0.042 -0.167 0.065 
HNRNPA1 0.065 -0.039 0.016 -0.083 0.004 
HNRNPA2B1 0.824 -0.014 0.060 -0.179 0.151 
HNRNPD 0.749 -0.074 0.214 -0.669 0.522 
HNRNPH3 0.146 0.119 0.066 -0.064 0.302 
HNRNPK 0.749 0.011 0.033 -0.081 0.104 
HNRNPM 0.967 0.006 0.133 -0.364 0.376 
HNRNPUL2 0.453 0.025 0.030 -0.058 0.107 
IMP3 0.006 0.084 0.016 0.039 0.128 
LSM14A 0.668 0.012 0.026 -0.060 0.084 
LSM2 0.438 0.533 0.620 -1.189 2.256 
PNISR 0.277 -0.046 0.037 -0.148 0.056 
SF3B1 0.270 -0.088 0.069 -0.279 0.103 
SRSF1 0.743 -0.005 0.013 -0.040 0.031 
SRSF2 0.639 -0.033 0.064 -0.211 0.146 
SRSF3 0.034 -0.096 0.031 -0.181 -0.012 
SRSF6 0.762 0.012 0.036 -0.089 0.112 
SRSF7 0.837 -0.013 0.059 -0.177 0.151 
TRA2B 0.118 -0.106 0.053 -0.254 0.042 
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Cytokine assay Independent Samples Test p=0.01 
  P value Mean Difference Std. Error Difference 
95% CI 
Lower Upper 
AKAP17A 0.002 0.240 0.032 0.151 0.329 
HNRNPA0 0.264 0.038 0.030 -0.044 0.120 
HNRNPA1 0.162 0.025 0.015 -0.016 0.066 
HNRNPA2B1 0.001 0.217 0.024 0.151 0.282 
HNRNPD 0.056 -0.364 0.136 -0.743 0.014 
HNRNPH3 0.053 0.143 0.053 -0.003 0.289 
HNRNPK 0.033 0.087 0.027 0.012 0.163 
HNRNPM 0.179 0.221 0.136 -0.156 0.597 
HNRNPUL2 0.656 -0.013 0.027 -0.087 0.061 
IMP3 0.736 -0.004 0.011 -0.035 0.027 
LSM14A 0.003 0.118 0.018 0.068 0.167 
LSM2 0.253 -0.790 0.508 -2.860 1.281 
PNISR 0.003 0.243 0.039 0.135 0.351 
SF3B1 0.030 0.168 0.051 0.026 0.309 
SRSF1 0.000 0.117 0.009 0.093 0.141 
SRSF2 0.006 0.274 0.051 0.134 0.414 
SRSF3 0.002 0.185 0.027 0.110 0.260 
SRSF6 0.113 0.058 0.029 -0.021 0.137 
SRSF7 0.370 -0.046 0.046 -0.172 0.081 
TRA2B 0.867 0.009 0.050 -0.131 0.149 
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Supplementary table S8: Effects of cell insult treatments on alternatively spliced gene expression.  
The p values for statistical significance as determined by independent t-test, Mean difference, Standard errors of measurement (SED) and the 95% 
confidence intervals are given below. Bold italic p=<0.016 Bonferroni correction for 3 tests: 1st, 2nd and 3rd time-points. Gene list is á priori  so no further 
corrections. Italic underlined p=<0.050. No correction for multiple testing 
 
25 mM high glucose Independent Samples Test p=0.016 
  p 
value 
Mean 
Diff. 
SED 95% CI   p 
value 
Mean 
diff 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI 
Lower Upper Lower Upper Lower Upper 
INS 0.619 -.0854 0.149 -0.493 0.664 INS 0.184 0.139 0.098 -0.357 0.078 INS 0.167 -0.122 0.082 -0.061 0.306 
NANOG 0.571 -0.653 0.111 -0.183 0.314 NANOG 0.962 0.005 0.107 -0.244 0.234 NANOG 0.595 -0.059 0.108 -0.181 0.300 
PAX6 0.007 0.494 0.147 -0.822 -0.166 PAX6 0.002 -0.357 0.082 0.169 0.546 PAX6 0.003 1.278 0.332 -2.018 -0.539 
PTPN1 0.045 0.398 0.174 -0.787 -0.011 PTPN1 0.011 -0.417 0.125 0.126 0.708 PTPN1 0.003 0.974 0.256 -1.545 -0.404 
POU5F1 0.004 0.277 0.075 -0.445 -0.111 POU5F1 0.014 -0.173 0.058 0.044 0.303 POU5F1 0.139 -0.090 0.056 -0.035 0.215 
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2.5 mM low glucose Independent Samples Test p=0.016 
  p 
value 
Mean 
Diff. 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI 
Lower Upper Lower Upper Lower Upper 
INS 0.135 -0.196 0.121 -0.073 0.465 INS 0.631 -0.086 0.156 -0.524 0.697 INS 0.631 -0.179 0.156 -0.524 0.697 
NANOG 0.728 -0.038 0.108 -0.201 0.279 NANOG 0.694 0.045 0.111 -0.293 0.203 NANOG 0.694 -0.128 0.111 -0.293 0.203 
PAX6 0.895 0.027 0.202 -0.477 0.423 PAX6 0.920 0.015 0.148 -0.345 0.315 PAX6 0.920 2.090 0.148 -0.345 0.315 
PTPN1 0.072 0.379 0.189 -0.800 0.041 PTPN1 0.821 -0.040 0.173 -0.345 0.426 PTPN1 0.821 0.442 0.173 -0.345 0.426 
POU5F1 0.304 0.202 0.151 -0.807 0.403 POU5F1 0.005 0.238 0.066 -0.385 -0.093 POU5F1 0.005 0.017 0.066 -0.385 -0.093 
 
<3% O2 Hypoxic conditions Independent Samples Test p=0.016 
  p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff.  
SED 95% CI   P 
value 
Mean 
diff. 
SED 95% CI 
Lower Upper Lower Upper Lower Upper 
INS 0.042 -0.117 0.052 -0.230 -0.005 INS 0.624 0.030 0.061 -0.101 0.162 INS 0.011 -0.264 0.084 -0.451 -0.077 
NANOG 0.955 -0.004 0.085 -0.187 0.178 NANOG 0.538 0.051 0.081 -0.124 0.227 NANOG 0.424 -0.094 0.113 -0.346 0.158 
PAX6 0.357 0.073 0.077 -0.093 0.241 PAX6 0.901 0.010 0.083 -0.169 0.190 PAX6 0.510 -0.056 0.083 -0.242 0.128 
PTPN1 0.784 0.049 0.174 -0.378 0.477 PTPN1 0.582 -0.079 0.141 -0.384 0.225 PTPN1 0.005 0.335 0.092 0.129 0.541 
POU5F1 0.007 -0.317 0.075 -0.504 -0.130 POU5F1 0.112 -0.127 0.056 -0.249 -0.006 POU5F1 0.029 0.179 0.070 0.023 0.336 
 
  
 
 
 
181 
 
0.5 mM Palmitic Acid Independent Samples Test p=0.016 
 
  
p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff 
SED 95% CI  p 
value 
 Mean diff. SED 95% CI 
Lower Upper Lower Upper Lower Upper 
INS 0.036 0.091 0.038 -0.175 -0.007 INS 0.840 0.007 0.035 -0.085 0.071 INS 0.904 0.015 0.117 -0.498 0.466 
NANOG 0.455 -0.244 0.314 -0.456 0.945 NANOG 0.313 -0.334 3.147 -0.367 0.103 NANOG 0.509 -0.216 0.315 -0.487 0.919 
PAX6 0.015 0.344 0.118 -0.606 -0.082 PAX6 0.914 -0.128 0.117 -0.247 0.273 PAX6 0.006 0.426 0.124 -0.702 -0.150 
PTPN1 0.614 -0.068 0.131 -0.224 0.362 PTPN1 0.308 -0.802 0.773 -0.896 0.225 PTPN1 0.380 -0.684 0.738 -0.101 0.238 
POU5F1 0.264 0.230 0.195 -0.665 0.204 POU5F1 0.168 -0.288 0.194 -0.144 0.720 POU5F1 0.002 -0.787 0.195 0.352 1.223 
 
Pro-inflammatory Cytokines Independent Samples Test p=0.016 
  p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI  p 
value 
 Mean diff. SED 95% CI 
Lower Upper Lower Upper Lower Upper 
INS 0.945 -0.003 0.054 -0.117 0.125 INS 0.764 0.0143 0.046 -0.118 0.089 INS 0.083 0.084 0.044 -0.182 0.013 
NANOG 0.138 -0.164 0.102 -0.063 0.391 NANOG 0.212 0.138 0.104 -0.371 0.093 NANOG 0.279 0.123 0.108 -0.364 0.117 
PAX6 0.527 -0.340 0.519 -0.815 1.496 PAX6 0.529 -0.347 0.533 -0.841 1.536 PAX6 0.211 -0.675 0.505 -0.450 1.800 
PTPN1 0.379 -0.356 7.366 -10.125 23.844 PTPN1 0.434 0.188 0.231 -0.703 0.326 PTPN1 0.218 -0.305 0.232 -0.212 0.824 
POU5F1 0.508 -0.242 0.352 -0.543 1.028 POU5F1 0.011 1.135 0.363 -1.943 -0.327 POU5F1 0.002 1.426 0.354 -2.216 -0.637 
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Supplementary table S9: Effects of rescue from treatment with either 25 mM high glucose or 0.5 mM tunicamycin by 72 hrs 
restoration to normal culture media on splicing factor, total gene expression and patterns of alternative splicing. 
The p values for statistical significance as determined by independent t-test, Standard errors of measurement (SED) and the 95% confidence intervals 
are given below. Statistically significant results are indicated in bold italic typeface p=<0.01. Bonferroni correction for multiple testing, 5 tests. Italic 
underlined p=0.050 no correction for multiple testing.  
 
 
Control vs 24 hrs 25 mM glucose p=0.050 
Treatment 24 hrs 25 mM glucose Treatment and rescue 
  P value Mean diff SED 95% CI P value Mean diff SED 95% CI 
Lower Upper Lower Upper 
ARX 0.620 -0.639 0.119 -0.268 0.396 0.996 -0.0008 0.150 -0.419 0.417 
FOXO1 0.010 -0.164 0.035 -0.262 -0.065 0.157 -0.050 0.288 -0.130 0.029 
GCG 0.269 -0.183 0.143 -0.214 0.581 0.832 -0.006 0.026 -0.805 0.068 
GCK 0.006 -0.137 0.026 0.065 0.210 0.418 0.044 0.049 -0.091 0.180 
Hhex 0.205 -0.226 0.149 -0.189 0.641 0.611 -0.074 0.134 -0.447 0.299 
INS 0.428 -0.071 0.071 -0.235 0.375 0.967 -0.044 0.966 -0.272 0.264 
MAFA 0.020 -0.122 0.032 0.032 0.213 0.257 0.035 0.026 -0.038 0.108 
ND1 0.370 -0.255 0.022 -0.069 0.120 0.279 0.042 0.034 -0.052 0.137 
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Control vs 24 hrs 25 mM glucose p=0.050 
Treatment 24 hrs 25 mM glucose Treatment and rescue 
NKX2-2 0.585 0.032 0.055 -0.186 0.121 0.424 0.345 0.247 -0.439 0.506 
NKX6-1 0.436 0.050 0.058 -0.211 0.111 0.502 -0.054 0.073 -0.259 0.150 
PAX4 0.021 -0.170 0.046 0.041 0.298 0.448 0.142 0.155 -0.470 0.754 
PAX6 0.300 -0.060 0.045 -0.113 0.234 0.481 -0.048 0.062 -0.222 0.125 
PDX1 0.236 -0.072 0.052 -0.072 0.216 0.205 -0.055 0.036 -0.157 0.046 
SST 0.955 -0.004 0.084 -0.228 0.238 0.715 -0.030 0.078 -0.249 0.188 
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Control Vs 24hrs 25 mM glucose p=0.050 
Treatment 24 hrs 25 mM glucose Treatment and rescue 
 
P value  Mean diff SED 95% CI P value Mean diff SED 95% CI 
Gene Lower Upper Lower Upper 
INS 0.004 0.424 0.072 -0.623 -0.226 0.476 0.058 0.077 -0.124 0.241 
NANOG 0.511 0.653 0.923 0.302 0.171 0.983 -0.002 0.107 -0.256 0.251 
PAX6 0.003 -1.278 0.127 0.539 0.131 0.364 -0.082 0.084 -0.255 0.090 
PTPN1 0.353 0.959 0.096 0.131 0.323 0.476 0.058 0.077 -0.124 0.241 
POU5F1 0.034 0.373 0.134 0.039 0.707 0.167 -0.373 0.237 -0.954 0.207 
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Supplementary table S10: Effects of SH6 AKT pathway inhibition and 
treatment with 25 mM high glucose on splicing factor and patterns of 
alternative splicing. 
The p values for statistical significance as determined by independent t-test, Standard 
errors of measurement (SED) and the 95% confidence intervals are given below. 
Statistically significant results are indicated in bold typeface. SH6 small molecule AKT 
pathway inhibitor S5 splicing factor expression 
 
SH6 and 25 mM glucose Independent Samples Test p=0.050 
  p 
value 
Std. Error 
Difference 
95% CI 
  Lower Upper 
18S-Hs99999901_s1 0.850 0.094 -0.281 0.243 
AKAP17A-Hs00946624_m1 0.621 0.104 -0.232 0.343 
GUSB-Hs00939627_m1 0.282 0.042 -0.168 0.064 
HNRNPA0-Hs00246543_s1 0.082 0.017 -0.008 0.084 
HNRNPA1-Hs01656228_s1 0.466 0.168 -0.331 0.601 
HNRNPA2B1-Hs00242600_m1 0.152 0.089 -0.090 0.404 
HNRNPD-Hs01086914_g1 0.543 0.038 -0.131 0.080 
HNRNPH3-Hs01032113_g1 0.945 0.056 -0.159 0.151 
HNRNPK-Hs00829140_s1 0.890 0.055 -0.160 0.144 
HNRNPM-Hs00246018_m1 0.638 0.056 -0.185 0.128 
HNRNPUL2 0.428 0.062 -0.227 0.117 
IDH3B-Hs00199382_m1 0.485 0.022 -0.044 0.078 
IMP3-Hs00251000_s1 0.313 0.058 -0.229 0.095 
LSM14A-Hs00385941_m1 0.619 0.353 -1.171 0.790 
LSM2-Hs01061967_g1 0.385 0.048 -0.179 0.086 
PNISR-Hs00369090_m1 0.817 0.087 -0.263 0.220 
PPIA-Hs04194521_s1 0.509 0.093 -0.190 0.324 
SF3B1-Hs00202782_m1 0.759 0.068 -0.211 0.167 
SRSF1-Hs00199471_m1 0.556 0.026 -0.055 0.088 
SRSF2-Hs00427515_g1 0.699 0.047 -0.111 0.150 
SRSF3-Hs00751507_s1 0.610 0.051 -0.112 0.168 
SRSF6-Hs00607200_g1 0.665 0.053 -0.122 0.172 
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SH6 and 25 mM glucose Independent Samples Test p=0.050 
  p 
value 
Std. Error 
Difference 
95% CI 
  Lower Upper 
SRSF7-Hs00196708_m1 0.729 0.084 -0.202 0.265 
TRA2B-Hs00907493_m1 0.922 0.044 -0.117 0.126 
 
 
 
Independent Samples Test p=0.050 
SH6 treated cells exposed to 25 mM high glucose 
  p value 
Std. Error 
Difference 
95% CI 
Lower Upper 
HPRT1 0.599 0.373 -1.250 0.824 
IDH3B 0.753 0.419 -1.305 1.023 
INS 0.866 0.083 -0.245 0.215 
NANOG 0.161 0.112 -0.504 0.119 
PAX6 0.179 0.030 -0.035 0.132 
POU5F1 0.146 0.104 -0.101 0.477 
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Chapter 5: 
Data Chapter. 
Cellular stress 
responses in the human 
beta cell line EndoC-βH1 
may be co-ordinated by 
microRNAs. 
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5.1 Introduction 
MicroRNAs (miRNA) are a class of small non-coding RNAs, which regulate gene 
expression through mRNA degradation and/ or translational repression(156, 164). 
This class of RNA regulators have important and defined roles on most cellular 
processes including development, metabolism, regulation of cell division and 
regulation of immune function(159, 169, 293). In accordance with their pivotal role in 
normal homeostasis(174), dysregulated miRNA expression is also apparent in a 
wide range of diseases including metabolic disorders(294), cancer(295-297) and 
neurodegenerative diseases(151). The biogenesis of miRNAs is thought to be 
linked to stress responses through stress granule-induced regulation of miRNA 
expression(176). Transcription and processing of miRNA genes has also been 
shown to be regulated by p53 in response to inflammation(176). These 
observations suggest that miRNAs may comprise an important component of the 
molecular stress response. 
 
The diabetic microenvironment is characterised by altered glycaemia, hypoxia, 
hyperinsulinaemia, dyslipidaemia and heightened inflammation. This yields 
enormous osmotic and metabolic stresses on beta cells, which adversely affects 
cell survival, function and differentiation status(31, 176). Tattikota et al have 
demonstrated a role for miR-184 targeting Argonaute2 in the regulation of beta 
cell proliferation during insulin resistance(298). The miRNA response to stress also 
includes mir-375(162) and the miR-200(299) family in particular, which have been 
demonstrated to have involvement in the regulation of apoptosis(160) and 
responses to inflammatory factors(160, 179). Well defined roles have also been 
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described for miRNAs in glucose homeostasis(155), such as miR-124 and miR185, 
beta cell proliferation, including miR-375 and differentiation, such as miR-7(158, 
300) as well as in management of insulin secretion and production (156, 301). 
MicroRNAs can directly target components of the insulin secretory machinery(160) 
in response to hyperglycaemia and their involvement in mediation of the unfolded 
protein response is also well documented(33). The cross-regulatory relationship 
between cellular stress and miRNA expression renders these small non-coding 
RNA regulators uniquely poised to interface between the cellular 
microenvironment and beta cell function(176, 179). 
 
Here we hypothesised that exposure to diabetes-related cellular stressors may 
affect the miRNA repertoire in human beta cells and that this may have functional 
consequences(151, 164, 179). We exposed the human EndoCH1 beta cell line to a 
variety of diabetes-associated cellular stressors and measured the effects on the 
miRNA milieu using qRTPCR. We identified 368 miRNAs expressed in 
EndoCH1 cells, of which 116 were dysregulated by aspects of the diabetic 
cellular microenvironment. The 10 most dysregulated miRNAs were validated 
and targets were predicted using bioinformatics. GSEA gene ontology analysis 
of dysregulated miRNAs revealed that the FOXO1 and HIPPO pathways, which 
have been demonstrated to be important in maintenance of beta cell fate and 
function(47, 302), were enriched in target genes of dysregulated miRNAs. 
Furthermore, a sub analysis of an a priori set of miRNAs predicted to target genes 
involved in beta cell fate or function revealed that, miR-199a, miR-21 and miR-
29a demonstrated dysregulated expression in response to one or more diabetes-
associated cellular stressors. These results suggest that the cellular 
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microenvironment can induce changes in the expression of miRNAs in human 
beta cells, and that these miRNAs may preferentially target genes involved in 
beta cell fate or function. 
 
5.2 Research Design and Methods 
 
5.2.1 Culture and treatment of EndoC-βH1 cells 
 
EndoC-βH1 cells at passage <25 were plated in 24-well plates at a density of 6.0 
x 105 cells/ ml and maintained according to a modified humanised culture 
protocol(282) for 72 hrs prior to treatment. Cells were then treated with low (2.5 
mM) or high glucose (25 mM) for 24, 36 or 48 hrs to mimic disrupted glycaemia, 
with 0.5 mM palmitic acid/ 0.5 mM oleic acid for 12, 24, and 48 hrs to mimic 
dyslipidaemia, with TNF𝛼 (1000 U/ mL, INF𝛾 (750 U/ mL) and IL1𝛽 (75 U/ mL) 
for 12, 24 and 36 hrs to mimic inflammatory changes or were grown in 1%, 3% 
or 21% O2 for a period of 4, 12 or 24 hrs to mimic hypoxia. . Each treatment was 
carried out in 3 biological replicates, along with vehicle-only controls.  
 
5.2.2 RNA extraction and reverse transcription 
 
Treated EndoC-βH1 cells were washed in Dulbecco’s phosphate buffered saline 
(D-PBS) before RNA extraction using TRI® reagent to harvest both the small 
(<200bp) and long RNA fractions (Sigma-Aldrich, Steinheim, Germany). RNA 
concentrations were adjusted to 100 ng/ μL prior to reverse transcription. For 
miRNA assessment, cDNA synthesis was carried out in 20 μL reactions using the 
Taqman® Advanced miRNA Assay kit (Thermo Fisher, Waltham, MA USA) 
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according to the manufacturer’s instructions. For assessment of mRNA target 
levels, cDNA synthesis was carried out using EvoScript Universal cDNA master 
(Roche life science, Burgess Hill, UK). Samples were normalised to 100 ng/ μL 
RNA prior to reverse transcription. 
 
5.2.3 Large-scale miRNA screen 
 
The miRNA milieu of treated and endogenous control cells was assessed using 
Taqman® Advanced miRNA (miR) open arrays on the Thermo Fisher 12K 
OpenArray Flex platform (Thermo Fisher, Waltham, MA USA). These arrays 
contain unique probes to 757 miR targets as detailed in supplementary table S11. 
Data was analysed using Thermo Fisher Connect your lab software (Thermo 
Fisher Connect™, Thermo Fisher, Waltham, MA USA, available at 
https://www.thermofisher.com). Target microRNAs were selected by choosing 
those with the largest fold changes in cells exposed to the cellular stressors 
compared to the endogenous controls, table 8 and supplementary table S11 for 
assay IDs. 
 
 
5.2.4 Validation of dysregulated miRNAs 
 
The 10 most dysregulated miRNAs were then validated using a separate probe 
set. In a sub analysis, we also validated a panel of 10 candidate miRNAs 
predicted by miRTarBase(303) to target an á priori  panel of genes selected on the 
basis of known roles in relation to beta cell fate, function or cellular stress. Genes 
associated with other pancreatic islet cell types were also included in the target 
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panel, see table 4 and supplemental table S12. MicroRNAs were validated using 
Taqman® advanced miR assays (Thermo Fisher, Waltham, MA USA). The three 
most stable miRNAs (miR 106b-3p, miR-191-3p and miR103-3p) were selected 
for use as endogenous controls. qRTPCR reaction mixes included 2.5 μL 
Taqman® Universal PCR mastermix II (no AmpErase® UNG) (Thermo Fisher, 
Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL cDNA and 0.25 μL Taqman® gene 
assay (Thermo Fisher, Foster City USA) in a 5 μL reaction volume. Cycling 
conditions were: 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 s at 95 °C 
for 30 s and 1 minute at 60 °C. Reactions were carried out in 3 biological 
replicates and 3 technical replicates. MicroRNA assay identifiers are given in 
supplementary table S13. The relative expression of each was determined by the 
comparative Ct approach and were calculated relative to the geometric mean of 
the endogenous controls. We also carried out an analysis relative to the global 
mean of expression across all transcripts tested. Expression levels were then 
normalised to the median level of expression seen in untreated EndoC-βH1 cells. 
Differences in gene expression levels between mock-treated and treated EndoC-
βH1 cells were compared to the same time point controls for each condition and 
investigated for statistical significance by student independent t-test carried out 
using SPSS version 23 (IBM, North Castle, NY, USA). Data were presented as 
means ± S.E.M. 
 
5.2.5 miRNA pathway enrichment analysis 
 
To assess pathway and gene targets for miRNAs dysregulated in response to the 
cellular stress assays, we used the DNA intelligent analysis (DIANA) miRPath 
v3.0 and the DIANA-microT-CDS v 5.0 algorithm(246, 247). The DIANA mirPath 
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database focuses on the identification of miRNA targeted cell pathways, the 
algorithm performs gene set enrichment analysis (GSEA) using a Fisher’s exact 
test to determine the statistical significance of microRNA gene targets in KEGG 
pathways. Identified pathways were fed into the DIANA microT-CDS database 
entries to determine pathway target genes predicted by this pattern of altered 
miRNA expression. Genes have a microRNA target (MITG) score which predicts 
the probability of the microRNA targeting that gene(248). A score of 0 means there 
is zero probability, a score of 1 means a very high probability of targeting the 
gene. Here, we used this platform to carry out GSEA using miRNAs differentially 
regulated across several treatment regimes to determine whether any were 
overrepresented in gene ontology or functional category pathways derived from 
KEGG. The p value was set to 0.05 and the MicroT threshold to 0.8, see table 8. 
 
5.2.6 Validation of miRNA target gene mRNA levels 
 
Target genes for validation were based on the MITG scores from the DIANA-
microT-CDS v5.0 algorithm(246), supplementary table S14. The MITG score is the 
predictive score, where the higher the score the higher the probability that the 
gene in question is a target of the miRNA on the basis of complementarity(248). A 
panel of 10 mRNAs were selected on the basis of highest MITG score, most 
statistically significant p value, number of genes predicted and number of 
miRNAs targeting the top 5 pathways; Lysine degradation, FOXO signalling 
pathway, HIPPO signalling pathway, TGF - estrogen signalling and Pathways 
in Cancer.  
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The expression levels of predicted target genes was then measured using IDT 
mini primetime gene expression assays (Integrated DNA Technologies, Skokie, 
Illinois, USA) as detailed in supplementary table S15. Reactions were run in 
triplicate on 384 well plates, using one assay per plate containing all samples. 
Each reaction included 2.5 μL Taqman® Universal PCR mastermix II (no 
AmpErase® UNG) (Thermo Fisher, Waltham, MA, USA), 1.75 μL dH2O, 0.5 μL 
cDNA and 0.25 μL using IDT mini primetime gene expression assays 
(Integrated DNA Technologies, Skokie, Illinois, USA) in a 5 μL reaction volume. 
Cycling conditions were: 50 °C for 2 min, 95 °C for 10 min and 50 cycles of 15 s 
at 95 °C for 30 s and 1 min at 60 °C. Associations between miRNA and mRNA 
target expression were assessed using independent t-tests carried out using 
SPSS v23 (IBM, North Castle, NY, USA). We identified correlations by integrating 
miR expression data with mRNA expression to assess expression changes that 
occurred in response to the same cellular stresses. This method was used to 
assess relationships between the miRNA and mRNA, particularly where the 
predicted miRNA target gene expression was contrary to that of the miRNA(304, 
305). 
 
5.3 Results 
 
5.3.1 Large scale dysregulation of miRNAs in response to the diabetic milieu 
 
368 out of 757 miRNAs tested were expressed in untreated EndoC-H1 human 
beta cells. 116 miRNAs demonstrated evidence of dysregulation upon treatment 
with altered glycaemia, dyslipidaemia, hypoxia or cytokines, (supplementary 
table S16). Independent validation of the miRNAs demonstrating the largest fold 
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change in the initial analysis showed that 5 miRNAs survived independent 
validation, as shown in figure 20 and supplemental table S17. miRNA miR-136-
5p was altered in response to 25 mM high glucose, palmitic acid and inflammatory 
factors (p=0.008, mean diff 0.782, p=0.01, mean diff 1.047 and p=0.002, mean 
diff -0.634 respectively). miR-299-5p showed altered expression in response to 
changes in glycaemia and <3% O2 (p=0.002, mean diff -0.619 and 0.01 mean diff 
-0.685 respectively). miR-454-5p responded to 2.5 mM low glucose (p=0.012, 
mean diff 4.145). Both miR-152 and miR-185 responded to 25 mM high glucose 
(p=0.005 mean diff 0.536 and p=0.024 mean diff -2.221 respectively).  
 
Table 8 Large scale microRNA screen.  
High throughout global microRNA screen results showing the most altered microRNAs 
for pathways analysis. Table shows microRNAs shown to have large fold changes from 
the near global screen that were also validated in studies in islets(159, 175). Possible switch 
refers to cases where a very large fold change might indicate the presence of an on/ off 
switch mechanism in response to specific stressors. 
 
miR name Cell assay 
Altered in 
top 50. 
Validated in 
islets(175)  
Possible 
switch:  
on/ off  
In top 20 most 
up/ down 
regulated 
Mir_hsa-185-3p 3 assays YES NO In 3 assays 
Mir_hsa-885-5p All assays YES YES In 3 assays 
miR_hsa-576-5p All assays YES NO In 3 assays 
miR_hsa-27b-3p All assays YES NO In 3 assays 
miR_hsa-124-3p All assays NO NO In 3 assays 
miR_hsa-136-5p All assays NO NO In 3 assays 
miR_hsa-152-3p 4 assays NO NO In 3 assays 
miR_hsa-299-5p All assays NO NO In 2 assays 
miR_hsa-93-5p All assays NO NO In 2 assays 
Mir_hsa-454-5p All assays YES YES in 1 
assay 
In 1 assay 
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Table 9 Large scale micro RNA screen. 
High throughput global microRNA screen results showing the most altered microRNAs 
validated for genes in beta cell target panel. Table shows those microRNAs identified by 
miRTarBase as experimentally validated to target genes in a panel of beta cell relevant 
genes with known roles in beta cell fate and function. miRTarBase defines strong 
validation as experimentally characterised and weak validation as those identified from 
NGS studies. Possible switch refers to cases where a very large fold change might 
indicate the presence of an on/ off switch mechanism in response to specific stressors.  
 
miR-376a-
3p 
SLC16A1 All assays YES YES NO 
miR-199a-
3p 
STK11 All assays 
 
YES YES YES 
miR-374b-
3p 
SLC16A1 All assays NO YES YES 
miR-29a-3p FOXO1 All assays YES YES NO 
 
  
Micro-RNA Genes in 
target 
panel 
Cell Assay Empirically 
validated(303) 
NGS 
validated 
Possible 
switch: 
on/off 
miR-202-5p SOX9 Glycaemia 
Hypoxia 
Cytokine 
YES YES YES – 
3 assays   
miR-92b-5p GCK All assays YES   
miR-9-5p FOXO1 All assays YES YES YES 
miR-34a-5p NANOG, 
MYC, 
LDHA 
Low 
glucose 
Hypoxia 
Palmitic 
acid 
YES YES YES 
miR-21-3p FOXO1, 
SOX9 
All assays YES YES NO 
miR-101-3p SOX9 All assays YES YES NO 
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Figure 20 Targeted microRNA expression of most altered miRNAs from 
large scale miRNA screen.  
Larger dotted line shows significance p=<0.016. Bonferroni multiple testing correction for 
3 tests. Coloured shapes denote significance. Smaller dotted line shows significance p -
<0.050 no correction for multiple testing. Circles: 25 mM high glucose. Squares: 2.5 mM 
low glucose. Diamonds: <3% O2. Triangles: 0.5 mM palmitic acid. Stars pro-
inflammatory factors. 
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5.3.3 The Lysine degradation, HIPPO and FOXO pathways are enriched in 
genes targeted by dysregulated miRNAs  
 
We then determined the gene ontology pathways enriched for genes targeted by 
the 5 responsive miRNAs. The top 5 pathways targeted by these miRNAs 
included: Lysine degradation 12 genes (p=3.0x10-3), HIPPO signalling pathway 
17 genes (p=5.84x10-5), FOXO signalling pathway 18 genes (p=0.02), TGF - 
oestrogen 15 genes (p=0.02) and Pathways in Central Cancer 9 genes 
(p=3.0x10-3), supplementary table S14. 
 
5.3.4 Correlation of miRNA and mRNA target expression 
 
Target genes of the dysregulated miRNAs were identified from the pathways 
analysis. We therefore correlated the mRNA expression level of the target genes 
in question with its respective miRNA as previously described(304, 305). We found 
that changes in the expression of 3 of the miRNAs, miR-136-5p, miR299-5p and 
miR-454-5P negatively correlated with expression changes in response to the 
cellular stressors in their respective target genes, MAPK1/ DLG2, PDK1 and 
MAPK1, see supplementary tables S17 and S18, figure 21. A positive correlation 
between miRNA and mRNA was also noted for miR-185 and MAPK1 in response 
to 25 mM high glucose.  
 
 
 
  
 
 
 
199 
Figure 21 mRNA expression of predicted target genes from DIANA 
pathways analysis.  
Smaller dotted line shows significance p -<0.050 no requirement of correction for multiple 
testing. Circles: 25 mM high glucose, dark blue p=0.050 Squares: 2.5 mM low glucose, 
dark green p=0.050. Diamonds: <3% O2, dark red p=0.050. Triangles: 0.5 mM palmitic 
acid, dark purple p=0.050. Inverse triangles: inflammatory factors, dark purple p=0.050. 
Inverse triangles: proinflammatory factors, dark pink p=0.050. 
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5.3.5 STK11, SOX9 and FOXO1 mRNA expression demonstrates negative 
associations with miR199a, miR-21 and miR-29a following diabetes-related 
cellular stresses. 
 
Three of ten miRNAs selected on the basis of miRTarBase(303) evidence of roles 
in the regulation of a beta cell-specific target panel also demonstrated expression 
changes in treated cells, supplementary table S19. We integrated miR expression 
with mRNA expression to identify expression changes, (either positive or 
negative correlations), that occurred in response to the same cellular stresses. 
Changes in the expression of miR-199a, miR-21 and miR-29a negatively 
correlated with expression changes in their gene targets (STK11, SOX9 and 
FOXO1 respectively) in response to 25 mM high glucose and inflammatory 
factors, see supplementary tables S19 and S20, figure 22. Altered expression 
levels were also apparent for miR-199a, miR-21 and miR-29a (p=0.001 mean diff 
4.438, p=0.016 mean diff -0.663 and p=0.001 mean diff 1.477) in response to 
either high glucose or inflammatory factors.  
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Figure 22 Targeted expression of microRNAs strongly validated to beta cell 
genes.  
Larger dotted line shows significance p=<0.016. Bonferroni multiple testing correction for 
3 tests. Smaller dotted line shows significance p -<0.050 no correction for multiple 
testing. Circles: 25 mM high glucose, dark blue p=0.016, light blue p=0.050. Squares: 
2.5 mM low glucose, light green p=0.050. Diamonds: <3% O2. Triangles: 0.5 mM palmitic 
acid. Inverse triangles: inflammatory factors, dark pink p=0.016, light pink p=0.050 
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5.4 Discussion 
 
A number of studies have reported the importance of miRNA regulation on gene 
expression relating to cellular stress responses in beta cells(151, 179). High 
throughput miRNA profiling in rodent models and human islets have identified a 
number of miRNAs that are associated with beta cell dysfunction(174, 175). 
MicroRNAs have been previously implicated in beta cell stress responses(30, 151, 
176, 177, 179, 306). Here, we found that cellular stresses associated with a T2D 
microenvironment caused dysregulation of miRNA expression for 5 miRNAs, 
miR136-5p, miR-299-5p, miR-454-5p, mir-152 and miR-185. Gene set 
enrichment analysis identified 3 KEGG pathways, lysine degradation, HIPPO and 
FOXO as predicted targets for these miRNAs. Subsequent gene target validation 
showed negative correlations for 3 miRNAs and their respective target genes, 
miR-136-5p and MAPK1/ DLG2, miR299-5p and PDK1 and miR454-5p and its 
predicted target MAPK1. Validation of miRNAs previously predicted to target beta 
cell genes also showed negative correlation for 3 miRNAs and their predicted 
targets, miR-199a and STK11, miR-21 and SOX9 and miR-29a and FOXO1.  
 
miRNAs have been shown to have various functions in mediating beta cell 
responses to stresses including regulation of beta cell proliferation, insulin 
secretion and glucose homeostasis, beta cell differentiation and apoptosis. 
MicroRNA miR-375 is known to regulate beta cell proliferation in response to 
chronic metabolic stresses and miR-21, miR-29a, along with the miR-200 family, 
are associated with regulation of apoptosis(162, 299, 307). Increased expression of 
miR-21 and miR-29a are associated with increased beta cell proliferation but also 
rates of apoptosis in the presence of cytokines(293, 307). Our data also show 
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elevated levels of miR-21 and miR-29a in response to inflammatory factors, 
supporting the hypothesis that microRNAs coordinate stress response in a 
manner which creates an intimate relationship between beta cell function and 
survival. 
 
Changes in glucose concentration in the cellular microenvironment have been 
shown to increase the expression of miR-124, which is known to negatively 
regulate insulin secretion. miRNAs miR-185, miR-152 and miR-21 have all be 
previously identified in relation to the regulation of glucose homeostasis via 
altered insulin secretion, signalling, glucose sensitivity and cell survival(151, 158, 307). 
(157-159). Increased levels of miR-185 have recently been shown to enhance insulin 
secretion(158). Here we found reduced levels of miR-185 after exposure to 25 mM 
glucose, suggesting, in line with the literature, that insulin secretion may be 
impaired under high glucose stresses. In contrast, elevated levels of miR-21 and 
miR-152 have been seen in patients with T2D(157, 170, 307) and have been shown 
to negatively impact glucose sensitive insulin secretion (GSIS)(157, 307). Our data 
show very marked increases in the levels of miR-152 in EndoC-H1 cells 
exposed to 25 mM high glucose and miR-21 in response to inflammatory factors, 
which again may suggest impaired insulin secretion as a result of altered miRNA 
expression. These data suggest a clear association between altered miRNA 
expression in response to cell stress and impaired insulin secretion and may 
implicate miRNAs in the coordination of beta cell stress response and 
pathogenesis of T2D. 
 
Correlation analysis is a recognised technique for identifying potential roles for 
miRNA in gene regulation, with negative correlations being the most commonly 
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observed phenomenon(304, 305). Investigation of miRNAs known to target genes 
with known beta cell and pancreatic endocrine functions show negative 
correlations for miR-199a and its validated target STK11 (LKB1), miR-21 and its 
validated target SOX9 and miR-29a and its validated target FOXO1. Here, STK11 
(LKB1) is significantly down regulated in response to high glucose with increased 
expression of miR-199-a. Increased levels of miR-199a are known to reduce 
STK11 expression(308). Importantly, STK11 (LKB1) has been shown to maintain 
beta cell identity(171) as well as increased beta cell size and polarity(309). A recent 
study has also shown that TCF7L2, a previously identified T2D GWAS hit(310), 
mediates a signalling mechanism that acts via STK11 (LKB1) to negatively 
regulate insulin secretion(311). This suggests that cellular stressors associated 
with T2D may contribute to increased cellular plasticity through dysregulation of 
miRNA expression. SOX9 is also a marker for beta cell plasticity and our data 
show significantly increased expression in response to glycaemia, hypoxia and 
dyslipidaemia along with reduced miR-21 expression. This again implies a role 
for miRNA dysregulation in changes to mature beta cell differentiation status in 
T2D. Finally, FOXO1 has been described as the master regulator for beta cell 
identity(43) and here we saw decreased expression in response to inflammatory 
factors with increased expression of miR-29a. Taken together, these data 
suggest that miRNA dysregulation is an important feature of the increased beta 
cell plasticity reported in T2D(159).  
 
Validation of miR targets identified from pathways analysis showed negative 
correlations for miR-454-5p and its predicted target MAPK1, miR-136-5p and its 
predicted target DLG2 and miR-299-5p and its predicted target PDK1. What is 
striking from these data is the number correlations for genes with known roles in 
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beta cell dysfunction and survival, which is likely due to their tight regulation 
during periods of cell stress. MAPK1 signalling in particular, occurs in response 
to microenvironmental changes affecting cellular metabolism and is implicated in 
the pathogenesis of metabolic syndrome(312). Both DLG2 and PDK1 have also 
been shown to have roles in beta cell stress response in relation to insulin 
signalling, survival and apoptosis(287, 313). Here, low glycaemia showed marked 
increases in expression of miR454-5p, compared to negligible levels in controls, 
along with significantly decreased expression of MAPK1. Downregulation of 
MAPK1 leads to increased apoptosis and so it may be possible that miR-454-5p 
is influencing rates of apoptosis during cellular stress. miR-299 showed 
significantly reduced expression in response to both high glucose and hypoxia, 
however, PDK1 only showed increased expression following exposure to 
<3%O2. Inflammatory factors resulted in lower levels of miR-136-5p with 
concomitant increases in its predicted target DLG2. Taken together, all these 
data may suggest that cellular stresses activate miRNA regulation of beta cell 
survival pathways that regulate rates of apoptosis.   
 
The increased expression of miR-21 and miR-29 we found in response to 
inflammatory factors is known to be associated with increased rates of apoptosis, 
implying that cytokine exposure negatively impacts beta cell survival(293, 307). 
Similarly, negative correlations between miR-454-5p, miR-136-5p and miR-299-
5p with their respective target genes MAPK1, DLG2 and PDK1 are also 
implicated in the negative regulation of beta cell survival in response to cell stress. 
Studies have indicated that miRNAs may also influence beta cell stress 
responses via changes in mature beta cell differentiation status(314, 315). miR-7 has 
been identified in association with beta cell differentiation in response to 
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metabolic stresses(179). Here, validation of miRNAs predicted to target beta cell 
genes showed negative correlations between miR-199a, miR-21, miR-29a and 
their target genes, STK11, SOX9 and FOXO1. The pattern of altered gene 
expression we identified may suggest increased beta cell plasticity in response 
to cell stress. We also found a pattern of dysregulated expression for miR-185, 
miR-21 and miR-152 that can potentially be explained by cellular stresses 
causing impaired insulin secretion in a manner that may be coordinated by 
microRNAs. Taking these data together, this could support a model where the 
cellular stress response is, at least in part, coordinated by miRNAs and affects 
beta cell survival, function and differentiation status.  
 
We acknowledge that our results are based upon an in vitro model and are not 
supported by data from in vivo or ex vivo islet comparisons. However, looking at 
these data as a whole, it supports a hypothesis where altered miRNA expression 
following exposure to the types of cellular stress seen in patients with T2D, can 
potentially influence genes with roles in both beta cell fate and survival. This 
would be consistent with recent reports in the literature which show that the beta 
cell mass loss seen in T2D are caused by both loss of mature beta cell identity 
as well as cell death(61, 86, 113). However, it may be that the miRNA expression 
changes we observed may be a secondary response to the cellular stressors 
rather than mediating phenotypic changes; miRNAs responding to cellular 
stressor rather than driving the beta cell stress response itself. To investigate this 
further, and experimentally validate these findings, studies employing either 
miRNA upregulation or miRNA loss of function techniques such as genetic 
knockouts, antisense oligonucleotide inhibitors(316, 317) and miRNA sponges(318) 
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would be advised to elucidate causality and better characterise the relationship 
between beta cell stress, miRNAs and their target genes. 
 
Within the literature there is considerable heterogeneity between studies, 
possibly the result of differences in islet handling and cell culture techniques(175). 
It is also notable that there are important distinctions between rodent and human 
datasets(169). However, perhaps surprisingly, given the levels of heterogeneity 
between studies, it is a strength of our study that these data confirm results that 
have been seen in a number of other studies relating to miR-185, miR-152, miR-
199a, miR-21, miR-29a, miR-376a and miR-136-5p. 
 
We have shown evidence that three miRNAs, miR-454-5p, miR136-5p and miR-
299-5p, correlate with expression changes in target genes which are associated 
with the cellular pathways FOXO and MAPK. These pathways are likely to 
regulate beta cell survival in response to cell stress. We also present evidence 
that three miRNAs, miR-199a, miR-21 and miR-29, correlate with altered 
expression in their respective beta cell target genes, STK11, SOX9 and FOXO1. 
These miRNA/ mRNA interactions may have implications for maintenance of beta 
cell identity following exposure to cell stress. Taken together, these data suggest 
that the beta cell stress response may be coordinated by microRNAs and their 
dysregulated expression is an important feature of T2D. 
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Supplementary table 11. Large scale microRNA screen assay IDs. 
 
Assay ID Target name Assay ID Target name Assay ID Target name 
478872 hsa-miR-409-5p 477906 hsa-miR-139-3p 478658 hsa-miR-1252-5p 
478092 hsa-miR-424-5p 479485 hsa-miR-517a-3p 478660 hsa-miR-1254 
478007 hsa-miR-30b-5p 478989 hsa-miR-520a-3p 478662 hsa-miR-1255b-5p 
478587 hsa-miR-29a-3p 478231 hsa-miR-199a-5p 477929 hsa-miR-15b-3p 
478125 hsa-miR-485-3p 478997 hsa-miR-526b-5p 478641 hsa-miR-1226-5p 
478308 hsa-miR-484 478585 hsa-miR-196b-5p 477880 hsa-miR-124-5p 
477854 hsa-miR-380-3p 479340 hsa-miR-519e-3p 477875 hsa-miR-1225-3p 
478826 hsa-miR-323b-5p 478995 hsa-miR-525-3p 478644 hsa-miR-1228-5p 
478126 hsa-miR-485-5p 478984 hsa-miR-518f-3p 478657 hsa-miR-1251-5p 
478293 cel-miR-39-3p 478153 hsa-miR-542-3p 477874 hsa-miR-122-3p 
478561 hsa-miR-449a 479393 hsa-miR-518d-3p 478730 hsa-miR-1825 
478591 hsa-miR-302b-3p 478112 hsa-miR-455-3p 479120 hsa-miR-641 
478086 hsa-miR-411-5p 478685 hsa-miR-1283 479176 hsa-miR-767-5p 
478024 hsa-miR-324-5p 478165 hsa-miR-576-5p 478661 hsa-miR-1255a 
478008 hsa-miR-30c-5p 478351 hsa-miR-200c-3p 479128 hsa-miR-649 
477816 hsa-miR-381-3p 479396 hsa-miR-525-5p 478638 hsa-miR-1224-3p 
478860 hsa-miR-376b-3p 479285 hsa-miR-524-5p 478340 hsa-miR-631 
478790 hsa-miR-296-3p 478210 hsa-miR-93-5p 478637 hsa-miR-1208 
478087 hsa-miR-412-3p 478991 hsa-miR-520g-3p 478161 hsa-miR-564 
477849 hsa-miR-429 479408 hsa-miR-518e-3p 479063 hsa-miR-581 
478106 hsa-miR-450a-5p 479343 hsa-miR-520f-3p 479040 hsa-miR-555 
478113 hsa-miR-455-5p 477825 hsa-miR-301b-3p 477973 hsa-miR-21-3p 
478509 hsa-miR-302c-3p 478498 hsa-miR-520e 478631 hsa-miR-1200 
478491 hsa-miR-204-5p 478914 hsa-miR-450b-5p 478788 hsa-miR-26a-2-3p 
478411 ath-miR159a 479053 hsa-miR-570-3p 479058 hsa-miR-578 
477916 hsa-miR-145-5p 478672 hsa-miR-1267 477862 hsa-let-7i-3p 
477925 hsa-miR-154-5p 478156 hsa-miR-544a 477850 hsa-let-7g-3p 
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Assay ID Target name Assay ID Target name Assay ID Target name 
477900 hsa-miR-132-3p 479501 hsa-miR-548a-5p 477869 hsa-miR-1180-3p 
477908 hsa-miR-140-3p 477833 hsa-miR-548d-3p 478341 hsa-miR-7-5p 
478789 hsa-miR-27b-5p 478418 hsa-miR-26b-5p 478221 hsa-let-7b-3p 
477858 hsa-miR-15a-5p 478544 hsa-miR-129-2-3p 478787 hsa-miR-26a-1-3p 
478399 hsa-miR-146a-5p 477835 hsa-miR-487b-3p 477984 hsa-miR-223-5p 
477824 hsa-miR-148b-3p 478132 hsa-miR-491-5p 478784 hsa-miR-24-1-5p 
477889 hsa-miR-127-3p 478139 hsa-miR-499a-5p 478630 hsa-miR-1197 
477857 hsa-miR-181a-5p 478744 hsa-miR-195-3p 478755 hsa-miR-202-5p 
478312 hsa-miR-139-5p 478049 hsa-miR-34b-3p 478774 hsa-miR-218-1-3p 
477911 hsa-miR-142-5p 478035 hsa-miR-337-3p 478745 hsa-miR-196a-3p 
477891 hsa-miR-127-5p 479057 hsa-miR-577 478625 hsa-miR-1178-3p 
477840 hsa-miR-130b-3p 478831 hsa-miR-33a-3p 478713 hsa-miR-143-5p 
477935 hsa-miR-182-5p 478188 hsa-miR-645 478846 hsa-miR-367-5p 
477918 hsa-miR-150-5p 478840 hsa-miR-363-5p 479115 hsa-miR-633 
477896 hsa-miR-129-5p 478317 hsa-miR-20a-3p 479125 hsa-miR-646 
478624 hsa-miR-10a-3p 478750 hsa-miR-19a-5p 479150 hsa-miR-665 
478584 hsa-miR-18b-5p 478710 hsa-miR-135b-3p 479139 hsa-miR-657 
478313 hsa-miR-15b-5p 477915 hsa-miR-145-3p 479116 hsa-miR-634 
477938 hsa-miR-184 477895 hsa-miR-1290 477899 hsa-miR-130b-5p 
478551 hsa-miR-18a-5p 478055 hsa-miR-361-3p 479140 hsa-miR-658 
479537 hsa-miR-548c-3p 479451 hsa-miR-1296-5p 479127 hsa-miR-648 
478166 hsa-miR-582-5p 477951 hsa-miR-191-3p 479151 hsa-miR-668-3p 
478164 hsa-miR-576-3p 478725 hsa-miR-154-3p 479146 hsa-miR-663b 
480870 hsa-miR-548d-5p 478505 hsa-miR-151a-5p 477958 hsa-miR-196b-3p 
477860 hsa-miR-16-5p 478051 hsa-miR-34c-3p 478342 hsa-miR-766-3p 
478792 hsa-miR-299-3p 477919 hsa-miR-151a-3p 479119 hsa-miR-640 
478000 hsa-miR-28-5p 478671 hsa-miR-1265 479204 hsa-miR-924 
478594 hsa-miR-320a 479478 hsa-miR-181a-2-3p 479206 hsa-miR-92a-2-5p 
478459 hsa-miR-376c-3p 478729 hsa-miR-182-3p 479210 hsa-miR-935 
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Assay ID Target name Assay ID Target name Assay ID Target name 
478090 hsa-miR-423-5p 479181 hsa-miR-802 479452 hsa-miR-1298-5p 
478481 hsa-miR-422a 479205 hsa-miR-92a-1-5p 479220 hsa-miR-944 
478075 hsa-miR-377-3p 479175 hsa-miR-767-3p 479214 hsa-miR-938 
478793 hsa-miR-299-5p 478681 hsa-miR-1278 479198 hsa-miR-892b 
477974 hsa-miR-214-3p 479191 hsa-miR-888-3p 479048 hsa-miR-563 
478133 hsa-miR-492 478650 hsa-miR-1243 479065 hsa-miR-583 
478432 hsa-miR-483-5p 478209 hsa-miR-93-3p 479055 hsa-miR-573 
478578 hsa-let-7f-5p 479217 hsa-miR-941 479039 hsa-miR-554 
478579 hsa-let-7e-5p 479071 hsa-miR-588 477836 hsa-miR-296-5p 
478131 hsa-miR-490-3p 479349 hsa-miR-513c-5p 477820 hsa-miR-1-3p 
477980 hsa-miR-219a-5p 479084 hsa-miR-603 479456 hsa-miR-216b-5p 
478602 hsa-miR-23b-3p 479212 hsa-miR-937-3p 477983 hsa-miR-223-3p 
479235 hsa-miR-30e-5p 479100 hsa-miR-617 478029 hsa-miR-329-3p 
478447 hsa-miR-17-5p 479117 hsa-miR-635 477992 hsa-miR-24-3p 
478580 hsa-let-7g-5p 479098 hsa-miR-614 477863 hsa-miR-101-3p 
477976 hsa-miR-216a-5p 479113 hsa-miR-630 477977 hsa-miR-218-5p 
477978 hsa-miR-219a-1-3p 479069 hsa-miR-586 477994 hsa-miR-25-3p 
478375 hsa-let-7i-5p 478168 hsa-miR-590-3p 478225 hsa-miR-106a-5p 
477940 hsa-miR-186-5p 479085 hsa-miR-604 478384 hsa-miR-27a-3p 
479189 hsa-miR-887-3p 477868 hsa-miR-10b-3p 477961 hsa-miR-199a-3p 
478200 hsa-miR-744-5p 478980 hsa-miR-517-5p 479544 hsa-miR-186-3p 
477883 hsa-miR-125a-3p 479075 hsa-miR-592 478363 hsa-miR-373-3p 
479134 hsa-miR-653-5p 479097 hsa-miR-613 478490 hsa-miR-200a-3p 
477987 hsa-miR-22-5p 479043 hsa-miR-557 478238 hsa-miR-374a-5p 
479196 hsa-miR-891a-5p 479025 hsa-miR-548p 478070 hsa-miR-371a-3p 
479121 hsa-miR-642a-5p 478173 hsa-miR-601 478025 hsa-miR-325 
478191 hsa-miR-655-3p 479038 hsa-miR-553 478059 hsa-miR-362-5p 
478519 hsa-miR-99a-5p 478727 hsa-miR-16-1-3p 478979 hsa-miR-516b-5p 
478343 hsa-miR-99b-5p 478711 hsa-miR-138-2-3p 478264 hsa-miR-19b-3p 
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Assay ID Target name Assay ID Target name Assay ID Target name 
479131 hsa-miR-651-5p 478719 hsa-miR-148b-5p 478323 hsa-miR-331-3p 
478207 hsa-miR-885-5p 479051 hsa-miR-569 478134 hsa-miR-493-3p 
478185 hsa-miR-636 477914 hsa-miR-144-5p 478350 hsa-miR-501-3p 
479197 hsa-miR-891b 478758 hsa-miR-203b-5p 478972 hsa-miR-512-5p 
479184 hsa-miR-875-3p 478680 hsa-miR-1276 478960 hsa-miR-507 
479371 hsa-miR-892a 477943 hsa-miR-188-5p 478145 hsa-miR-505-3p 
478513 hsa-miR-146b-5p 478699 hsa-miR-1304-5p 479089 hsa-miR-608 
478785 hsa-miR-24-2-5p 477811 hsa-miR-151b 478982 hsa-miR-518c-3p 
478205 hsa-miR-874-3p 478147 hsa-miR-515-5p 478142 hsa-miR-501-5p 
479186 hsa-miR-876-3p 477890 hsa-miR-1275 479530 hsa-miR-518d-5p 
479517 hsa-miR-181d-5p 477936 hsa-miR-183-3p 478958 hsa-miR-506-3p 
478036 hsa-miR-337-5p 478673 hsa-miR-1270 478309 hsa-miR-500a-5p 
478027 hsa-miR-326 478647 hsa-miR-1236-3p 478971 hsa-miR-512-3p 
477806 hsa-miR-208b-3p 477933 hsa-miR-181c-3p 479101 hsa-miR-618 
478389 hsa-miR-374b-5p 479078 hsa-miR-595 478088 hsa-miR-421 
478590 hsa-miR-98-5p 477944 hsa-miR-18a-3p 478968 hsa-miR-510-5p 
478076 hsa-miR-378a-5p 479091 hsa-miR-609 478367 hsa-miR-590-5p 
478855 hsa-miR-374a-3p 479104 hsa-miR-620 479073 hsa-miR-589-5p 
478091 hsa-miR-424-3p 479067 hsa-miR-585-3p 479469 hsa-miR-625-5p 
478084 hsa-miR-409-3p 478691 hsa-miR-1292-5p 478977 hsa-miR-516a-3p 
478002 hsa-miR-29a-5p 478362 hsa-miR-548e-3p 478177 hsa-miR-616-3p 
479362 hsa-miR-30d-3p 479024 hsa-miR-548n 478215 hsa-miR-96-5p 
478388 hsa-miR-30e-3p 479512 hsa-miR-623 478427 hsa-miR-627-5p 
479448 hsa-miR-30a-5p 479532 hsa-miR-518f-5p 478348 hsa-miR-502-3p 
478859 hsa-miR-376a-5p 478349 hsa-miR-378a-3p 479064 hsa-miR-582-3p 
478799 hsa-miR-302b-5p 479338 hsa-miR-524-3p 478077 hsa-miR-379-5p 
478237 hsa-miR-302d-3p 479110 hsa-miR-626 477879 hsa-miR-124-3p 
479401 hsa-miR-30c-2-3p 479020 hsa-miR-548g-3p 478532 hsa-miR-23a-3p 
478012 hsa-miR-31-3p 479297 hsa-miR-513b-5p 478586 hsa-miR-20a-5p 
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Assay ID Target name Assay ID Target name Assay ID Target name 
478888 hsa-miR-431-3p 479082 hsa-miR-600 477904 hsa-miR-137 
478800 hsa-miR-302c-5p 480874 hsa-miR-548i 478136 hsa-miR-495-3p 
478775 hsa-miR-218-2-3p 479391 hsa-miR-548l 478060 hsa-miR-363-3p 
478101 hsa-miR-432-5p 477852 hsa-miR-550a-5p 477814 hsa-miR-148a-3p 
478311 hsa-miR-138-1-3p 478990 hsa-miR-520d-3p 478030 hsa-miR-330-3p 
478801 hsa-miR-302d-5p 478951 hsa-miR-500a-3p 478066 hsa-miR-367-3p 
479281 hsa-let-7e-3p 478988 hsa-miR-519e-5p 478324 hsa-miR-335-5p 
478939 hsa-miR-488-5p 479054 hsa-miR-571 478325 hsa-miR-339-3p 
478782 hsa-miR-23a-5p 477848 hsa-let-7d-3p 478052 hsa-miR-34c-5p 
478476 hsa-miR-1260a 479491 hsa-miR-518e-5p 477957 hsa-miR-195-5p 
477948 hsa-miR-190b 478198 hsa-miR-7-1-3p 478071 hsa-miR-372-3p 
478642 hsa-miR-1227-3p 477887 hsa-miR-126-3p 477917 hsa-miR-149-5p 
478663 hsa-miR-1256 478102 hsa-miR-433-3p 477954 hsa-miR-193a-5p 
478655 hsa-miR-1250-5p 478109 hsa-miR-452-5p 478307 hsa-miR-136-5p 
477998 hsa-miR-27a-5p 478094 hsa-miR-425-5p 478058 hsa-miR-362-3p 
478634 hsa-miR-1205 478006 hsa-miR-302a-3p 478040 hsa-miR-339-5p 
477877 hsa-miR-1233-3p 478074 hsa-miR-375 478830 hsa-miR-330-5p 
478633 hsa-miR-1204 477853 hsa-miR-323a-3p 478986 hsa-miR-519d-3p 
477888 hsa-miR-126-5p 478105 hsa-miR-448 479228 hsa-miR-19a-3p 
477882 hsa-miR-1247-5p 478240 hsa-miR-376a-3p 478306 hsa-miR-193a-3p 
478669 hsa-miR-1263 478889 hsa-miR-431-5p 477956 hsa-miR-194-5p 
478654 hsa-miR-1249-3p 478369 hsa-miR-29b-3p 478970 hsa-miR-511-5p 
478635 hsa-miR-1206 478329 hsa-miR-454-3p 479249 hsa-miR-518a-5p 
478666 hsa-miR-125b-2-3p 478015 hsa-miR-31-5p 478616 hsa-miR-520d-5p 
478652 hsa-miR-1245a 478128 hsa-miR-486-5p 477927 hsa-miR-155-5p 
478186 hsa-miR-637 479483 hsa-miR-513a-5p 478999 hsa-miR-541-3p 
478651 hsa-miR-1244 478078 hsa-miR-382-5p 479003 hsa-miR-545-5p 
478047 hsa-miR-34a-3p 479528 hsa-miR-449b-5p 478994 hsa-miR-523-3p 
478668 hsa-miR-1262 478501 hsa-miR-141-3p 478152 hsa-miR-539-5p 
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Assay ID Target name Assay ID Target name Assay ID Target name 
479035 hsa-miR-551b-5p 478026 hsa-miR-32-5p 478336 hsa-miR-532-3p 
478649 hsa-miR-1238-3p 478430 hsa-miR-298 479495 hsa-miR-519c-3p 
479137 hsa-miR-656-3p 478422 hsa-miR-486-3p 479002 hsa-miR-545-3p 
479045 hsa-miR-559 479229 hsa-miR-29c-3p 479509 hsa-miR-520b 
478167 hsa-miR-584-5p 478581 hsa-miR-135a-5p 479534 hsa-miR-519a-3p 
478273 hsa-miR-30a-3p 478715 hsa-miR-146b-3p 478993 hsa-miR-522-3p 
478704 hsa-miR-1324 478717 hsa-miR-147b 479404 hsa-miR-520a-5p 
477843 hsa-let-7f-2-3p 477892 hsa-miR-128-3p 478149 hsa-miR-521 
477866 hsa-miR-106b-3p 477851 hsa-miR-130a-3p 478163 hsa-miR-574-3p 
477991 hsa-miR-23b-5p 478779 hsa-miR-222-5p 478151 hsa-miR-532-5p 
478778 hsa-miR-221-5p 477912 hsa-miR-143-3p 479503 hsa-miR-548h-5p 
478626 hsa-miR-1179 477910 hsa-miR-142-3p 479018 hsa-miR-548b-3p 
478619 hsa-miR-100-3p 477905 hsa-miR-138-5p 480872 hsa-miR-548am-5p 
479405 hsa-miR-181a-3p 478670 hsa-miR-1264 479041 hsa-miR-556-3p 
478628 hsa-miR-1182 478589 hsa-miR-548b-5p 478157 hsa-miR-548a-3p 
477861 hsa-let-7a-3p 478514 hsa-miR-147a 478107 hsa-miR-451a 
478742 hsa-miR-193b-5p 478582 hsa-miR-135b-5p 478214 hsa-miR-9-5p 
478622 hsa-miR-105-3p 477937 hsa-miR-183-5p 478175 hsa-miR-615-3p 
477996 hsa-miR-26b-3p 477942 hsa-miR-188-3p 477901 hsa-miR-134-5p 
478620 hsa-miR-101-5p 478511 hsa-miR-133a-3p 478752 hsa-miR-200a-5p 
477962 hsa-miR-19b-1-5p 477921 hsa-miR-152-3p 478753 hsa-miR-200b-5p 
477870 hsa-miR-1183 478159 hsa-miR-551b-3p 479032 hsa-miR-550a-3p 
479162 hsa-miR-708-3p 478721 hsa-miR-150-3p 478741 hsa-miR-192-3p 
479165 hsa-miR-744-3p 477939 hsa-miR-185-5p 478754 hsa-miR-200c-5p 
478187 hsa-miR-638 477952 hsa-miR-191-5p 478764 hsa-miR-20b-3p 
479144 hsa-miR-661 480871 hsa-miR-133b 478193 hsa-miR-664a-3p 
479129 hsa-miR-650 478358 hsa-miR-190a-5p 477902 hsa-miR-136-3p 
478199 hsa-miR-7-2-3p 478575 hsa-let-7a-5p 478712 hsa-miR-141-5p 
479126 hsa-miR-647 478507 hsa-miR-211-5p 478743 hsa-miR-194-3p 
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Assay ID Target name Assay ID Target name Assay ID Target name 
478033 hsa-miR-335-3p 479059 hsa-miR-579-3p 477968 hsa-miR-206 
479145 hsa-miR-662 479042 hsa-miR-556-5p 479036 hsa-miR-552-3p 
479141 hsa-miR-659-3p 478085 hsa-miR-410-3p 478041 hsa-miR-340-3p 
478196 hsa-miR-675-5p 477826 hsa-miR-487a-3p 478347 hsa-miR-33a-5p 
479209 hsa-miR-934 477999 hsa-miR-28-3p 477913 hsa-miR-144-3p 
478211 hsa-miR-9-3p 478079 hsa-miR-383-5p 478720 hsa-miR-149-3p 
479124 hsa-miR-644a 478254 hsa-miR-107 478693 hsa-miR-1294 
479203 hsa-miR-922 478080 hsa-miR-384 478718 hsa-miR-148a-5p 
479118 hsa-miR-639 478913 hsa-miR-450b-3p 478212 hsa-miR-942-5p 
478245 hsa-miR-939-5p 477995 hsa-miR-26a-5p 478697 hsa-miR-1302 
479030 hsa-miR-549a 478327 hsa-miR-423-3p 478690 hsa-miR-1291 
479207 hsa-miR-92b-5p 479241 hsa-miR-10a-5p 477931 hsa-miR-16-2-3p 
479044 hsa-miR-558 478130 hsa-miR-489-3p 479202 hsa-miR-921 
479061 hsa-miR-580-3p 477982 hsa-miR-222-3p 479208 hsa-miR-933 
478702 hsa-miR-130a-5p 477865 hsa-miR-105-5p 478686 hsa-miR-1284 
478224 hsa-miR-100-5p 477981 hsa-miR-221-3p 479526 hsa-miR-411-3p 
478439 hsa-let-7d-5p 477884 hsa-miR-125a-5p 479201 hsa-miR-920 
477970 hsa-miR-210-3p 478494 hsa-miR-10b-5p 479173 hsa-miR-765 
478773 hsa-miR-217 477815 hsa-miR-301a-3p 479211 hsa-miR-936 
477985 hsa-miR-22-3p 477934 hsa-miR-181c-5p 478946 hsa-miR-497-3p 
478253 hsa-miR-103a-3p 478942 hsa-miR-491-3p 479076 hsa-miR-593-3p 
478065 hsa-miR-365a-3p 477979 hsa-miR-219a-2-3p 478050 hsa-miR-34b-5p 
477971 hsa-miR-2110 478516 hsa-miR-215-5p 479088 hsa-miR-607 
477986 hsa-miR-224-5p 478270 hsa-miR-27b-3p 479087 hsa-miR-606 
478056 hsa-miR-361-5p 478368 hsa-miR-654-5p 479106 hsa-miR-622 
478318 hsa-miR-212-3p 478412 hsa-miR-106b-5p 478983 hsa-miR-518c-5p 
478262 hsa-miR-192-5p 477864 hsa-miR-103a-2-5p 478181 hsa-miR-628-3p 
478577 hsa-let-7c-5p 477885 hsa-miR-125b-5p 479070 hsa-miR-587 
478044 hsa-miR-342-5p 478192 hsa-miR-660-5p 479072 hsa-miR-589-3p 
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478046 hsa-miR-346 478038 hsa-miR-338-5p 479077 hsa-miR-593-5p 
478042 hsa-miR-340-5p 478197 hsa-miR-708-5p 479177 hsa-miR-769-3p 
478366 hsa-miR-345-5p 478194 hsa-miR-671-3p 477893 hsa-miR-1286 
478965 hsa-miR-509-5p 477922 hsa-miR-153-3p 478338 hsa-miR-596 
478749 hsa-miR-198 477975 hsa-miR-21-5p 479105 hsa-miR-621 
478316 hsa-miR-203a-3p 479135 hsa-miR-654-3p 478174 hsa-miR-605-5p 
477963 hsa-miR-200b-3p 478048 hsa-miR-34a-5p 479047 hsa-miR-562 
478417 hsa-miR-202-3p 479192 hsa-miR-888-5p 478158 hsa-miR-551a 
478576 hsa-let-7b-5p 478189 hsa-miR-652-3p 478162 hsa-miR-572 
478948 hsa-miR-499a-3p 477823 hsa-miR-92b-3p 479373 hsa-miR-566 
478135 hsa-miR-494-3p 479188 hsa-miR-885-3p 478216 hsa-miR-99b-3p 
478144 hsa-miR-504-5p 478204 hsa-miR-873-5p 477932 hsa-miR-17-3p 
478976 hsa-miR-515-3p 477855 hsa-miR-122-5p 478688 hsa-miR-1288-3p 
478203 hsa-miR-769-5p 479123 hsa-miR-643 478674 hsa-miR-1271-5p 
479487 hsa-miR-517c-3p 479187 hsa-miR-876-5p 479522 hsa-miR-1269a 
478129 hsa-miR-488-3p 478583 hsa-miR-181b-5p 480873 hsa-miR-129-1-3p 
478148 hsa-miR-518b 478208 hsa-miR-889-3p 477897 hsa-miR-1301-3p 
478143 hsa-miR-503-5p 477827 hsa-miR-92a-3p 478732 hsa-miR-185-3p 
477909 hsa-miR-140-5p 479166 hsa-miR-758-3p 478675 hsa-miR-1272 
478963 hsa-miR-509-3-5p 479194 hsa-miR-890 478714 hsa-miR-146a-3p 
478954 hsa-miR-502-5p 477967 hsa-miR-205-5p 478230 hsa-miR-196a-5p 
478978 hsa-miR-516a-5p 477941 hsa-miR-187-3p 478687 hsa-miR-1285-3p 
478961 hsa-miR-508-3p 479421 hsa-miR-374b-3p 478692 hsa-miR-1293 
478981 hsa-miR-518a-3p 478863 hsa-miR-377-5p 477928 hsa-miR-15a-3p 
478183 hsa-miR-629-5p 478917 hsa-miR-452-3p 478689 hsa-miR-1289 
478172 hsa-miR-598-3p 479049 hsa-miR-567 478659 hsa-miR-1253 
479219 hsa-miR-943 478798 hsa-miR-302a-5p 478698 hsa-miR-1303 
478339 hsa-miR-597-5p 478804 hsa-miR-30b-3p 478310 hsa-miR-1203 
478176 hsa-miR-615-5p 478093 hsa-miR-425-3p 478683 hsa-miR-1282 
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479108 hsa-miR-624-3p 479178 hsa-miR-770-5p 478664 hsa-miR-1257 
479112 hsa-miR-628-5p 478003 hsa-miR-29b-2-5p 479099 hsa-miR-616-5p 
478160 hsa-miR-561-3p 479412 hsa-miR-30c-1-3p 478178 hsa-miR-624-5p 
478023 hsa-miR-324-3p 478892 hsa-miR-432-3p 479074 hsa-miR-591 
478213 hsa-miR-95-3p 478827 hsa-miR-32-3p 478182 hsa-miR-629-3p 
478335 hsa-miR-496 478919 hsa-miR-454-5p 479081 hsa-miR-599 
478326 hsa-miR-370-3p 478606 hsa-miR-30d-5p 478179 hsa-miR-625-3p 
478028 hsa-miR-328-3p 478865 hsa-miR-380-5p 479499 hsa-miR-520h 
477959 hsa-miR-197-3p 478786 hsa-miR-25-5p 478138 hsa-miR-497-5p 
478037 hsa-miR-338-3p 478588 hsa-miR-320b 478155 hsa-miR-543 
478043 hsa-miR-342-3p 478623 hsa-miR-106a-3p 478957 hsa-miR-505-5p 
478314 hsa-miR-193b-3p 478794 hsa-miR-29b-1-5p 479022 hsa-miR-548j-5p 
478486 hsa-miR-199b-5p 478768 hsa-miR-214-5p 479023 hsa-miR-548m 
477804 hsa-miR-20b-5p 478629 hsa-miR-1184 479000 hsa-miR-541-5p 
478032 hsa-miR-331-5p 477801 hsa-let-7f-1-3p 479536 hsa-miR-520c-3p 
478479 hsa-miR-33b-5p 478122 hsa-miR-483-3p 478705 hsa-miR-132-5p 
478067 hsa-miR-369-3p 478734 hsa-miR-18b-3p 479333 hsa-miR-519b-3p 
478068 hsa-miR-369-5p 478665 hsa-miR-125b-1-3p 479374 hsa-miR-548k 
477819 hsa-miR-208a-3p 478653 hsa-miR-1248 479056 hsa-miR-575 
478337 hsa-miR-542-5p 477926 hsa-miR-155-3p 479222 hsa-miR-96-3p 
478962 hsa-miR-508-5p 479185 hsa-miR-875-5p 479224 hsa-miR-99a-3p 
478005 hsa-miR-29c-5p 
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Supplementary table S12. Genes with known roles in beta cell fate, 
function, markers of cell stress or other pancreatic endocrine cell type. 
 
Gene 
Symbol 
Assay ID Role in beta cells 
GUSB Hs00939627_m1 Housekeeper 
PPIA Hs04194521_s1 Housekeeper 
HPRT1 Hs02800695_m1 Housekeeper 
STK11 Hs00176092_m1 Beta cell function 
FOXO1 Hs01054576_m1 Beta cell differentiation and beta cell function 
PAX6 Hs00240871_m1 Beta cell differentiation and beta cell function 
GCK Hs01564555_m1 Beta cell function 
MAFA Hs01651425_s1 Beta cell function 
NKX6-1 Hs00232355_m1 Beta cell differentiation and beta cell function 
NEUROD1 Hs01922995_s1 Beta cell differentiation and beta cell function 
NKX2-2 Hs00159616_m1 Beta cell differentiation and beta cell function 
INS Hs00355773_m1 Beta cell function 
PDX1 Hs00236830_m1 Beta cell differentiation and beta cell function 
PTPN1 Hs00942477_m1 Beta cell function 
SLC16A1 Hs01560299_m1 Lactate/ pyruvate solute carrier – disallowed in beta cells 
SYP Hs00300531_m1 Beta cell function 
LDHA Hs01378790_g1 Lactate/ pyruvate solute carrier – disallowed in beta cells 
PAX4 Hs00173014_m1 Beta cell differentiation and beta cell function 
MAFB Hs00271378_s1 Beta cell function 
SLC2A2 Hs01096908_m1 Beta cell function 
ARX Hs00292465_m1 Alpha cell differentiation and function 
GCG Hs01031536_m1 Alpha cell function 
SST Hs00356144_m1 Delta cell function 
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Gene 
Symbol 
Assay ID Role in beta cells 
HHEX Hs00242160_m1 Delta cell marker 
SOX9 Hs01001343_g1 Beta cell progenitor marker 
NEUROG3 Hs01875204_s1 Beta cell progenitor marker 
HES1 Hs00172878_m1 Beta cell progenitor marker 
POU5F1 Hs04260367_gH Beta cell progenitor marker 
NANOG Hs04399610_g1 Beta cell progenitor marker 
HIF1A Hs00153153_m1 Hypoxia marker 
ARNT Hs01121918_m1 Cellular stress and hypoxia marker 
MYCL Hs00420495_m1 Cellular stress and proliferation marker 
DDIT3 Hs00358796_g1 Cellular stress and apoptosis marker 
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Supplementary table S13. Selected microRNA assay IDs 
 
Assay name Assay ID Assay name Assay ID 
hsa-miR-576-5p  478165_mir  hsa-miR-885-5p  478207_mir  
hsa-miR-376a-3p  478240_mir  hsa-miR-374b-3p  479421_mir  
hsa-miR-9-5p  478214_mir  hsa-miR-148b-5p  478719_mir  
hsa-miR-101-3p  477863_mir  hsa-miR-454-5p  478919_mir  
hsa-miR-365a-3p  478065_mir  hsa-miR-30c-2-3p  479401_mir  
hsa-miR-202-5p  478755_mir  hsa-miR-27b-3p  478270_mir  
hsa-miR-34a-5p  478048_mir  hsa-miR-186-3p  479544_mir  
hsa-miR-93-5p  478210_mir  hsa-miR-34a-5p  478048_mir  
hsa-miR-23a-3p  478532_mir  hsa-miR-195-3p  478744_mir  
hsa-miR-34b-3p  478049_mir  hsa-miR-593-5p  479077_mir  
hsa-miR-34c-5p  478052_mir  hsa-miR-106b-3p  477866_mir  
hsa-miR-30c-1-3p  479412_mir  hsa-miR-577  479057_mir  
hsa-miR-27a-3p  478384_mir  hsa-miR-299-5p  478793_mir  
hsa-miR-92b-5p  479207_mir  hsa-miR-199a-3p  477961_mir  
hsa-miR-30a-5p  479448_mir  hsa-miR-99a-3p  479224_mir  
hsa-miR-185-3p  478732_mir  hsa-miR-124-3p  477879_mir  
hsa-miR-152-3p 477921_mir  hsa-miR-29a-3p  478587_mir  
hsa-miR-21-3p  477973_mir  hsa-miR-136-5p  478307_mir  
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Supplementary table S14. Targets from DIANA pathways analysis 
 
 
GENE Pathway Pathway 
p-value 
MITG 
score(s) 
ASSAYS 
KMT2
C 
Lysine 
degradation 
3.00 x 10-3 0.97/0.9
2/0.80 
All assays 
BCL2L
11 
FOXO 0.02 0.99/ 
0.89 
Glycaemia and Palmitic acid 
DLG2 Hippo 5.84 x 10-5 0.92/0.8
1 
Glycaemia, Palmitic acid and pro-
inflammatory cytokines 
SP1 TGF and 
Estrogen 
0.02 0.99 Glycaemia and Hypoxia 
SOD FOXO 0.02 0.98 Glycaemia and Palmitic acid 
MAPK
1 
FOXO 0.02 0.9 Glycaemia and Palmitic acid 
TEAD
1 
Hippo 5.84 x 10-5 0.85 Glycaemia and Hypoxia 
SERPI
NE1 
Hippo 5.84 x 10-5 0.82 Glycaemia 
MOB1
A 
Hippo 5.84 x 10-5 0.82 Glycaemia 
PDK1 Central 
carbon 
cancer 
3.00 x 10-3 0.82 Glycaemia and Hypoxia 
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Supplementary table S15. Assay IDs for predicted mRNA targets. 
 
Gene Assay ID RefSeq 
PPIA Hs.PT.58v.38887593.g NM_021130 
HPRT1 Hs.PT.58.2145446 NM_000194 
IDH3B Hs.PT.19660618  NM_174855 
MOB1A Hs.PT.58.1530191 NM_018221 
PDK1 Hs.PT.58.19794808 NM_002610 
SOD1 Hs.PT.58.20593019 NM_000454 
SP1 Hs.PT.58.19745651 NM_138473 
KMT2C Hs.PT.19586130 NM_170606 
DLG2 Hs.PT.58.28262784 NM_001142702 
BCL2L1 Hs.PT.56a.39595693.g NM_138578 
MAPK1 Hs.PT.58.39782850 NM_138957 
SERPINE1 Hs.PT.58.3938488.g NM_000602 
TEAD1 Hs.PT.58.22785339 NM_021961 
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Supplementary table S16. miRNAs showing dysregulation following treatment with cellular stresses associated with T2D. 
 
Assay ID miRNA Assay ID miRNA Assay ID miRNA 
478591 hsa-miR-302b-3p 478163 hsa-miR-574-3p 478183 hsa-miR-629-5p 
478719 hsa-miR-148b-5p 478270 hsa-miR-27b-3p 479177 hsa-miR-769-3p 
477962 hsa-miR-19b-1-5p 478131 hsa-miR-490-3p 478826 hsa-miR-323b-5p 
479224 hsa-miR-99a-3p 478193 hsa-miR-664a-3p 478785 hsa-miR-24-2-5p 
479064 hsa-miR-582-3p 477952 hsa-miR-191-5p 477833 hsa-miR-548d-3p 
478732 hsa-miR-185-3p 478439 hsa-let-7d-5p 478318 hsa-miR-212-3p 
477913 hsa-miR-144-3p 478831 hsa-miR-33a-3p 478065 hsa-miR-365a-3p 
478687 hsa-miR-1285-3p 478165 hsa-miR-576-5p 478629 hsa-miR-1184 
478914 hsa-miR-450b-5p 479217 hsa-miR-941 478273 hsa-miR-30a-3p 
479003 hsa-miR-545-5p 478329 hsa-miR-454-3p 478411 ath-miR159a 
478168 hsa-miR-590-3p 478660 hsa-miR-1254 477936 hsa-miR-183-3p 
478175 hsa-miR-615-3p 477934 hsa-miR-181c-5p 477895 hsa-miR-1290 
478177 hsa-miR-616-3p 479067 hsa-miR-585-3p 479087 hsa-miR-606 
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Assay ID miRNA Assay ID miRNA Assay ID miRNA 
478786 hsa-miR-25-5p 478913 hsa-miR-450b-3p 478514 hsa-miR-147a 
478917 hsa-miR-452-3p 478293 cel-miR-39-3p 478238 hsa-miR-374a-5p 
478979 hsa-miR-516b-5p 477863 hsa-miR-101-3p 478048 hsa-miR-34a-5p 
478307 hsa-miR-136-5p 478179 hsa-miR-625-3p 477933 hsa-miR-181c-3p 
478827 hsa-miR-32-3p 477963 hsa-miR-200b-3p 478532 hsa-miR-23a-3p 
478012 hsa-miR-31-3p 478620 hsa-miR-101-5p 478513 hsa-miR-146b-5p 
477921 hsa-miR-152-3p 478432 hsa-miR-483-5p 479530 hsa-miR-518d-5p 
478491 hsa-miR-204-5p 478793 hsa-miR-299-5p 478623 hsa-miR-106a-3p 
478742 hsa-miR-193b-5p 478384 hsa-miR-27a-3p 477896 hsa-miR-129-5p 
479059 hsa-miR-579-3p 478691 hsa-miR-1292-5p 477912 hsa-miR-143-3p 
479041 hsa-miR-556-3p 478753 hsa-miR-200b-5p 477942 hsa-miR-188-3p 
477991 hsa-miR-23b-5p 477998 hsa-miR-27a-5p 477961 hsa-miR-199a-3p 
478003 hsa-miR-29b-2-5p 478755 hsa-miR-202-5p 478589 hsa-miR-548b-5p 
478032 hsa-miR-331-5p 478790 hsa-miR-296-3p 478622 hsa-miR-105-3p 
478044 hsa-miR-342-5p 479024 hsa-miR-548n 478655 hsa-miR-1250-5p 
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Assay ID miRNA Assay ID miRNA Assay ID miRNA 
478105 hsa-miR-448 479178 hsa-miR-770-5p 478662 hsa-miR-1255b-5p 
478130 hsa-miR-489-3p 479374 hsa-miR-548k 478717 hsa-miR-147b 
478157 hsa-miR-548a-3p 479391 hsa-miR-548l 478919 hsa-mir-454-5p 
478174 hsa-miR-605-5p 479412 hsa-miR-30c-1-3p 479401 hsa-mir-30c-2-3p 
478182 hsa-miR-629-3p 480870 hsa-miR-548d-5p 479544 hsa-mir-186-3p 
478185 hsa-miR-636 478240 hsa-miR-376a-3p 478744 hsa-mir-195-3p 
478207 hsa-miR-885-5p 478210 hsa-miR-93-5p 478754 hsa-miR-200c-5p 
478214 hsa-miR-9-5p 478049 hsa-mir-34b-3p 478399 hsa-miR-146a-5p 
478337 hsa-miR-542-5p 478052 hsa-mir-34c-5p 478561 hsa-miR-449a 
478342 hsa-miR-766-3p 479207 hsa-mir-92b-5p 479448 hsa-mir-30a-5p 
479421 hsa-mir-374b-3p     
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Supplementary table S17 Targeted expression of most altered microRNAs high throughput global microRNA screen. 
The p values for statistical significance as determined by independent t-test, Mean difference, Standard errors of measurement (SED) and the 95% 
confidence intervals are given below. Bold italic p<0.016 Bonferroni correction for 3 tests: 1st, 2nd and 3rd time-points. Gene list is á priori  so no further 
corrections. Italic underlined p<0.050. No correction for multiple testing. 
 
25 mM glucose Independent Samples Test- t- test p = 0.016 
24 hrs 36 hrs 48 hrs 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-185-3p 0.297 -0.743 0.675 -2.247 0.762 miR-185-3p 0.024 -2.221 0.820 -4.076 -0.366 miR-185-3p 0.035 -1.629 0.667 -3.116 -0.142 
miR-885-5p 0.646 0.226 0.470 -0.886 1.338 miR-885-5p 0.98 0.007 0.272 -0.609 0.624 miR-885-5p 0.575 0.226 0.387 -0.665 1.118 
miR-27b-3p 0.999 0.000 0.184 -0.411 0.411 miR-27b-3p 0.113 0.312 0.179 -0.088 0.711 miR-27b-3p 0.116 0.312 0.181 -0.091 0.715 
miR-124-3p 0.206 0.296 0.219 -0.192 0.783 miR-124-3p 0.819 0.053 0.226 -0.450 0.556 miR-124-3p 0.592 -0.120 0.216 -0.601 0.362 
miR-136-5p 0.252 0.318 0.262 -0.266 0.902 miR-136-5p 0.008 0.782 0.236 0.257 1.306 miR-136-5p 0.571 0.143 0.244 -0.400 0.685 
miR-152-3p 0.448 -0.141 0.179 -0.539 0.257 miR-152-3p 0.005 0.536 0.148 0.206 0.866 miR-152-3p 0.111 0.288 0.165 -0.079 0.655 
miR-299-5p 0.002 -0.619 0.139 -0.933 -0.304 miR-299-5p 0.035 -0.255 0.103 -0.487 -0.023 miR-299-5p 0.155 0.164 0.106 -0.075 0.404 
miR-576-5p 0.514 -0.322 0.464 -1.456 0.813 miR-576-5p 0.101 -0.514 0.266 -1.164 0.136 miR-576-5p 0.032 -0.683 0.224 -1.275 -0.091 
miR-93-5p 0.232 0.263 0.207 -0.197 0.724 miR-93-5p 0.097 0.395 0.216 -0.086 0.876 miR-93-5p 0.073 0.446 0.223 -0.050 0.942 
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2.5 mM glucose Independent Samples Test- t- test p = 0.016 
24 hrs 36 hrs 48 hrs 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
miR-185-3p 0.188 -1.019 0.721 -2.626 0.587 miR-185-3p 0.146 -3.828 1.737 -10.675 3.019 miR-185-3p 0.108 -5.380 2.020 -13.523 2.763 
miR-885-5p 0.188 -2.368 1.677 -6.105 1.368 miR-885-5p 0.325 0.905 0.862 -1.082 2.892 miR-885-5p 0.924 -0.184 1.876 -4.365 3.997 
miR-454-5p 0.62 0.781 1.529 -2.625 4.187 miR-454-5p 0.033 3.320 1.346 0.321 6.318 miR-454-5p 0.012 4.145 1.350 1.138 7.153 
miR-27b-3p 0.188 0.311 0.220 -0.179 0.801 miR-27b-3p 0.922 0.024 0.239 -0.508 0.556 miR-27b-3p 0.349 0.211 0.215 -0.267 0.690 
miR-124-3p 0.689 -0.122 0.296 -0.782 0.538 miR-124-3p 0.056 -0.614 0.284 -1.247 0.020 miR-124-3p 0.521 -0.203 0.305 -0.882 0.476 
miR-136-5p 0.075 0.518 0.260 -0.062 1.097 miR-136-5p 0.84 -0.056 0.269 -0.656 0.544 miR-136-5p 0.69 0.124 0.301 -0.548 0.795 
miR-152-3p 0.637 -0.125 0.257 -0.697 0.447 miR-152-3p 0.299 -0.251 0.229 -0.762 0.260 miR-152-3p 0.239 0.288 0.230 -0.225 0.800 
miR-299-5p 0.49 0.831 1.159 -1.752 3.414 miR-299-5p 0.457 0.897 1.160 -1.687 3.482 miR-299-5p 0.539 0.739 1.161 -1.848 3.326 
miR-576-5p 0.352 1.439 1.475 -1.846 4.725 miR-576-5p 0.237 1.044 0.818 -0.839 2.928 miR-576-5p 0.946 -0.117 1.676 -3.852 3.618 
miR-93-5p 0.332 0.244 0.239 -0.289 0.778 miR-93-5p 0.873 -0.042 0.257 -0.614 0.530 miR-93-5p 0.551 0.145 0.235 -0.378 0.668 
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<3% O2 Independent Samples Test- t- test p = 0.016 
4 hrs 12 hrs 24 hrs 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-27b-3p 0.14 -0.411 0.262 -0.977 0.155 miR-27b-3p 0.387 -0.229 0.256 -0.781 0.323 miR-27b-3p 0.18 -0.353 0.249 -0.891 0.185 
miR-124-3p 0.065 1.816 0.852 -0.139 3.770 miR-124-3p 0.168 1.301 0.866 -0.665 3.268 miR-124-3p 0.389 1.083 1.215 -1.542 3.708 
miR-136-5p 0.52 0.441 0.668 -1.001 1.884 miR-136-5p 0.468 0.502 0.672 -0.949 1.953 miR-136-5p 0.486 0.493 0.686 -0.990 1.975 
miR-152-3p 0.142 -0.336 0.209 -0.807 0.135 miR-152-3p 0.511 -0.141 0.205 -0.607 0.326 miR-152-3p 0.11 -0.472 0.276 -1.068 0.123 
miR-299-5p 0.01 -0.685 0.220 -1.171 -0.200 miR-299-5p 0.035 -0.532 0.221 -1.020 -0.045 miR-299-5p 0.182 -0.373 0.265 -0.945 0.199 
miR-93-5p 0.102 -0.396 0.217 -0.889 0.097 miR-93-5p 0.229 -0.282 0.218 -0.777 0.213 miR-93-5p 0.097 -0.483 0.270 -1.067 0.101 
miR-21-3p 0.238 0.826 0.650 -0.660 2.311 miR-21-3p 0.171 0.976 0.652 -0.512 2.464 miR-21-3p 0.265 0.771 0.645 -0.710 2.253 
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0.5 mM Palmitic acid Independent Samples Test- t- test p = 0.016 
12 hrs 24 hrs 48 hrs 
  p value Mean diff. SED 95% CI     p value Mean diff. SED 95% CI     p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-185-3p 0.147 2.754 1.749 -1.144 6.651 miR-185-3p 0.992 -0.017 1.772 -3.966 3.931 miR-185-3p 0.368 1.731 1.835 -2.357 5.820 
miR-885-5p 0.819 0.062 0.266 -0.531 0.656 miR-885-5p 0.634 -0.146 0.297 -0.809 0.516 miR-885-5p 0.046 -0.522 0.230 -1.034 -0.010 
miR-27b-3p 0.682 -0.184 0.435 -1.152 0.785 miR-27b-3p 0.693 0.194 0.478 -0.872 1.260 miR-27b-3p 0.454 0.341 0.438 -0.635 1.318 
miR-124-3p 0.814 -0.053 0.218 -0.540 0.434 miR-124-3p 0.651 -0.103 0.220 -0.594 0.388 miR-124-3p 0.226 0.228 0.169 -0.186 0.641 
miR-136-5p 0.803 -0.060 0.235 -0.583 0.463 miR-136-5p 0.79 0.110 0.401 -0.783 1.002 miR-136-5p 0.002 1.047 0.259 0.469 1.624 
miR-152-3p 0.357 -0.213 0.221 -0.705 0.279 miR-152-3p 0.563 0.160 0.268 -0.437 0.757 miR-152-3p 0.17 0.450 0.305 -0.229 1.129 
miR-299-5p 0.076 -0.242 0.122 -0.515 0.030 miR-299-5p 0.86 -0.055 0.305 -0.736 0.625 miR-299-5p 0.415 0.178 0.209 -0.287 0.642 
miR-576-5p 0.508 -0.192 0.280 -0.816 0.432 miR-576-5p 0.368 1.650 1.440 -4.412 7.712 miR-576-5p 0.129 -0.408 0.230 -0.978 0.163 
miR-93-5p 0.794 -0.112 0.417 -1.042 0.818 miR-93-5p 0.683 0.201 0.479 -0.867 1.269 miR-93-5p 0.371 0.416 0.444 -0.574 1.406 
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proinflammatory cytokines Independent Samples Test- t- test p = 0.016 
12 hrs 24 hrs 36 hrs 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-885-5p 0.993 0.004 0.380 -0.857 0.864 miR-885-5p 0.773 -0.130 0.436 -1.116 0.856 miR-885-5p 0.121 0.667 0.389 -0.214 1.547 
miR-454-5p 0.583 0.198 0.342 -0.638 1.034 miR-454-5p 0.702 -0.107 0.265 -0.755 0.542 miR-454-5p 0.57 -0.166 0.278 -0.823 0.492 
miR-27b-3p 0.477 0.294 0.398 -0.593 1.180 miR-27b-3p 0.706 0.155 0.400 -0.737 1.048 miR-27b-3p 0.481 0.291 0.398 -0.595 1.178 
miR-124-3p 0.146 0.411 0.261 -0.170 0.992 miR-124-3p 0.336 0.254 0.251 -0.305 0.813 miR-124-3p 0.55 0.148 0.240 -0.385 0.682 
miR-136-5p 0.002 -0.634 0.156 -0.982 -0.286 miR-136-5p 0.562 0.190 0.282 -0.890 1.269 miR-136-5p 0.266 -0.547 0.368 -2.020 0.926 
miR-152-3p 0.674 -0.069 0.158 -0.422 0.284 miR-152-3p 0.756 -0.060 0.188 -0.480 0.360 miR-152-3p 0.544 -0.251 0.353 -1.633 1.131 
miR-299-5p 0.822 0.036 0.154 -0.308 0.379 miR-299-5p 0.152 -0.302 0.194 -0.735 0.132 miR-299-5p 0.371 0.128 0.137 -0.177 0.433 
miR-576-5p 0.798 0.040 0.154 -0.302 0.383 miR-576-5p 0.194 0.276 0.198 -0.165 0.717 miR-576-5p 0.157 0.269 0.176 -0.123 0.660 
miR-93-5p 0.257 -0.098 0.082 -0.281 0.084 miR-93-5p 0.533 -0.243 0.328 -1.605 1.118 miR-93-5p 0.156 -0.199 0.130 -0.489 0.090 
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Supplementary table S18 Validated of gene targets identified from DIANA 
pathways analysis. 
 
The p values for statistical significance as determined by independent t-test, Mean 
difference, Standard errors of measurement (SED) and the 95% confidence intervals are 
given below. Bold italic p<0.050 Gene list is á priori  and single test applied so no 
correction for multiple testing. 
 
25 mM high glucose Independent Samples Test p = 0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
BCL211 0.392 0.060 0.066 -0.096 0.217 
DLG2 0.215 0.184 0.135 -0.135 0.504 
KMT2C 0.451 -0.069 0.087 -0.275 0.136 
MAPK1 0.099 -0.048 0.025 -0.107 0.012 
MOB1A 0.263 -0.075 0.061 -0.219 0.070 
PDK1 0.373 0.094 0.099 -0.140 0.328 
SERPINE1 0.11 0.085 0.046 -0.025 0.194 
SOD1-1 0.024 -0.085 0.030 -0.155 -0.015 
SP1 0.367 -0.064 0.067 -0.222 0.093 
TEAD1 0.682 -0.033 0.077 -0.216 0.150 
 
 
 
2.5 mM low glucose Independent Samples Test p = 0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
BCL211 0.206 0.083 0.060 -0.058 0.225 
DLG2 0.122 0.234 0.133 -0.080 0.549 
KMT2C 0.259 -0.054 0.044 -0.158 0.050 
MAPK1 0.039 -0.117 0.046 -0.226 -0.007 
MOB1A 0.117 -0.103 0.057 -0.238 0.033 
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2.5 mM low glucose Independent Samples Test p = 0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
PDK1 0.179 0.151 0.101 -0.088 0.391 
SERPINE1 0.448 0.037 0.046 -0.071 0.145 
SOD1-1 0.957 -0.002 0.037 -0.090 0.086 
SP1 0.475 -0.052 0.069 -0.216 0.111 
TEAD1 0.931 -0.007 0.077 -0.190 0.176 
 
 
 
Hypoxia Independent Samples Test p=0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
BCL211 0.266 -0.088 0.072 -0.264 0.088 
DLG2 0.004 -0.457 0.091 -0.689 -0.225 
KMT2C 0.934 0.005 0.057 -0.135 0.145 
MAPK1 0.153 0.054 0.033 -0.027 0.134 
MOB1A 0.449 -0.058 0.072 -0.233 0.117 
PDK1 0.0003 0.873 0.121 0.577 1.170 
SERPINE1 0.285 -0.082 0.070 -0.254 0.089 
SOD1-1 0.025 -0.077 0.025 -0.140 -0.013 
SP1 0.95 0.005 0.083 -0.197 0.208 
TEAD1 0.525 0.071 0.105 -0.186 0.328 
 
  
 
 
 
232 
 
0.5 mM Palmitic Acid Independent Samples Test p=0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
BCL211 0.692 0.023 0.057 -0.110 0.157 
DLG2 0.598 0.073 0.133 -0.240 0.387 
KMT2C 0.06 -0.138 0.061 -0.283 0.007 
MAPK1 0.252 -0.031 0.025 -0.090 0.028 
MOB1A 0.13 -0.099 0.057 -0.234 0.037 
PDK1 0.023 0.281 0.097 0.053 0.510 
SERPINE1 0.423 0.043 0.050 -0.076 0.161 
SOD1-1 0.905 0.005 0.040 -0.090 0.099 
SP1 0.882 -0.010 0.068 -0.171 0.150 
TEAD1 0.51 0.054 0.078 -0.130 0.237 
 
 
 
Pro-inflammatory cytokines Independent Samples Test p=0.050 
Gene 
  
p value 
  
Mean Diff. 
  
SED 
  
95% CI 
Lower Upper 
BCL211 0.766 0.015 0.049 -0.101 0.132 
DLG2 0.032 0.267 0.095 0.032 0.502 
KMT2C 0.861 -0.014 0.076 -0.193 0.165 
MAPK1 0.729 -0.012 0.034 -0.094 0.069 
MOB1A 0.104 -0.104 0.056 -0.236 0.028 
PDK1 0.407 0.086 0.097 -0.144 0.315 
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Pro-inflammatory cytokines Independent Samples Test p=0.050 
SERPINE1 0.746 -0.017 0.051 -0.138 0.104 
SOD1-1 0.741 -0.014 0.040 -0.110 0.082 
SP1 0.273 -0.102 0.085 -0.304 0.100 
TEAD1 0.615 0.045 0.085 -0.156 0.246 
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Supplementary table S19 Targeted expression of microRNAs strongly validated to target panel of genes with known roles in 
beta cells 
 
The p values for statistical significance as determined by independent t-test, Mean difference, Standard errors of measurement (SED) and the 95% 
confidence intervals are given below. Bold italic p<0.016 Bonferroni correction for 3 tests: 1st, 2nd and 3rd time-points. Gene list is á priori  so no further 
corrections.Italic underlined p<0.050. No correction for multiple testing 
 
 
25 mM High glucose Independent Samples Test p=0.016 
  MiRNA p value 
 
Mean diff. 
 
SED 
 
95% CI 
  miRNA p value 
 
Mean diff. 
 
SED 
 
95% CI 
 miRNA  
p value 
  
Mean diff. 
  
SED 
  
95% CI 
Lower Upper Lower Upper Lower Upper 
miR-101-3p 0.099 -0.435 0.239 -0.968 0.098 miR-101-3p 0.773 0.093 0.315 -0.609 0.796 miR-101-3p 0.187 -0.312 0.221 -0.804 0.179 
miR-199a-3p 0.001 4.438 0.917 2.395 6.482 miR-199a-3p 0.11 2.021 1.151 -0.544 4.587 miR-199a-3p 0.005 3.436 0.944 1.332 5.539 
miR-21-3p 0.755 0.080 0.251 -0.478 0.639 miR-21-3p 0.952 0.019 0.301 -0.652 0.689 miR-21-3p 0.049 -0.532 0.238 -1.063 -0.002 
miR-29a-3p 0.267 -2.144 1.432 -8.023 3.734 miR-29a-3p 0.861 -0.077 0.428 -1.030 0.876 miR-29a-3p 0.555 -0.249 0.407 -1.157 0.659 
miR-376a-3p 0.013 -1.208 0.399 -2.099 -0.317 miR-376a-3p 0.769 -0.225 0.744 -1.882 1.433 miR-376a-3p 0.009 -1.252 0.374 -2.108 -0.397 
miR-92b-5p 0.504 0.911 1.315 -2.019 3.841 miR-92b-5p 0.51 -1.046 1.529 -4.453 2.361 miR-92b-5p 0.651 0.607 1.304 -2.299 3.514 
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2.5 mM Low glucose Independent Samples Test p=0.016 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-101-3p 0.361 0.226 0.235 -0.305 0.757 miR-101-3p 0.209 0.322 0.238 -0.217 0.860 miR-101-3p 0.157 0.361 0.234 -0.168 0.891 
miR-21-3p 0.333 0.197 0.194 -0.235 0.628 miR-21-3p 0.134 0.309 0.189 -0.113 0.731 miR-21-3p 0.546 0.122 0.195 -0.313 0.557 
miR-29a-3p 0.746 0.116 0.347 -0.658 0.890 miR-29a-3p 0.507 -0.257 0.374 -1.089 0.575 miR-29a-3p 0.124 0.579 0.344 -0.188 1.345 
miR-376a-3p 0.423 -0.477 0.571 -1.751 0.796 miR-376a-3p 0.545 -0.353 0.564 -1.609 0.903 miR-376a-3p 0.039 -1.345 0.565 -2.603 -0.087 
miR-92b-5p 0.907 0.031 0.261 -0.560 0.622 miR-92b-5p 0.551 0.13321 0.215 -0.3532 0.619 miR-92b-5p 0.118 0.454 0.259 -0.144 1.052 
 
<3% O2 Hypoxia Independent Samples Test p=0.016 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-101-3p 0.495 0.097 0.138 -0.202 0.396 miR-101-3p 0.263 0.178 0.152 -0.151 0.507 miR-101-3p 0.78 0.061 0.213 -0.403 0.524 
miR-21-3p 0.782 0.038 0.133 -0.256 0.331 miR-21-3p 0.391 -0.159 0.177 -0.549 0.232 miR-21-3p 0.226 -0.172 0.134 -0.470 0.125 
miR-29a-3p 0.466 0.227 0.303 -0.427 0.881 miR-29a-3p 0.879 -0.053 0.343 -0.795 0.688 miR-29a-3p 0.393 0.329 0.371 -0.480 1.138 
miR-376a-3p 0.74 -0.146 0.430 -1.076 0.784 miR-376a-3p 0.576 0.217 0.378 -0.600 1.034 miR-376a-3p 0.355 0.464 0.483 -0.588 1.516 
miR-92b-5p 0.852 0.058 0.302 -0.600 0.715 miR-92b-5p 0.858 0.06112 0.333 -0.6814 0.803 miR-92b-5p 0.418 -0.342 0.405 -1.244 0.560 
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 0.5 mM Palmitic Acid Independent Samples Test p=0.016 
  p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI   p value Mean diff. SED 95% CI 
        Lower Upper         Lower Upper         Lower Upper 
miR-101-3p 0.625 0.064 0.127 -0.219 0.346 miR-101-3p 0.692 -0.066 0.162 -0.428 0.295 miR-101-3p 0.338 -0.190 0.188 -0.616 0.235 
miR-21-3p 0.193 -0.316 0.227 -0.821 0.189 miR-21-3p 0.697 -0.091 0.227 -0.597 0.415 miR-21-3p 0.321 -0.276 0.265 -0.866 0.314 
miR-29a-3p 0.34 0.144 0.144 -0.177 0.465 miR-29a-3p 0.114 0.260 0.150 -0.074 0.594 miR-29a-3p 0.587 0.109 0.194 -0.323 0.541 
miR-376a-3p 0.157 0.275 0.180 -0.126 0.676 miR-376a-3p 0.847 0.040 0.204 -0.415 0.496 miR-376a-3p 0.705 -0.221 0.569 -1.488 1.045 
miR-92b-5p 0.732 0.106 0.296 -0.594 0.805 miR-92b-5p 0.601 0.15959 0.291 -0.5292 0.848 miR-92b-5p 0.122 0.705 0.401 -0.244 1.653 
 
Pro-inflammatory cytokines Independent Samples Test p=0.016 
  p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI   p 
value 
Mean 
diff. 
SED 95% CI 
        Lower Upper         Lower Upper         Lower Uppe
r 
miR-101-3p 0.776 -0.151 0.516 -1.319 1.017 miR-101-3p 0.724 0.184 0.50
6 
-
0.961 
1.330 miR-101-3p 0.862 0.091 0.50
8 
-
1.058 
1.240 
miR-199a-
3p 
0.585 0.192 0.336 -0.603 0.987 miR-199a-
3p 
0.039 0.576 0.21
9 
0.040 1.112 miR-199a-
3p 
0.966 -0.021 0.46
9 
-
1.131 
1.089 
miR-202-5p 0.749 -0.493 1.502 -3.840 2.853 miR-202-5p 0.001 -3.623 0.75
8 
-
5.355 
-
1.890 
miR-202-5p 0.208 -2.071 1.53
8 
-
5.498 
1.356 
miR-21-3p 0.115 0.404 0.234 -0.117 0.925 miR-21-3p 0.016 -0.663 0.22
9 
0.152 1.174 miR-21-3p 0.091 0.448 0.23
9 
-
0.085 
0.982 
miR-29a-3p 0.094 0.824 0.434 -0.177 1.825 miR-29a-3p 0.001 1.477 0.26
3 
0.857 2.097 miR-29a-3p 0.011 0.930 0.28
1 
0.281 1.580 
miR-374b3p 0.471 -0.343 0.439 -1.473 0.787 miR-374b3p 0.279 0.372 0.31
7 
-
0.378 
1.123 miR-374b3p 0.059 0.618 0.27
4 
-
0.030 
1.266 
miR-376a-
3p 
0.829 0.116 0.522 -1.047 1.278 miR-376a-
3p 
0.982 0.012 0.52
5 
-
1.158 
1.182 miR-376a-
3p 
0.623 -0.301 0.59
3 
-
1.622 
1.020 
miR-9-5p 0.195 -0.541 0.371 -1.448 0.366 miR-9-5p 0.35 -0.292 0.28
8 
-
0.998 
0.414 miR-9-5p 0.683 0.140 0.32
7 
-
0.660 
0.940 
miR-92b-5p 0.624 -0.2902 0.5722
5 
-
1.5847 
1.0043
6 
miR-92b-5p 0.98 -0.012 0.43
9 
-
0.990 
0.967 miR-92b-5p 0.817 0.112 0.47
0 
-
0.935 
1.159 
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Supplementary table S20: Effects of cell insult treatments on total gene 
expression of significant miRNA target genes from beta cell specific target 
panel. 
 
The p values for statistical significance as determined by independent t-test, Mean 
difference, Standard errors of measurement (SED) and the 95% confidence intervals are 
given below. Bold italic p<0.016 Bonferroni correction for 3 tests: 1st, 2nd and 3rd time-
points. Gene list is á priori  so no further corrections. 
 
 
Gene Associated miRNA p value 
 
Mean 
diff. 
SED 95% C I 
Lower Upper 
STK11  miR-199a 0.002 -0.107 0.04 0.2 0.02 
SOX9 miR-21 0.005 0.421 0.12 0.16 0.68 
FOXO1 miR-29a 0.000 -0.258 0.050 -0.369 -0.146 
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Chapter 6: 
Discussion 
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Summary of thesis 
 
Type 2 Diabetes (T2D) is characterised by cell stressors associated with the 
diabetic physiology including: poor glucose homeostasis, dyslipidaemia, hypoxia 
and pro-inflammatory cytokines. Studies in rodent models have shown that 
exposure to these cellular stresses elicits a change in beta cell differentiation 
status, which contributes to the beta cell mass loss that is seen in the disease.  I 
have investigated this phenomenon using the EndoC-H1 human beta cell line, 
along with human islets from cases with Type 2 Diabetes and long duration Type 
1 Diabetes.  To characterise the importance of the cellular microenvironment on 
the EndoC H1 cell modeI, I investigated the importance of the species origin on 
markers of beta cell fate and function, which allowed optimisation of an entirely 
human culture protocol. I found that using human culture reagents improved 
glucose sensitive insulin secretion and improved the physiological relevance of 
the model for assessing cellular stress response.  Having optimised the cell 
model, I assessed changes in response to diabetes related cell stresses to the 
targeted transcriptomic profile, splicing changes, altered microRNA expression 
and changes in protein expression, in both cells and islets from cases with either 
T2D or T1D. I found that changes to beta cell differentiation status occur in 
response to these cellular stressors via altered expression of genes known to 
influence beta cell fate and altered splicing factor expression, leading to changes 
in the patterns of alternative splicing and altered microRNA expression.  This 
altered transcriptomic profile causes a beta to delta phenotypic shift in a 
proportion of cells and this is also seen in the islets of patients with T2D and long 
duration type 1 Diabetes.   
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Summary of data chapters 
 
Chapter 3. The species origin of the cellular microenvironment influences 
markers of beta cell fate and function in EndoC-βH1 cells 
 
Summary 
 
In chapter 3, I investigated the effects of species origin on the cellular 
microenvironment on markers of beta cell fate and function in EndoC-H1 cells. 
I compared the responses of the cells to non-human and human derived culture 
reagents and assessed these in relation to growth, morphology, gene expression 
and glucose simulated insulin secretion (GSIS). I found that EndoC-H1 cells 
cultured in entirely human derived culture reagents demonstrated a greater 
tendency to form cell clusters and exhibited reduced alpha cell markers at the 
mRNA level, for ARX and GCG genes respectively. No differences were noted in 
the protein expression of mature beta cell markers, such as PDX1 and 
NEUROD1, in EndoC-βH1 cells cultured in a human microenvironment but the 
cells were more sensitive to glucose, showing a 4.3-fold increase in insulin 
secretion following glucose challenge compared with a 1.9-fold increase in cells 
grown in a non-human microenvironment.  
 
Importance of findings 
 
Our data suggest that the tissue origin of the cellular microenvironment has 
effects on the function of EndoC-βH1 cells in vitro, and the use of a more human-
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like culture microenvironment may bring benefits in terms of increased 
physiological relevance. 
 
Future work 
 
It would be beneficial for understanding the importance of reagent species origin 
in tissue culture for these findings to be replicated in other human cell lines, to 
evaluate if this should be considered when assessing the effect of 
microenvironment on gene expression. It would also be of interest to investigate 
genome wide effects. Creating a 3D culture microenvironment to investigate 
whether formation of beta-cell only pseudo islets affect responses to cellular 
stresses may provide greater insights into how beta cells interact with their 
immediate microenvironment as well as their proliferation. This has been shown 
to improve beta cell survival and insulin secretion in rodent cell lines and so it 
would be important for these results to be validated in human models(319). 
However, these considerations have not been investigated further here, as they 
lay outside the remit of this project. 
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Chapter 4. Cellular stressors may influence transdifferentiation in human beta 
cells by moderation of alternative splicing patterns. 
 
Summary 
 
In Chapter 4, I investigated changes in beta cell differentiation status via 
assessing total gene expression for a target gene panel, alternative splicing 
patterns, splicing factor expression, protein expression in both EndoC-H1 cells 
and pancreatic sections from cases with either T2D or T1D (compared to 
individuals without diabetes) and the effects of small molecule inhibition of the 
AKT pathway. The in vitro work involved exposing the EndoC-H1 human beta 
cell line to relevant cellular stresses associated with a T2D physiology in order to 
assess their effects. Assessment of total gene expression was carried out by 
analysis of a target panel of 35 genes, chosen for their roles in either beta cell 
fate and function, or as markers of plasticity, cellular stress or other pancreatic 
islet cell type. Data from each of the cell treatment assays showed dysregulation 
of the majority of these genes, including a network known to be important to the 
maintenance of beta cell fate. Altered splicing patterns were assessed by 
analysing ratio changes in genes within the target panel, with functionally relevant 
isoform changes, and where it was possible to design probes to distinguish 
between the isoforms. These data showed significant dysregulation at the level 
of splicing. Splicing factor expression was also investigated and again showed 
widespread dysregulation in expression levels, indicating the importance of 
altered splicing in changes to beta cell differentiation status.  
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Immunofluorescence was used to investigate changes to hormone expression in 
both treated EndoC-H1cells, as well as pancreatic sections islets from cases 
with either T2D or long duration (>5 y) T1D. The in vitro data showed a statistically 
significant shift from a beta to delta cell phenotype in a proportion of treated cells, 
with loss of insulin and gain of somatostatin expression in these altered cells. 
Immunofluorescent staining of pancreatic sections from cases with either T2D or 
T1D also showed statistically significant increases in the number of delta cells 
within diabetic islets.  
  
Our group had previously identified FOXO1 as a regulator of splicing factor 
expression via the AKT pathway and, given the altered splicing patterns and 
splicing factor expression seen in response to cellular stresses, I used small 
molecule inhibition of the AKT pathway to determine effects on splicing and 
protein expression. I found that inhibition of the AKT pathway, via the small 
molecule SH6, prevented the beta to delta phenotypic shifts following exposure 
to 25 mM high glucose. 
 
Importance of findings 
 
This is, to my knowledge, the first demonstration using human models that 
changes in beta cell differentiation status, following exposure to cellular stresses 
relevant to T2D physiology, occur due to altered splicing as a result of 
dysregulated splicing factor expression via dysregulation of FOXO1. These data 
offer the possibility of targeting splicing patterns for therapeutic benefit in the 
management of diabetes.  
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Future work 
 
It would be of benefit to characterise the specific splicing regulatory changes that 
occur following exposure to cellular stresses associated with the diabetic 
physiology. This would potentially allow identification of targets for small molecule 
and antisense oligonucleotide interventions to restore mature beta cell identity. 
This could be achieved by sorting those cells that appear to have 
transdifferentiated, following cell stress treatment, to identify the regulators that 
are responsible for splicing decisions. It may then be possible to restore splicing 
patterns in the transdifferentiated cells using small molecules to target individual 
splice sites using antisense oligonucleotides. Assessing the subcellular location 
of FOXO1, possibly using sub-cellular fractionation would also be an important 
next step. Investigating the effect of these changes on beta cell function would 
also be beneficial. Dynamic studies investigating the effect of these cellular 
stressors on insulin release via the use of insulin reporters would be a useful 
technique, along with calcium imaging and electrophysiology(320).   
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Chapter 5. Cellular stress responses in the human beta cell line EndoC-βH1 may 
be co-ordinated by microRNAs. 
 
Summary 
 
In Chapter 5, I investigated the effects of T2D related cellular stresses on 
MicroRNA expression. A global high throughout miRNA screen was used to 
identify miRs expressed in the EndoC-H1 cell line, and those with the greatest 
fold change in response to cellular stresses were used for pathways analysis. 
Validation of target genes from pathway analysis was also investigated. I found 
negative correlations for miR-454-5p and its predicted target MAPK1, miR-136-
5p and its predicted target DLG2 and miR-299-5p and its predicted target PDK1. 
Each of these genes is known to influence beta cell dysfunction and survival. This 
may suggest miRNA regulation of rates of beta cell apoptosis in response to 
these cellular stressors.    
 
miRNAs that were strongly validated against targets in an á priori  target panel of 
genes with roles in beta cell fate and function, marker for cellular stress, and 
markers for other pancreatic endocrine cell types, were assessed for altered 
levels of expression. Target panel genes were also assessed for altered 
expression in response to these cellular stressors. I found that there were 
negative correlations for miR-199a and its validated target STK11 (LKB1), miR-
21 and its validated target SOX9 and miR-29a and its validated target FOXO1. 
These findings are interesting because both STK11 and FOXO1 are associated 
with maintenance of mature beta cell differentiation status. SOX9 is a beta cell 
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marker and the increased expression that is observed in response to T2D 
relevant cellular stresses may suggest increased cellular plasticity.  
 
Importance of findings 
 
Taking all these data together, this may suggest that beta cell responses to these 
cellular stressors involves altered miRNA regulation of genes with roles in both 
beta cell fate and beta cell survival. 
 
Future work 
 
These findings support recent studies which have shown that microRNAs are an 
intrinsic part of the cell’s adaptive response to cellular stresses. This is of 
particular importance in relation to maintenance of mature beta cell differentiation 
status and survival. Assessment of miRNA regulation of beta cell stress 
responses offers the potential for targeting specific miRNAs as a possible 
therapeutic intervention. However, the exact mechanism of how miRNAs are 
dysregulated in response to diabetes related cell stresses remains to be 
elucidated(157). This would be an important area for future research. In relation to 
miRNA regulation of beta cell de-differentitaion, it would also be important to 
evaluate whether restoring those miRNAs which are dysregulated in response to 
cell stress promote beta cell redifferentitaion. In this work, we identified changes 
in differentiation status in only a proportion of the culture and hypothesized that 
these cells might form a subset within the culture. Assessing whether there are 
miRs which specifically target different beta cell subsets, or promote beta cell 
diversity within islets would also be a critical next step.  
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Discussion of thesis 
 
This thesis discusses the effects of cell stresses, associated with T2D, on beta 
cell differentiation status. To do this, I first optimised the EndoC H1 cell model 
to develop a physiologically relevant system for studying the effects of cell stress. 
I then went on to consider the effects of these cell stresses on gene expression, 
splicing patterns, splicing factor expression, microRNA expression and hormone 
expression. I have provided key insights into changes in beta cell fate and have 
identified, for the first time, that dysregulation of alternative splicing, associated 
with changes in splicing factor expression via dysregulation of FOXO1, causes a 
beta to delta shift in a proportion of EndoCH1 cells. I have also found that this 
shift in phenotype from beta to delta is seen in islets from cases with either T2D 
or long duration T1D. To complete this targeted transcriptomic profile, I also 
investigated the effects of diabetes related cellular stresses on microRNA 
expression and used gene enrichment analysis to identify the pathways 
implicated by altered microRNA expression. This work identified that cellular 
stresses do cause changes in microRNA expression, which may increase cellular 
plasticity via miRNA regulation of genes known to be important for maintenance 
of beta cell fate. It also showed changes in the expression of microRNAs 
associated with beta cell survival, with changes in the expression of miRNAs 
targeting genes with known roles in rates of apoptosis. Taking the findings from 
each of these studies together, it may suggest that cell stress affects beta cell 
plasticity and may influence beta cell differentiation status.  
 
The development of the EndoC H1 cell line has allowed, for the first time, a 
reliable model for studying human disease. Previous human beta cell lines have 
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been derived from ductal cells, such as the fusion cell line 1.1B4, and so 
assessing differentiation using cells of this type is problematic(264). Improving the 
physiological validity of the cell model for studying human disease was an 
important first step in this project. To study the effects of changes in beta cell 
differentiation status in response to a diabetic physiology in humans, I first 
investigated the importance of the species origin of culture reagents on the 
EndoC-H1 cell model. It is known that cellular microenvironment is particularly 
important to beta cells as they interact intimately with their environment to sense 
changes in glucose and react to other pancreatic islet cell hormones(70, 249, 321). 
Communication between beta cells is intrinsic to their function and beta cell 
subsets exist within islets, including beta cell hubs, which regulate insulin 
secretion across the islet(79, 281). Beta cell hubs show increased plasticity and are 
particularly vulnerable to cellular stressors in the islet microenvironment(79). It has 
been shown that beta cell mass loss alone can drive changes in beta cell 
differentiation, underlining the importance of close cell-cell communication, not 
only for function, but also maintenance of beta cell fate(69, 70). Considering how 
important cellular microenvironment is to beta cell fate and function, assessing 
the impact of species origin of culture reagents was an important first step in 
assessing the effects of T2D related cellular stresses on beta cell differentiation 
status.    
  
The effect of the species origin on the EndoC-H1 human beta cell model was 
assessed by analysing changes in total gene expression, hormone expression 
and GSIS between non-human and human culture reagents. I have 
demonstrated that cells cultured using human reagents showed reduced 
expression of alpha cell markers and improved GSIS compared to those cultured 
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using animal derived reagents. This suggests that species origin should be 
considered when investigating the effects of changes in the cellular 
microenvironment to avoid potentially confounding results. It also optimised the 
cell model to a fully human system for investigating human disease.  
  
Having optimised the cell model in this way, I investigated the effects of the 
diabetic physiology (changes in glucose homeostasis, dyslipidaemia, hypoxia 
and proinflammatory cytokines) on total gene expression for genes in the 
previously described target panel. Across each of the assays there were changes 
to a number of genes in a network that is known to influence beta cell fate.  The 
network, comprising: PAX6, PDX1, NEUROD1, NKX2-2, NKX6-1, PAX4 and 
FOXO1 regulate insulin synthesis, maintenance of beta cell function during cell 
stress and maintenance of beta cell fate. Reduced expression of genes within 
this network has been associated with a loss of mature beta cell status and 
transdifferentiation to an alpha cell phenotype in murine models, please refer to 
figure 23(96, 197). PAX6 is vital for beta cell function and is known to directly bind 
and activate the INS, PDX1, and MAFA gene promotor regions(79, 196). It also 
interacts with the beta cell specific transcription factors PDX1, NEUROD1, NKX2-
2 and NKX6-1, of which NKX2-2 activates PAX6(288). It has been shown to 
regulate beta cell identity by promoting the expression of glucose sensing genes 
and by inhibition of the disallowed beta cell gene SLC16A1(288). In conjunction 
with PDX1, PAX6 is known to bind the somatostatin gene promoter and studies 
using PAX6 knockouts have shown reduced expression of insulin, glucagon and 
somatostatin(271, 322).  
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Figure 23. Schematic representation of transcriptional network and model 
of FOXO1 inhibition of splicing factor expression.  
The tight regulation of the genes within this network are important to establishing and 
maintaining mature beta cell status. The schematic shows gene interactions and 
indicates the importance of nodal genes within the network. 
 
 
 
Loss of PDX1 expression has been shown to result in the loss of mature beta 
cells status(269). It also has roles in the maintenance of beta cell function, 
proliferation during cell stress and ageing via beta cell neogenesis. As a 
transcription factor, it forms a nucleoprotein complex with NEUROD1 on the INS 
gene to allow interactions with transcription factors and transcriptional 
machinery(323). PDX1 also maintains beta cell differentiation status via inhibition 
of the alpha cell genes ARX and GCG(57, 323). Similarly to PDX1, NKX2-2, NKX6-
1 and PAX4 also maintain mature beta cell status via repression of the alpha cell 
gene ARX(107). NKX2-2 and PAX4 are known to form an axis with ARX, whereby 
NKX2-2 and PAX4 repress ARX to favour a beta cell phenotype, but in alpha 
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cells, increased ARX expression suppresses them in turn to maintain mature 
alpha cell status(119). Together, PAX6, PDX1, NEUROD1, NKX2-2, NKX6-1 and 
PAX4 form interactions which maintain beta cell function and beta cell fate, as 
shown in figure 23(84, 107, 324). However, the majority of these genes are also 
expressed in the other islet cell types and so it is the tight regulation of expression 
levels which confers each cell types differentiation status(57). Importantly, 
changes in the expression levels of genes within this network disrupt 
maintenance of the mature beta cell fate(71).  
 
FOXO1 is also known to have key roles in beta cell fate and function. It has been 
shown in rodent models to be important for beta cell compensation for insulin 
resistance via augmentation of glucose sensing and management of oxidative 
stress(289). In euglycaemic states, FOXO1 is located in the cytoplasm of beta cells 
in response to insulin production which activates AKT, leading to phosphorylation 
of serine and threonine sites in FOXO1(274). During oxidative stress FOXO1 is 
acetylated, which both protects it from ubiquitination and targets it to the 
nucleus(47, 274). ER stress also induces FOXO1 to translocate to the nucleus but 
acts via MAPK activation(103, 273, 274). There is controversy over its role in beta cell 
replication, Kitamura et al, using Foxo1-ADA, suggest Foxo1 inhibits the 
proliferative activities of Pdx1(47), however, Zhang et al used a wtFoxo1 in their 
study(289), arguing that Foxo1 improves beta cell responses to hyperglycaemia 
via increasing beta cell mass, glucose sensing and anti-oxidative function(289). 
There is also disagreement over its interaction with PDX1, with Kawamori et al(325) 
and Kitamura et al(47) suggesting FOXO1 inhibits the activity and expression of 
PDX1, while Zhang et al(289) and Al-Masri et al(273) argue that it acts in parallel 
with PDX1. Our group have recently discovered a potential role for dysregulated 
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FOXO1 in the regulation of splicing factor expression and alternative splicing 
patterns, as a downstream activator of AKT, as shown in figure 23. Here, FOXO1 
expression is dysregulated in response to a number of the cellular stresses. Cells 
also showed increased expression of markers for cellular stress that are known 
to occur in response to hyperglycaemia, ER stress and oxidative stress. These 
conditions are known to alter the subcellular location of FOXO1, thereby affecting 
its activity(103, 274, 325). This led to a hypothesis where dysregulated FOXO1 
expression and activity may result in dysregulation of splicing via altered splicing 
factor expression, resulting in changes to mature beta cell differentiation status. 
  
As alternative splicing is well known to respond to cellular stresses(277), I 
investigated whether dysregulation of the pathways which regulate splicing may 
affect beta cell differentiation status, by assessing their effect on splicing factor 
expression and alternative splicing for specific genes in the target panel. 
Importantly, expression of splicing factor, serine arginine rich (SR) and 
heterogenous ribonucleoprotein particle (HnRNP) genes, which encode positive 
and negative regulators of alternative splicing, were also dysregulated by 
exposure to the cell stresses. Assessment of the alternative splicing patterns for 
genes selected from the target panel, showed significant differences in PAX6, 
PTPN1 and POU5F1 isoform expression.  
 
Changes in the ratio of isoforms are important as this may result in change of 
function(326). In the case of PAX6, switches in isoform ratio are known to affect 
DNA binding of downstream targets(224, 227). The PAX6 exon 5 insertion isoform 
(PAX6-5a) lacks the DNA binding ability of the N-terminal subdomain and 
unmasks the DNA binding ability of the C-terminal subdomain(224, 227). This 
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change in DNA binding activity is thought to function as a molecular switch that 
specifies target genes(228, 288). POU5F1 isoform differences are known to confer 
differences in response to cellular stress and increased plasticity(327), with the 
OCT4B and B1 variants believed to shuttle to the cytoplasm in response to cell 
stress(230). I found ratio changes in the expression of OCT4 isoforms in response 
to all of the cellular stressors tested. Protein tyrosine phosphatase PTPN1 
(PTP1B) is known to negatively regulate insulin and leptin signalling via 
dephosphorylation of the activating phosphorotyrosines on the insulin 
receptor(144, 212, 235). There are two variants resulting from alternative splicing: a 
long transcript which includes intron 9 and a shorter form where intron 9 is 
excised(235). Studies have shown that the long isoform is associated with body fat 
percentage and fasting insulin scores and has been suggested as a biomarker 
for hyperinsulinaemia in Diabetes(235). Taken together, the dysregulation of 
splicing factor expression and patterns of alternative splicing in response to 
cellular stresses support the hypothesis that this may be a mechanism for the 
loss of mature beta cell status in T2D.   
  
To investigate the effects of the T2D relevant cellular stressors on hormone 
expression, I assessed insulin, glucagon and somatostatin expression in EndoC-
βH1 cells using immunofluorescence microscopy. I found that in treated cells a 
small, but statistically significant, proportion of the cells lost insulin expression 
and gained somatostatin expression following exposure to the noxious stimuli. 
There was no evidence of glucagon expression in any of the treated cells. To test 
whether these effects related to non-specific stresses, I also treated the cells with 
oleic acid, a fatty acid that is not known to induce metabolic stress in human beta 
cells and has been reported to confer protection from beta cell apoptosis to cells 
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co-treated with palmitic acid(28, 207). Here, oleate did not cause an increase in 
somatostatin positivity, but it also conferred no protective effect against palmitate. 
This indicates that the shift from a beta to delta phenotype was not indiscriminate 
and occurs through different mechanisms to those involved in oleate-mediated 
protection from palmitate-induced apoptosis. 
  
As these findings may have been purely a characteristic of EndoC-βH1 cell 
responses, I also assessed changes in hormone expression in islets from donors 
with long duration T1D and T2D using immunofluorescence microscopy. This 
showed statistically significant increases in somatostatin staining in both T1D and 
T2D islets. In T2D islets the increase in somatostatin staining was not associated 
with a significant loss in total islet area.  The increase in somatostatin staining in 
T1D islets was particularly striking, although this was also associated with a loss 
in total islet area due to the depletion of beta cells. These findings support the 
idea that there may be a change in the differentiation status of islets cells in 
response to stresses associated with diabetes. Importantly, it also suggests that 
transdifferentiation in humans appears to be from beta to delta, rather than from 
beta to alpha, in the manner that has been seen in rodent models(61).   
 
To investigate the idea that ER stress may contribute to changes in beta cell 
differentiation via altered splicing, as a result of altered FOXO1 activity and 
expression, EndoC-βH1 cells were treated with the ER stress inducer 
tunicamycin. I found that tunicamycin treatment also caused a statistically 
significant loss of insulin and gain of somatostatin expression in a proportion of 
the cells. ER stress has been shown to regulate transcriptional and translational 
responses in T2D, particularly because high demand for insulin makes beta cells 
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extremely sensitive to ER stress(11, 38). It has been proposed that ER stress leads 
to beta cell dysfunction and cell death as a result of impaired insulin secretion 
and increased sensitivity to glucotoxicity(11, 33, 38). Here, levels of FOXO1 
transcript expression were reduced following exposure to tunicamycin. Zhang et 
al have suggested that FOXO1 activity is vital for the enhancement of beta cell 
function during oxidative and ER stress(289), under which conditions it is known to 
translocate from the cytoplasm to the nucleus, where it acts as a transcription 
factor(325). These findings support the idea that cellular stresses disrupt mature 
beta cell status and again imply a role for dysregulation of FOXO1 in this process.  
 
While it is acknowledged that only a small, but significant, proportion of cells 
shifted from a beta to delta-like phenotype, it is known there are at least 4 subsets 
of beta cells and it may be possible these subsets respond differently to cellular 
stresses(281, 328). Beta cell hubs in particular are considered to be more 
susceptible to changes in their cellular microenvironment and are known to have 
increased plasticity(79). It may be that the proportion of cells in the culture which 
respond to cellular stresses, by a shift from a beta to delta phenotype, do so 
because they are more sensitive to stresses than other cells in the culture. This 
is a feature of the EndoC-βH1 model that should be investigated in the future, as 
it will better characterise their use as a model system as well as potentially 
providing insight into the effects of cell stress on beta cell subsets. To determine 
whether there was evidence for full transdifferentiation from beta to delta, gene 
and protein expression levels for HHEX were also carried out. HHEX is known to 
be exclusively associated with delta cells in the endocrine pancreas and its 
absence may indicate that the cells were probably not fully transdifferentiated(329). 
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To determine whether the effects of cellular stresses caused permanent changes 
to beta cell differentiation status, I investigated whether removal of the cellular 
stress and restoration under standard culture conditions could rescue a mature 
beta cell phenotype in the EndoC-H1 cells. As in the previous assays, I found 
that cells that had been treated with high glucose for 24 hours showed a loss of 
insulin expression and gain of somatostatin expression using 
immunofluorescence microscopy, indicating a shift from beta to delta-like 
phenotype. However, when treated cells were restored to standard culture 
conditions for 72 hours there was no longer any evidence of somatostatin 
staining, indicating that it is possible to rescue the cells to a mature beta cell 
status. This finding may offer an explanation for anecdotal evidence from patients 
with T2D who report remission of their disease following a strict diet and exercise 
regime.  
 
Taking all these data together in the context of the model which describes 
changes to beta cell differentiation status occurring due to dysregulation of 
splicing, possibly caused by altered FOXO1 activity, I investigated the potential 
role of the AKT pathway. I assessed the effects of AKT pathway inhibition via the 
small molecule inhibitor of AKT, SH6, to determine whether this affected the beta 
to delta cell like shift in phenotype. EndoC-H1 cells treated with SH6, showed 
no increase in somatostatin hormone expression following treatment with 25 mM 
high glucose. Importantly, there was also no evidence for dysregulation of 
splicing factor expression or patterns of alternative splicing. This may suggest 
that disruption of the AKT pathway, in particular FOXO1, is important for 
transdifferentiation from a mature beta cell status to a delta cell like phenotype to 
occur. This would fit a model where cellular stressors relevant to T2D cause 
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dysregulation of the activity and expression of FOXO1, which in turn disrupts 
splicing factor expression and patterns of alternative splicing in genes with known 
roles in the maintenance of beta cell fate and function.   
  
Since microRNA (miRNA) expression is also known to be significantly altered by 
exposure to cellular stresses and a number of miRNAs have been linked to 
T2D(300, 301, 330), I performed a large scale miRNA screen to identify the most 
altered miRNAs for further investigation. I selected 10 miRNAs that are known to 
be empirically strongly validated to targets in the panel of genes with relevance 
to beta cell fate and function and found negative correlations for 3 miRNAs and 
their target genes. miR-199a and its validated target STK11 (LKB1), a gene that 
has been shown to maintain beta cell identity(171), responded to 25mM high 
glucose, with STK11(LKB1) significantly decreased in expression. miR-29a has 
FOXO1 as one of its targets and here levels were increased, in contrast to 
reduced FOXO1 expression in response to inflammatory factors. Importantly, 
STK11 (LKB1) is required for AKT mediated phosphorylation and activation of 
FOXO1(331). Following treatment with low glucose, hypoxia and palmitic acid, 
miR-21 showed reduced expression while there was increased expression of its 
target SOX9, a gene associated with increased cellular plasticity(213). Taking 
these findings together, a model can be hypothesized whereby cellular stresses 
cause dysregulation of miRNA expression for miRNAs that are known to target 
genes important for the maintenance of beta cell fate and function.   
  
Along with assessment of miRNA expression of miRNAs strongly validated to the 
target panel, 10 miRNAs were selected that had the highest fold change across 
all of the cell treatment assays. These were assessed for their response to the 
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cellular stresses and the list of significant mRNAs were taken into pathways 
analysis. This identified a number of pathways which were ranked according to p 
value, MITG score and number of genes affected(248). Genes from the top ranked 
pathways were selected for further validation. Notably, one of the pathways 
selected included FOXO, with genes from the other pathways that were selected 
also known to interact with FOXO1, in particular MAPK1. From validation of the 
genes identified by the pathways analysis, 3 negative correlations were detected: 
miR-454-5p and its predicted target MAPK1, miR-136-5p and its predicted target 
DLG2 and miR-299-5p and its predicted target PDK1. These genes all have roles 
in pathways that are important for beta cell survival and which also interact with 
the FOXO pathway. Here, each of the negative correlations favoured pro-
apoptotic responses, with increases in PDK1 and DLG2 expression, with 
concomitant decreases in the expression of the miRs known to target them. 
Increased expression of these genes favours activation of proapoptotic 
pathways(287, 297, 313, 332). There was increased expression of miR454-5p with 
decreased expression of its predicted target MAPK1, which is also known to 
increase rates of apoptosis. 
 
It is acknowledged that there are limitations with the work described in this thesis. 
There is a strong emphasis on the transcriptomic profile of beta cell responses to 
T2D related cellular stressors and future work elucidating functional responses, 
including electrophysiology, will be important. It will also be critical to extend the 
transcriptomic profile to genome wide, as this study was restricted to investigating 
changes in a target panel of specific beta cell relevant genes. The EndoC βH1 
cell model, while an important recent development in the study of diabetes, does 
have a number of issues that needs to be taken into account when interpreting 
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results. The cell line is derived from foetal pancreatic buds and may be more 
prone to changes in differentiation status. These cells are also known to express 
genes that have been previously described as ‘disallowed’ in beta cells, although 
these were derived from murine studies. For this reason, this study also utilised 
ex vivo human islets to characterise possible changes in differentiation status. It 
is also acknowledged that the work on altered miRNA expression in the final 
chapter will benefit from replication in human islets and that validation of the 
results to determine causality will be an important next step.  
 
Conclusion 
 
T2D has strong associations with obesity and a sedentary lifestyle, with well 
documented increases in the levels of physiological stresses in the islet 
microenvironment. These stresses are known to lead to beta cell mass loss 
resulting from apoptosis. However, recent studies in mice show changes to beta 
cell differentiation status in response to cellular stresses. These findings require 
corroboration using human models and elucidation of the mechanisms 
underpinning changes in differentiation status are important for understanding 
human disease. Characterisation of these mechanisms also presents an 
opportunity for identifying future treatment targets. The results of this study show, 
for the first time, that exposure to cellular stresses causes a shift from a beta to 
delta cell phenotype in a proportion of beta cells. These changes are associated 
with dysregulation of key genes with roles in beta cell fate, including FOXO1, as 
well as disruption of alternative splicing and splicing factor expression. This 
supports a model where disruption to the activity and expression of FOXO1 
affects splicing factor expression and alternative splicing. Inhibition of the AKT 
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pathway, which activates FOXO1, prevented changes in differentiation status in 
cells exposed to high glucose. Assessment of miRNA expression showed 
dysregulation of miRs strongly validated to target genes important for beta cell 
fate, including FOXO1 and genes known to be important for FOXO1 activation. 
Pathways analysis of miRs most altered following exposure to the cell stresses 
also implicated FOXO related pathways and cell survival.  
 
These findings provide a new insight into the response of human beta cells to 
cellular stresses associated with T2D. They show that, in human disease, 
changes in beta cell differentiation status are an important feature of T2D but that 
changes in phenotype are from beta to delta cell. This contrasts with findings from 
studies in mice which suggest transdifferentiation occurs from a beta to alpha cell 
phenotype. These data may suggest that dysregulation of FOXO1 activity and 
expression leads to dysregulation of splicing factor expression and alternative 
splicing which in turn increases beta cell plasticity allowing for changes in mature 
beta cell differentiation status. The data also show that beta cell stress responses 
may be co-ordinated by microRNAs and again imply a role for FOXO1 in this 
process in relation to both maintenance of beta cell fate and survival.   
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